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Parkinson’s disease (PD) is a complex neurodegenerative disorder which can have a 
significant effect on a patient’s quality of life. Psychiatric symptoms and cognitive decline 
are common, with dementia (PDD) ultimately occurring in approximately 90% of patients. 
Mild cognitive impairment in PD (PD-MCI) is an intermediate state of cognitive decline, 
where patients are at a higher risk of progression to PDD than non-PD-MCI patients. The 
high rates of patients who develop PDD demonstrate that it is pertinent to have indicators of 
imminent PDD; particularly should a preventative therapy ever become available. Therefore, 
the aim of my PhD project was to use cognitive and neuropsychiatric measures to predict 
cognitive decline within a four-year period.  
Firstly, we examined permitted variations within Movement Disorder Society Task 
Force (MDS-TF) Level II diagnostic PD-MCI criteria. We aimed to identify a PD-MCI 
criterion which optimally captured individuals who later progressed to PDD.  To evaluate 
this, we followed 121 non-demented PD patients for up to 4.5 years; 21% converted to PDD 
over this period. Three unique groups of patients were classified as PD-MCI using baseline 
neuropsychological assessments. Each patient was required to have two impaired cognitive 
test scores, with impairment defined as (1) -2SD, (2) -1.5SD or (3) -1SD below normative 
data. Relative risk (RR) of PDD for each criterion was calculated, with the -1.5SD criterion 
found to be optimal for maximizing progression to PDD over four-years. 
Secondly, another variation within the MDS-TF PD-MCI criteria was examined - 
whether the impaired tests need to occur within a single cognitive domain or only across two 
or more cognitive domains. The same sample of PD patients was reassessed to determine (1) 
RR of PDD when two impairments at -1.5SD existed within one cognitive domain, followed 
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by (2) RR of PDD in the unique group whose two impairments at -1.5SD did not exist within 
one cognitive domain. The -1.5SD cut-off produced a high RR of PDD only when two 
impairments were identified within one cognitive domain (7.2, 95% confidence interval (CI) 
= 3.4–16.6, p<0.0001). This suggests that if the intent of a PD-MCI diagnosis is to detect 
increased risk of PDD in the next four years, optimal criteria should identify at least two 
impairments at -1.5SD within a single cognitive domain.  
Next, we examined the number of tests permitted per cognitive domain by the MDS-
TF criteria. We tested a reduced test battery of only two tests per cognitive domain, to 
determine if it could identify PD-MCI patients who were at risk of PDD within the next four-
years. Tests were ranked for each cognitive domain based on the number of PD-MCI level 
impairments they identified. Subsequently, we used an improved methodology, logistic 
regression, to select two tests sensitive to PDD over four-years in each of five cognitive 
domains. The 10 neuropsychological test battery consisted of map search, digit ordering 
(Attention), Stroop interference, Trails B (Executive), picture completion, Rey copy 
(Visuospatial), CVLT-II SF free recall, Rey-short delay (Memory), DRS-2 similarities and 
ADAS-Cog language measures (Language). To determine if at-risk patients could be 
identified RR was conducted on an updated sample of 138 PD patients; 28 progressed to 
PDD. Using this 10 neuropsychological test battery, patients who classified as PD-MCI 
defined by ‘two impairments at -1.5SD in one cognitive domain’ had an equivalent RR (7.0, 
95% CI 3.8-12.6) to the same group classified using the full 24 neuropsychological test 
battery (RR = 6.9, 95% CI 3.3-14.6). PD-MCI in patients with ‘one impairment in each of 
two cognitive domains’ now showed significance (RR = 3.6, 95% CI 1.3-9.5), unlike when 
the same criterion when applied to the 24 neuropsychological test battery. A modified PD-
MCI criterion of ‘two impairments in any of the 10 neuropsychological tests’ was used and 
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showed a similar RR (7.1, 95% CI 3.2-16.1) to the PD-MCI ‘two impairments in one 
cognitive domain’ criterion. This study demonstrated that a 10 neuropsychological test 
battery can identify PD patients at-risk of PDD within four-years and demonstrated that a 
modified PD-MCI criterion (‘two impairments in any 10 neuropsychological tests’) can be 
used when the battery consists of tests sensitive to PDD.  
Lastly, the relationship between neuropsychiatric symptoms in PD and progression to 
dementia was explored. One-hundred-and-twenty-three non-demented PD patients, followed 
over 3.5-4.5 years were included; 27 progressed to PDD. All received comprehensive Level 
II neuropsychological testing and neuropsychiatric evaluations. ROC analysis was used to 
analyse whether neuropsychiatric measures at study entry were associated with future PDD 
progression. Patient-reported hallucinations was the only neuropsychiatric measure which 
related to future progression to PDD (PD Questionnaire hallucinations measure: AUC=0.70, 
CI=0.60-0.80; Unified PD Rating Scale hallucinations measure: AUC=0.69, 95% CI=0.57-
0.80). By contrast, hallucinations reported by the patient’s significant other on the 
Neuropsychiatric Inventory did not discriminate patients. Neither patient-reported 
hallucinations (OR=1.70, 95% CI=0.73-4.03) nor motor function (OR=1.02, 95% CI=0.97-
1.09) were found to add any additional useful information above global cognitive ability 
(OR=26.34, 95% CI=6.44-184.71) and age (OR=1.28, 95% CI=1.11-1.54) for predicting 
PDD. Cognitive ability and age were stronger predictors of conversion to PDD within the 
next four-years than any neuropsychiatric measures tested. 
The findings of this thesis show that MDS-TF PD-MCI criteria can identify patients 
at-risk of PDD within a four-year period, even when a reduced 10 neuropsychological test 
battery is used for classification. Cognition and age were found to be more useful at 
predicting future PDD than any neuropsychiatric symptom assessed. Hence, specific PD-MCI 
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 Introduction and Orientation Chapter 1:
 Rates of Parkinson’s disease (PD) are expected to double over the next 25 years in New 
Zealand (Myall et al., 2017). Dementia in Parkinson’s disease (PDD) is common, with over 
80-90% of patients expected to develop the condition (Gratwicke, Jahanshahi, & Foltynie, 
2015). The time course to PDD, however, can vary anywhere from 2-25 years after diagnosis. 
This makes it difficult to determine the efficacy of potential treatments or interventions to 
slow or halt the progression to dementia. In 2011, the Movement Disorders Society 
sanctioned a Task Force (MDS-TF) to develop criteria for diagnosing PD patients with Mild 
Cognitive Impairment (PD-MCI; Litvan et al., 2012). The primary idea behind setting up this 
Task-Force was that patients who meet PD-MCI criteria may be at an intermediate stage of 
cognitive decline and are therefore more likely to develop PDD than PD patients who have 
‘normal’ cognition.  The last 20 years has shown a greater recognition that PD is far more 
than just a motor disorder and before the development of the MDS-TF PD-MCI criteria in 
2011, there was little consensus on what level of impairment constituted to PD-MCI 
classification being made. This resulted in many different PD-MCI classifications being 
employed in the literature. The true frequency and nature of PD-MCI and its trajectory course 
towards progression to dementia is largely uncharted. 
This thesis aims to validate the MDS-TF PD-MCI Level II criteria by specifically 
determining their relevance to progression to PDD over a four-year period. Several currently 
permitted PD-MCI criteria will be compared to assess which criterion captures patients who 
have a high risk of developing PDD within this period. Key variations between the different 
PD-MCI criteria are (1) cut-off scores used to define impairment, and (2) whether the 
impairments occur within or across different cognitive domains. Once optimal PD-MCI 
criterion has been determined, we will test its performance on a reduced Level II 10 
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neuropsychological test battery to assess whether the shortened battery captures at-risk 
patients. Finally, the predictive nature of neuropsychiatric symptoms over the same four-year 
period will be evaluated and compared to that of cognition. 
1.1. Study overview 
This Thesis will begin by discussing the PD literature with a focus on the cognitive and 
neuropsychiatric aspects of PD (Chapter 2) and then discuss the findings of four research 
chapters (Chapters 3-6). This thesis looks to validate the MDS-TF PD-MCI Level II criteria 
in terms of their ability to capture patients at high risk of dementia, by applying different 
variants of the accepted PD-MCI criteria to a four-year longitudinal PD cohort who live in 
the Canterbury region of New Zealand. The research chapters will assess (1) the influence of 
different permitted impairment cut-off scores (1SD, 1.5SD or 2SD) on relative rates of 
dementia in patients classified as PD-MCI (Chapter 3), (2) The difference in relative risk of 
PDD in PD-MCI patients who have their impairments falling in a single cognitive domain 
only or across multiple cognitive domains only (Chapter 3), (3) whether a reduced 10 
neuropsychological test battery can identify patients at a high risk of developing PDD 
(Chapter 4 and 5), and (4) the relationship between neuropsychiatric symptoms and future 
progression to PDD (Chapter 6). All aspects of this study will look at progression to PDD 
over a four-year period, which is a clinically relative period of time in terms of considering 
the utility of PD-MCI criteria in future clinical intervention or therapy trials (Eberling et al., 
2014). Finally, the overall findings of this thesis will be discussed along with study 
limitations and the future direction of the work (Chapter 7). 
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 Overview of the Parkinson’s disease literature Chapter 2:
2.1. PD diagnosis and differential diagnosis 
Parkinson’s disease (PD) is a complex, multisystem, neurodegenerative disorder that affects 
every aspect of an individual’s life, physically, emotionally and cognitively. Diagnosing 
Parkinson’s disease (PD) is not straight forward. Most clinicians agree that a combination of 
cardinal clinical signs must be present, but there are no definitive diagnostic tests to diagnose 
the disorder. Thus, an autopsy is required for a ‘definite’ PD diagnosis (Berg et al., 2014). 
This presents an issue, as (1) not all patients who experience the clinical symptoms of PD 
will receive an autopsy to confirm pathology, or (2) some will experience PD symptoms but 
at autopsy show no PD pathology. Diagnostic criteria, based only on clinical features of the 
disease, have however been developed to aid clinicians in making the correct diagnosis. 
These include the criteria developed by the United Kingdom Parkinson’s Disease Society 
Brain Bank (UKBB; Hughes, Daniel, Kilford, & Lees, 1992), the diagnostic criteria proposed 
by Gelb, Oliver, and Gilman (1999) and more recently the revised Movement Disorder 
Society Clinical Diagnostic Criteria for Parkinson’s disease (MDS-PD; Postuma et al., 2015). 
A few differences exist across these three diagnostic PD criteria. For example, a probable PD 
diagnosis according to the UKBB guidelines is based on clinical criteria. Bradykinesia is the 
only required symptom, with at least one of either rigidity, rest tremor or postural instability, 
and three other supporting features, such as unilateral onset, progressive disorder or an 
excellent response to levodopa (Hughes et al., 1992). To meet a definite PD diagnosis using 
the Gelb et al. (1999) criteria, there must be pathological evidence (i.e. at autopsy) plus the 
patient must have met all of the criteria for probable PD during life. A probable diagnosis 
requires the presence of any three of the four cardinal PD symptoms (rest tremor, 
bradykinesia, rigidity, asymmetric onset) as well as a positive response to dopamine 
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treatment. For a possible PD diagnosis, there only needs to be two of the four cardinal PD 
symptoms present, with bradykinesia not necessary if a rest tremor is present. For the MDS-
PD criteria bradykinesia must be present, with at least one other symptom of either rest 
tremor or rigidity. When these symptoms are present and there are no alternate ‘red flags’, 
such as rapid progression of gait impairment or a complete absence of progression of motor 
symptoms, then a clinically-established PD diagnosis can be made. If the ‘red flags’ that are 
present, can be counterbalanced with other supportive features (e.g. a dramatic beneficial 
response to dopaminergic therapy), then a clinically-probable PD diagnosis can be made 
(Postuma et al., 2012). This therefore means that bradykinesia for example is not an essential 
requirement when using the Gelb et al. (1999) PD criteria, but it is when using more-
commonly-used MDS-PD and the UKBB PD criteria. 
2.2. Epidemiology and pathophysiology 
Of particular relevance to this thesis is that PD is the second most common 
neurodegenerative disease that causes dementia, after Alzheimer’s disease (Sharma et al., 
2013). Older age is the primary risk factor for developing PD (Lees, Hardy, & Revesz, 2009; 
Reeve, Simcox, & Turnbull, 2014; Sharma et al., 2013). A recent New Zealand Brain 
Research Institute study showed that the 2013 prevalence of PD was estimated as 191 per 
100,000 population while the incidence rate was 29 per 100,000 person-years, with males 
being 1.7 times more likely to develop the disease than females (Myall et al., 2017). These 
rates were estimated by this study to double over the next 25 years as the baby-boomer 
population reach retirement age. Clearly, PD is becoming an increasing relevant burden for 
New Zealand. 
2.2.1. PD - The pathology of the motor disorder 
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The principal pathology of PD was originally characterised in the late 1930’s as the death of 
pigmented nigrostriatal dopaminergic neurons in the substantia nigra pars compacta (SNc; 
Bezard & Gross, 1998). After the death of dopaminergic cells in the SNc cells death extends 
into other areas of the brain, including the locus coeruleus, Meynert’s nucleus basalis and the 
hypothalamus, as PD pathology progresses (Agid, 1991; Bezard & Gross, 1998). Bezard and 
Gross (1998) summarised the functional organisation of the motor circuit model for both the 
normal and parkinsonian state. The motor circuit links the cortex, basal ganglia (BG) and 
thalamus in (A) the normal brain and (B) the parkinsonian brain (Figure 2-1). In this model, 
there are two pathways to the output structures, one ‘direct’ and the other ‘indirect’, both of 
which are under the modulatory control of dopamine. In the direct pathway of a normal brain, 
outputs from the putamen inhibit the internal globus pallidus (GPi) and substantia nigra pars 
reticulata (SNr), which in turn inhibits the thalamus. The indirect pathway of the motor 
circuit also begins in the putamen which projects to output structures via a pathway which 
has an inhibitory effect on the globus pallidus pars externalis (GPe) which in turn inhibits the 
subthalamic nucleus (STN). The STN then has an excitatory effect on the GPi (and SNr) 
which has an inhibitory effect on the thalamus. Motor dysfunction in PD occurs over time 
due to the progressive death of dopaminergic neurons in the SNc. This upsets the balance in 
the ‘direct’ and ‘indirect’ pathways, causing the thalamus to become over-inhibited, which 




Figure 2-1. The functional connectivity within the basal ganglia-thalamo-cortical of the 
motor circuit.(Bezard & Gross, 1998). (A) The normal circuit. (B) The parkinsonian circuit. 
White arrows are excitatory connections and black arrows are inhibitory Reproduced with 
permission from Elsevier. 
 
 The progressive nigrostriatal death in PD is relentless, with the cardinal motor 
symptoms of PD beginning to appear once cell death exceeds the critical threshold of about 
50-60% of SNc cell bodies and 70-80% of the striatal nerve terminals (Agid, 1991). Once 
motor symptoms are present, neuronal death continues to accelerate compared to the normal-
age-related neuronal cell loss (Agid, 1991), which only exacerbates these symptoms. 
However, the gradual appearance of symptoms associated with PD suggests that the BG has 
inherent properties within these pathways that act as compensatory mechanisms to adapt to 
cell loss in the SNc (Agid, 1991; Obeso & Schapira, 2009). Furthermore, extensive dopamine 
loss in the caudate nucleus and putamen, as seen at autopsy, can be associated with relatively 
White = Excitatory connections 
Black = Inhibitory connections 
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few clinical symptoms (Agid, 1991; Bezard & Gross, 1998). Zigmond and Stricker (1989) 
suggest that compensatory mechanisms initially maintain a sufficient amount of dopamine in 
the striatum and then optimise supply from the remaining neurons. The first compensatory 
mechanism alters the discharge frequency of dopamine. This increases the amount of 
dopamine that is released per pulse and/or synthesises a greater quantity. The second 
compensatory mechanism increases the responsiveness of striatal neurons to dopamine and 
supplements the synthesis of tyrosine hydroxylase. In a healthy brain, there is a provision for 
dopamine ‘redundancy’ in the nigrostriatal pathway, thus allowing the circuit to tolerate some 
degree of damage to dopamine neurons before these compensatory mechanisms are needed. 
 The functional connectivity model (Figure 2-1) outlined by Bezard and Gross (1998) 
implies that the basal ganglia’s role in the control of movement is a serial and hierarchical 
process. This suggests that movement control follows an arrangement of excitatory and 
inhibitory events, assuming that the motor system uses a procedural approach to facilitate the 
execution of movement. This model has been supported, as it explains the motor 
consequences of lesions in the SNc and GPi, but it fails to explain several other features of 
PD, including the cognitive and emotional aspects of the disorder (Obeso et al., 2000). This 
suggests that PD is more than just a disorder affecting motor circuitry, but more likely a 
disease that involves multiple brain circuits and systems.   
The anatomy of the motor circuit is much more complex than first envisioned. Not 
only is it arranged in separate, parallel, loops, but each individual cortical motor area is 
somatotopically organised (Obeso et al., 2000). The cortical regions (Brodmann area 4 and 6, 
and supplementary motor area) and the primary somatosensory cortex project to the striatum 
in this same organised manner. The motor control area is located in the dorsolateral section of 
the basal ganglia, with the leg represented in the dorsal region, the face in the ventral region 
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and the arm in between the two on a coronal plane (Figure 2-2). Neural activity of the STN 
and GPi has been observed during PD surgery to follow the same pattern of organisation, 
with cortical projections from area 4 and the supplementary motor area (SMA) in the 
putamen, STN and GPi (Hoover & Strick, 1993; Obeso et al., 2008; Rodriguez-Oroz et al., 
2001; Theodosopoulos, Marks, Christine, & Starr, 2003). However, no clear arrangement has 
been found for the SNc and the dopaminergic projections of the nigrostriatum (Obeso et al., 
2008). 
 
Figure 2-2. The somatotopically-organised basal ganglia tends to mimic the cortical 
representation of the body, with the leg represented dorsally, the face ventrally and the arm 
in-between (Obeso et al., 2008). Reproduced with permission from John Wiley and Sons. 
 
The motor circuit of the basal ganglia is therefore regarded as a complex network, 
connected by separate and hierarchically arranged cortico-basal ganglia-cortical parallel 
circuits and ‘internal’ loops which project motor inputs to different areas of the motor cortex. 
The cortico-basal ganglia-cortical parallel loops are regarded as positive feed-forward signals 
to aid the preparation and execution of movement while the ‘internal’ circuits may primarily 
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serve a feedback-stabilisation function (Figure 2-3). Monkey studies suggest that the main 
role of neurons in the direct pathway is the performance of complex oculomotor and manual 
movements, whereas the indirect pathway’s role has yet to be as clearly established (Obeso et 
al., 2000). Obeso et al. (2000) surmised from animal studies that cortical activation of the 
region do tend to have immediate and influential disynaptic effects on the GPi/SNr. These 
effects are not driven by inhibitory pathways (i.e. direct) from the GPi/SNr nor excitatory 
pathways (i.e. indirect) originating from the STN. This finding suggests the projections from 
the cortico-STN may be involved with learned motor sequences and repetitive movement 
control. The polysynaptic indirect pathway, in contrast, directly excites the GPi/SNr 
suggesting this pathway is involved in complex motor-learning tasks. BG excitability is 
controlled closed-loop ‘internal’ circuits along with the dopaminergic system, which also 
plays a stabilising role. A depletion of dopamine would destabilise the network and would 
lead to instability within these circuits, resulting in an increase in parkinsonian symptoms 




Figure 2-3. The cortico-basal ganglia-cortical feedback loop of motor control. The black 
loops represent closed somatotopically-organised parallel projection circuits between the 
motor cortex, the basal ganglia and the motor circuit. The horizontal loops provide ‘internal’ 
stabilisation of basal ganglion activity. The blue loop represents the centromedian-
parafascicular complex (CM/Pf) which is a CM/Pf-striatum-GPi-CM/Pf positive feedback 
circuit. The red loop is the CM/Pf-SNT-GPi-CM/Pf negative feedback loop. The green arrows 
represent the STN’s control of GPi activity through a direct STN-GPi monosynaptic 
excitatory connection and STN-GPe-GPi excitatory-inhibitory loop. The GPe has a 
reciprocal inhibitory effect on the STN. The grey arrows represent the dopaminergic 
modulation of the striatum, SNT, GPi, GPe and SMA motor cortex (Obeso et al., 2000). 
Reproduced with permission from Elsevier. 
 
2.2.2. PD is more than just a dopaminergic disorder: It is a multisystem neurodegenerative 
disorder 
Braak, Ghebremedhin, Rub, Bratzke, and Del Tredici (2004) developed a staging system of 
PD progression based on neuroanatomical changes that happen over time. The model consists 
of six sequential stages where α-synuclein deposits (Lewy body pathology; LB) aggregate 
and disperse throughout the brain (Braak et al., 2006; Braak & Del Tredici, 2008; Braak et 
al., 2004; Hawkes, Del Tredici, & Braak, 2010). Predictable changes of the disease 
progression drive the idea behind this staging system (Figure 2-4). LBs in the brain stem and 
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olfactory regions of individual’s that do not yet experience any motor symptoms are the 
characteristic features of the presymptomatic phase. When an individual has progressed to the 
symptomatic phase LB pathology exceeds (Figure 2-4) the threshold and is particularly 
evident in the SNc. Most neuropathologist’s support the concepts underlying Braak’s PD 
staging model, but acknowledge that in about 10-20% of PD cases pathology differs from 
what is outlined (Hawkes et al., 2010). Jellinger (2008, 2009) however has argued that in 
retrospective PD studies, 6.3-43% of cases differ from the proposed stages of 
neuroanatomical changes outline by Braak. Furthermore, Jellinger (2008, 2009) observes that 
there is considerable overlap within each stage in terms of the LB pathology related to other 
neurodegenerative multisystem disorders, especially the related condition known as dementia 
with Lewy bodies (DLB).
 
Figure 2-4. Braak’s staging model of PD. (A) PD progression is divided into two phases, the 
presymptomatic and symptomatic phases. The increasing slope and the intensity of the 
coloured areas that are below the diagonal line show the growing severity of the Lewy 
pathology. The severity of Lewy pathology in different regions of the brain is shown by the 
degree of red shading and it’s spread from the brain stem and olfactory bulb through to the 
cortical regions are illustrated by the coloured arrow. (B) This diagram shows the ascending 
pathological processes (white arrows) while the shading corresponds to Figure 2-4A (Braak 
et al., 2004). Reproduced with permission from Springer for the purposes of thesis 





 At stage one, LB pathology is sparse and isolated to the vagal nerve dorsal motor 
nucleus and olfactory structures of the anterior bulb (Figure 2-4; Braak et al., 2006; Braak et 
al., 2004; Hawkes et al., 2010). No other pathology is found anywhere else in the brain, 
suggesting these regions are where PD pathology begins before spreading to other areas of 
the brain. Signs of pathology in the enteric motor system (EMS) could include constipation. 
A study looking at the relationship between constipation and the development of PD found 
that men who had less than one bowel movement a day were at an increased risk (2.7 times) 
of later developing PD compared to those who had one bowel movement a day. The risk 
increased further (4.5 times) when compared to men who had more than two movements a 
day (Abbott et al., 2001). A follow-up study found additional evidence to support the 
relationship between constipation and an increased risk of developing PD with incidental LB 
pathology present in the SNc which was four time greater in men who had less than one 
bowel movement a day. This would suggest constipation may be early prodromal symptom of 
PD (Abbott et al., 2007). Olfactory dysfunction may also be present at this stage along with 
urinary, bladder and erectile problems. However, although these symptoms may indicate the 
initial phases of PD, they are not specific to PD and thus are not diagnostic features of the 
disorder (Hawkes et al., 2010). 
 At Braak’s stage two of PD, there is increasing LB pathology in the areas already 
involved and the pathology has spread into the lower raphe nucleus, coeruleus-subcoeruleus 
complex (CSC) and reticular formation (Figure 2-4). The ‘gain setting’ system comprised of 
these structures, controls motor and pain function. The pathological changes as LBs 
aggregate in these regions could be the underpinnings of the painful symptoms which can 
develop during the course of PD. Depression is a common co-morbidity of PD, and if it is 
related to serotonergic pathways, CSC changes could be the basis of the depressive symptoms 
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experienced by the patient. The changes in the CSC could also be the underpinning of sleep 
disorders in PD (Braak et al., 2006; Braak et al., 2004; Hawkes et al., 2010). Stages one and 
two are both popular research areas surrounding the prediction of PD in the prodromal stage 
of the disorder (Morley & Hurtig, 2010; Postuma et al., 2012). Some risk factors include loss 
of smell, REM sleep behaviour disorder (RBD) and constipation (Postuma et al., 2012). 
 The classic characteristic motor-features of PD emerge during stage three of Braak’s 
model. The spread of LB pathology has reached the upper limits of the pontine tegmentum 
and basal areas of the mid and forebrain (Figure 2-4), including the SNc, central subnucleus 
of the amygdala, the magnocellular nuclei of the basal forebrain (MBF) and nucleus basalis 
of Meynert. The loss of more than 50% of neurons in the SNc are the basis of the cardinal 
motor signs (bradykinesia, rigidity and rest tremor) seen in PD. Changes in the MBF are 
attributed to attention and sleep-wake cycle dysfunction. Disordered behaviour, poor memory 
and hallucinations are thought to relate to pathology within Meynert’s nucleus among other 
regions (Braak et al., 2006; Braak et al., 2004; Hawkes et al., 2010). 
 By stage four of Braak’s PD model, pathology is severe in the amygdala and the 
anteromedial temporal mesocortex. There is also evidence of pathology developing in the 
second sector of Ammon’s horn, characteristic of advanced stage PD (Figure 2-4). At stage 
four, the pathology is wide-spread which makes it problematic to discern what pathological 
changes are the underpinnings of which specific symptoms/signs that the individual is 
experiencing clinically. Cognitive decline is one of the most noticeable clinical signs and 
could be related to pathological changes in thalamic intralaminar nuclei. The LB pathology 
may impede higher-order sensory information from reaching structures such as the entorhinal 
region, amygdala and hippocampal formation (Braak et al., 2006; Braak et al., 2004; Hawkes 
et al., 2010). 
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 In stage five, the LB pathology invades the insular, anterior cingulate regions and 
subgenual mesocortex, while intensifying in regions where pathology had developed 
previously (Figure 2-4). Cortical areas are now involved which can be the cause of balance 
impairments and cognitive decline. Layers V-VI neocortical pyramidal cells now also exhibit 
pathology, chiefly in the secondary and tertiary association areas. The regions affected in 
stage five all have a role in viscerosensory and visceromotor function, meaning that heart 
rate, the regulations of breathing, blood pressure and even bowel motility can be affected 
(Braak et al., 2006; Braak et al., 2004; Hawkes et al., 2010). 
 In the sixth and final stage of Braak’s PD model, the pre-existing damage to the 
limbic, autonomic and somatomotor systems is aggravated by the spread of LBs to centres of 
the superordinate limbic system. Pathology can now be seen in virtually every area of the 
brain, including primary motor and sensory areas, first-order sensory association regions and 
the premotor regions of the neocortex (Figure 2-4). If an individual was to progress to stage 
six of Braak’s model, they would have severe dementia and be practically immobile due to 
the extent of this pathology (Braak et al., 2006; Braak et al., 2004; Hawkes et al., 2010). 
 Earlier models of PD, discussed previously, attributed the underlying neuropathology 
of PD to a dopaminergic deficiency in the dorsal striatum but failed to include other non-
dopaminergic systems that are now known to be affected by PD as the disease progresses. An 
updated model illustrates the wider pathological changes that occur in PD (Figure 2-5). The 
amendments to the earlier models suggest that PD is not just a dopaminergic dysfunction but 
a multi-system neurodegenerative disorder (Braak & Del Tredici, 2008). This change in 
thinking has transformed PD research, as now the focus has shifted from purely motor-related 
studies to multi-system research. Parallel neurochemical models could further explain the 
cognitive and non-cognitive symptoms that are associated with dementia in PD and the 
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interaction between these neurochemical systems that could result in the parkinsonian 
condition (Calabresi, Picconi, Parnetti, & Di Filippo, 2006). 
 
Figure 2-5. Braak’s updated model of dopamine depletion in PD. This includes the motor 
areas of the spinal cord through to the neocortex. It not only shows the consequences of 
dopamine depletion in the dorsal striatum but also the non-dopaminergic centres that become 
consecutively and severely impaired as PD progresses. The cortico-striatal projection is most 
probably impaired because of the cortical pathology while the cortico-subthalamic 
contention remains intact. The neuropathological stages are illustrated by the various 
degrees of shading (Braak & Del Tredici, 2008). Reproduced with permission from Elsevier. 
 
2.3. Signs and symptoms of PD 
The non-motor symptoms associated with PD can have the biggest impact on an individual’s 
ability to function in everyday life (Lawson et al., 2014). The cardinal features of PD are 
bradykinesia, tremor at rest and rigidity and some include the later development of loss of 
postural reflexes which can result in falls and postural deformities (Jankovic, 2008). Some of 
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these secondary motor symptoms and non-motor symptoms are listed in Table 2-1. 
Table 2-1. Common secondary motor and non-motor features of PD 
Motor Symptoms Description 
Hypomimia A paucity facial of expression. 
Dysarthria The poor articulation of phonemes. 
Dysphagia Difficulty swallowing. 
Sialorrhoea Excessive build-up of saliva. 
Micrographia Abnormally small, cramped handwriting and/or the 
progressives to smaller handwriting across the page. 
Shuffling gait Where the individual’s feet skate across the ground because 
they make contact too early. 
Festination The involuntary quickening of gait of shortened stride length. 
Akinesia/Freezing Difficulties in the initiation of movement. 
Dystonia An abnormal tonicity of muscles characterised by prolonged, 
repetitive muscle contractions that may cause twisting or 
jerking movements. 
Gabellar reflexes The inability to resist blinking when the forehead (gabellar) is 
repetitively tapped. 
Postural instability This usually presents in the later stages of the disease and is 
the most common cause of fall related to PD. 
Non-Motor Symptoms Description 
Orthostatic hypotension Low blood pressure occurring when an individual stands up. 
Sweating dysfunction Excessive sweating (hyperhidrosis). 
Sphincter dysfunction This can lead to incontinence (the loss of regular control of 
bladder or bowel). 
Cognitive decline Studies have shown that that most patients diagnosed with 
PD have some degree of cognitive decline and are at a six-
time increased risk of developing dementia. 
Depression There is a high comorbidity between PD and depression      
(> 55%). 
Apathy A state of indifference (high prevalence in PD patients          
> 50%) 
Anxiety About 50% of patients develop anxiety. 
Hallucinations About 40% of patients report hallucinations. 
Impulse control disorders Some patients develop behaviour that may manifest as 
pathological gambling, hypersexuality, or compulsive 
shopping and binge eating; these are related to dopamine 
agonist therapy in particular. 
Excessive sleepiness Some patients may exhibit excessive daytime sleepiness; this 
can be caused or aggravated by dopaminergic therapy. 
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Rapid eye movement sleep 
behavioural disorder (RDB) 
Characterised by a tendency to talk or act out dreams. May be 
associated with an increase in violent dream content coupled 
with injurious motor activity. At least one third of patients 
exhibit this and it frequently presents in the pre-motor stages 
of PD. 
Insomnia About 50% of patients have fragmented sleep patterns. 
Paraesthesias A skin sensation, such as burning, prickling, itching, or 
tingling, with no apparent physical cause. 
Olfactory dysfunction Loss or altered sense of smell. Some individuals may 
experience olfactory hallucinations. 
Note: Information adapted from Jankovic (2008). 
 
2.3.1. Cognitive decline 
Cognitive decline is the most common non-motor feature of Parkinson’s disease. Cognitive 
impairments arguably have the greatest impact on a patient’s quality of life, their family and 
the health care system (Lawson et al., 2014; Leroi, McDonald, Pantula, & Harbishettar, 
2012). Parkinson’s disease with dementia (PDD) has been associated with early mortality 
(Lawson et al., 2014; Oosterveld et al., 2015). The issue facing PD patients is that at least 80-
90% of patients ultimately experience dementia (Aarsland, Andersen, Larsen, Lolk, & Kragh-
Sorensen, 2003; Hobson & Meara, 2015), though an individual’s time course to dementia is 
highly variable (2-25 years; Aarsland et al., 2003; Buter et al., 2008; Hely, Reid, Adena, 
Halliday, & Morris, 2008). Surprisingly, the recognition of cognitive impairment and its role 
within PD has only recently become center stage in the literature, primarily after longitudinal 
cohort studies were recently published. Another reason is that life span has increased, 
primarily due to more effective cardiovascular intervention. This has resulted in PD patient’s 





The highest risk factors for cognitive decline in PD are older age and severity of 
motor symptoms. Early decline in cognition, Parkinson’s disease with mild cognitive 
impairment (PD-MCI), is increasingly recognized as an important sign of future decline to 
PDD (Aarsland & Kurz, 2010; Dubois et al., 2007; Palavra, Naismith, & Lewis, 2013; 
Troster, 2011; Yarnall, Rochester, & Burn, 2013). Other risk factors include lower education, 
being male, REM sleep behaviour disorder (RBD), hallucinations, smoking and hypertension 
(Palavra et al., 2013; Xu, Yang, & Shang, 2016). 
PD-MCI is believed to be present in approximately one-in-three newly diagnosed 
patients (Lewis et al., 2003; Litvan et al., 2012), despite being considered an intermediate 
stage of cognition between ‘normal’ cognition in PD (PD-N) and PDD. This observation 
underscores the prevalence of cognitive impairment in PD. Cognitive impairment in PD can 
include any of the classic cognitive domains – attention, working memory, executive 
functioning, memory, language and visuospatial functioning. Thus, all cognitive domains 
should be assessed when determining if a patient is cognitively impaired (Dubois et al., 2007; 
Emre et al., 2007; Litvan et al., 2012). Diagnostic criteria for both PDD and PD-MCI have 
been proposed by the Movement Disorder Society Task Force (MDS-TF) and are used in 
both clinical and research settings (Dubois et al., 2007; Emre et al., 2007; Litvan et al., 2012). 
PD patients who do not meet either of these cognitive status criteria are deemed by exclusion 
to have ‘normal’ cognition for PD (PD-N). 
The CamPaIGN study was the first study to examine the evolution of PD from 
diagnosis in an unselected representative population of patients. They have consistently 
reported that impaired reproduction of the overlapping pentagons copy, age, poor semantic 
fluency performance, UPDRS motor scores 25 points or higher and the microtubule-
associated protein tau gene were all baseline predictors of future dementia up to 10-years 
19 
 
later (Foltynie, Brayne, Robbins, & Barker, 2004; Goris et al., 2007; Williams-Gray et al., 
2009; Williams-Gray et al., 2013). This group has also attempted to determine what the 
underlying processes are which result in the heterogeneity of cognitive impairment that is 
seen in PD patients. They suggest that there are two broad syndromes of cognitive 
impairment where (1) one syndrome results in frontal-striatal dysfunction causing cognitive 
impairments in planning, working memory and executive functioning and (2) the other 
syndrome is dominated by early deficits in semantic fluency and visuospatial functioning 
which rapidly declines to dementia (Kehagia, Barker, & Robbins, 2012). 
 Brain-related changes in PD have been shown to associate with cognitive decline in 
MRI studies. Hattori et al. (2012) found that decreases in fractional anisotropy (FA) – 
indicating white matter (WM) damage – related to MMSE scores. This decrease was 
particularly evident in the bilateral parietal WM. The authors claimed that the underlying 
cause of cognitive impairment in PD could be a result of the WM damage. They also suggest 
that as the degree of cognitive impairments worsens from PD-N to PD-MCI and finally to 
PDD, functional changes are seen in the early stages of cognitive decline and structural 
changes appear later.  These changes preceded grey matter (GM) atrophy and the authors 
hope that these changes could be useful at identifying early PD, possibly during the 
prodromal phase. Melzer et al. (2012) reported that GM loss correlated with global cognitive 
scores, even after accounting for motor impairment, sex, age, education and intracranial 
volume. This atrophy was mostly limited to the cortex, with clustering around the lateral-
frontal regions adjacent to the insula cortex and posterior regions of the brain. Changes in the 
cerebral metabolism have been found in positron-emission tomography (PET) studies which 
relate to cognition in PD. These include metabolic decreases in the dorsolateral prefrontal 
cortex, medial and superior parietal regions as well as the rostral supplementary motor area. 
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An increase was also found in the dentate nucleus region of the cerebellum (Eckert, Tang, & 
Eidelberg, 2007; Huang et al., 2007). 
2.3.1.1. PDD classification 
In 2007, the Movement Disorder Society Task Force (MDS-TF) developed diagnostic criteria 
for probable and possible PDD (Emre et al., 2007) and a two-level set of practical guidelines 
for diagnosis (Table 2-2; Dubois et al., 2007). A PDD classification requires significant 
cognitive impairment to be present in at least two cognitive domains, and can be supported by 
behavioural features (i.e. hallucinations or depression) but requires that the cognitive 
impairment, results in the individual’s inability to cope with everyday tasks. These new PDD 
criteria were found to be more sensitive than the diagnostic and statistical manual of mental 
disorders-IV criteria for diagnosing PDD (Martinez-Martin et al., 2011). A Level I PDD 
classification can be made on patients who would not cope with the cognitive demands of 
comprehensive testing required by Level II criteria or in a clinical setting where resources can 
restrict testing times (Dubois et al., 2007). Like the diagnostic criteria for PD itself, criteria 
for PDD classification mirror the same structure (i.e. probable PDD or possible PDD). The 
two different Levels of PDD diagnosis are outlined in Table 2-2. Both PDD criteria require 
an established PD diagnosis, cognitive deficits severe enough to interfere with daily life, and 
the presence of behavioural symptoms such as depression or anxiety. Furthermore, the Level 
I Dubois et al. (2007) criteria need evidence of motor symptom onset before the cognitive 
decline began. This is to rule out the existence of Dementia with Lewy bodies, where the 
cognitive impairment usually occurs around the same time as motor symptom onset. The 
abbreviated Level I criteria require a global cognitive measure, such as the MMSE, to show 
cognitive impairment (i.e. score <26) and evidence of cognitive impairment on at least two 
other brief cognitive assessments (i.e. MMSE pentagons or 3-word recall; Dubois et al., 
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2007). For a Level II diagnosis of PDD the dementia type symptoms need to have slowly 
developed, impairments must be severe, affecting at least one cognitive domain, and there 
needs to be evidence of premorbid decline in the individual’s functioning. In addition to these 
features, a probable PDD classification requires that both core features are present 
(established PD and progressive decline), at least one behavioural symptom, and cognitive 
impairment, when formally assessed and in everyday life. A possible PDD classification, 
however, only needs the two core symptoms, atypical cognitive impairment (i.e. storage-
failure type amnesia where cueing does not improve memory ability), but does not require the 
presence of behavioural symptoms (Emre et al., 2007). The Level I and Level II probable 
PDD criteria are very similar as both require cognitive and behavioural impairments, 
although the cognitive testing is much more robust when the Level II criteria are used, while 
the Level II possible PDD criteria do not require the presence of behavioural symptoms. 
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 Diagnosis of PD 
 A dementia syndrome with an insidious onset and a slow progression that 
develops within an established context of PD, where: 
o Impairments need to be present in at least one cognitive domain. 
o There is evidence of a decline from premorbid functioning 
o Deficits are severe enough to affect daily life (social, occupational or 
personal), but cannot be attributed to the patient’s motor impairments. 
Associated clinical features 
 Cognitive features of PDD include impaired performance on attentional, 
executive functional, visuospatial, memory and language-based tasks (both when 
formally assessed and in everyday life). 
 Behavioural features include apathy, changes in mood and personality, 
hallucinations, delusions and even excessive daytime sleepiness. 
Probable PDD classification 
 Both core features present 
 Associated clinical features including: 
o Cognitive decline where there is a presence of impairment in at least two 
cognitive domains 
o At least one behavioural symptom present 
Possible PDD classification 
 Both core features present 
 Associated clinical features: 
o Atypical cognitive impairment in one or more domains. 








































 A diagnosis of PD 
 PD developed prior to onset of dementia 
 MMSE < 26 
 Cognitive deficits severe enough to affect everyday living 
 Impairments in at least two of these scales: 
o Months reversed or sevens backwards 
o Lexical fluency or clock drawing 
o MMSE pentagons 
o 3-word recall 




o Excessive daytime sleepiness 




2.3.1.2. PD-MCI classification 
The concept of mild cognitive impairment (MCI) began in the Alzheimer’s disease (AD) 
literature, where it was initially used to indicate a measure of decline beyond an age-expected 
norm and in particular a decline in episodic memory. Today, it has evolved into a more 
general cognitive syndrome, in part due to the emphasis on biomarkers, which is used as both 
a clinical and a research diagnostic classification (Albert et al., 2011; Petersen et al., 2009). 
Most early studies reported that individuals who have amnestic MCI are more likely to 
develop AD than those with other sub-types of MCI (Petersen et al., 1999). Not every 
individual who is classified as MCI will progress to dementia, but the MCI construct does 
suggest that a continuum exists from normal age-related cognition through to dementia, such 
as AD or PDD. The MCI state therefore represents an intermediate or pre-clinical stage of 
cognitive decline. This MCI framework has since been applied to PD research, where PD-
MCI is defined as the transitional state between PD-N and PDD. Cognitive impairment is 
present but, unlike PDD, individuals experience no significant impact from this cognitive 
impairment on their ability to function in everyday life (Litvan et al., 2012). Studies have 
found that there is a higher, albeit variable, rate of progression to PDD in PD-MCI than non-
PD-MCI patients (19-62% vs 0-20%, respectively) when patients were followed for two to 
five years (Broeders, de Bie, et al., 2013; Janvin, Larsen, Aarsland, & Hugdahl, 2006; 
Pedersen, Larsen, Tysnes, & Alves, 2013). In a group of PD patients followed for 16 years, 
91% of those identified as PD-MCI eventually reached PDD. This was over four times the 
proportion of non-PD-MCI who progressed to PDD (Hobson & Meara, 2015). It is, however, 
difficult to directly compare these studies as each one used different diagnostic criteria to 
define their group of PD-MCI patients.  
The heterogeneous methods employed to define the cognitive status of “PD-MCI” 
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have led to substantial variation in the percentage of patients so classified (Aarsland et al., 
2010; Dalrymple-Alford et al., 2011; Goldman et al., 2013; Janvin et al., 2006; Liepelt-
Scarfone et al., 2011), where anywhere from 10-90% of patients in a given sample can be 
classified as PD-MCI, simply by applying different PD-MCI criteria to the same group of 
patients. Using non-dementing PD patients from the NZBRI cohort, I extended the dot plot 
from Dalrymple-Alford et al. (2011) where parameters of the PD-MCI criteria were varied to 
illustrate theses diagnostic problems (Figure 2-6) by separating the patients within each group 
who developed PDD within the four-year follow-up period from those who did not develop 
PDD. Clearly, not all PD-MCI criteria are sensitive to capturing patients at risk of 
progression to PDD. This issue forms the basis for the study described in Chapter 3. 
 
Figure 2-6. Global cognitive scores of PD patients who have been classified as PD-MCI or 
PD-N based on different allowable parameters of MDS-TF PD-MCI Level II criteria.  All 
non-dementing patients at study entry are shown on the left panel (converters to PDD are 
shown as red dots). Baseline scores as a function of the six PD-MCI criteria are displayed on 
the subsequent panels along the x-axis, with the percentage of patients classified as PD-MCI 
varying markedly (79% to 21%). We see that as the cut-off score become more stringent (i.e. 
2SD) fewer patients classify as PD-MCI, whereas when the cut-off is more lenient (i.e.1SD) 
more patients are classified as PD-MCI. The similar pattern emerges when the location of 
tests impairments is restricted to two or more impairments only within a cognitive domain 
(fewer patients meet the PD-MCI criterion) vs. one impairment in each of two or more 
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cognitive domains (larger proportions of patients meet the PD-MCI criterion) across cut-off 
variants. When progression to PDD within the next four-years is considered (red dots 
represent patients who convert) when criterions require more stringent cut-off scores and 
restrict impairments to both occur in the same cognitive domain (i.e. ‘2 @ 2SD in 1 
domain’), there is a high proportion of patients who convert to PDD in the PD-MCI group, 
but a large number of converts are not captured by this criterion. The opposite occurs when a 
criterion with more lenient cut-off scores is employed (i.e. ‘1 @ 1SD in 2 domains’), here 
almost all of the converters to PDD are captured by the criterion, but there is a very high 
false positive rate. 
PD-N, normal cognition, not meeting the relevant MCI criteria;  
PD-MCI, mild cognitive impairment for the relevant MCI criteria. For example, “1 @ 1SD in 
2 domains” represents a deficit score of -1SD in at least 1 test in each of two cognitive 
domains. 
 
To guide the research field, standardised diagnostic criteria were proposed by the 
Movement Disorder Society PD-MCI Task Force (MDS-TF; Litvan et al., 2012). The Task 
Force’s Level I criteria permit the use of global cognition scales or an abbreviated 
neuropsychological assessment that includes fewer than two tests in each of five cognitive 
domains (attention/working memory; executive function; episodic memory; visuoperceptual/ 
visuospatial function; language) or assessment of less than five cognitive domains (Table 
2-3). The more comprehensive (Level II) criteria require the application of at least two tests 
in each of the five cognitive domains. PD-MCI is established when any two (or more) 
impaired neuropsychological test scores are present, but everyday function is generally 
preserved.  Nonetheless, the Level II PD-MCI recommendations still allow for variations 
within the permitted PD-MCI criteria, such as cut-off scores to define an impaired score 
being free to range from 1SD to 2SD below normative data, in part to account for the 
interpretation of a decline from premorbid levels. Additionally, the maximum number of tests 
permitted per cognitive domain is not defined. Lastly, both test impairments are permitted to 
occur within a single cognitive domain, or can occur across two or more cognitive domains 
(Figure 2-7; Litvan et al., 2012). This variation can result in differences as PD-MCI 
criterions which require that more than one test be impaired within a single cognitive domain 
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have a stricter statistical threshold. This stricter threshold reduces the likelihood of false 
alarms (i.e. patients who are not declining towards PDD to be classified as PD-MCI) but the 
trade-off is lower sensitivity to impairments. The MDS-TF found that about 27% of PD 
patients met their criteria for PD-MCI. Both the Level I and Level II PD-MCI criteria 
outlined in Table 2-3 require a clinically-established PD diagnosis and gradual cognitive 
decline that is attributed to the underlying disease processes rather than to any other cause. 
The cognitive decline can be reported by the patient, their significant other or a clinician and 
must not be severe enough to interfere with the patient’s functional independence. 

























Level I PD-MCI classification requires ONE of the below: 
 Impairment on a global cognitive scale validated for use in PD (i.e. 
MoCA). 
 Impairment on at least two tests, when a limited test battery is 
preformed (i.e. fewer than five cognitive domains assessed or when 





























 At least two tests assessed within each of five cognitive domains 
(attention, executive function, visuospatial, memory and language). 
 Impairment on at least two of these tests (can be two tests within a 
single cognitive domain or across more than one cognitive domain). 
  Impairments on neuropsychological testing is demonstrated via ONE 
of the below: 
o Performance between 1SD – 2SD below normative data 
o Significant decline on serial cognitive testing 







































 PD-MCI-single-domain: at least two impaired test scores that occur 
within a single cognitive domain, with other cognitive domains 
remaining unimpaired (specify the domain). 
 PD-MCI-multiple-domains: the two impaired test scores occur on at 
least one test in two or more cognitive domains (specify the 
domains). 





Figure 2-7. Illustration of where impairments can occur within MDS-TF PD-MCI Level II 
criteria. (A) Two or more test impairments must occur within one or more cognitive domain. 
(B) Two or more test impairments can occur, across any number of cognitive domains. 
 
2.3.2. Neuropsychiatric symptoms  
PD has an extremely high comorbidity with neuropsychiatric conditions, with up to 90% of 
patients experiencing at least one symptom such as depression, apathy or hallucinations 
during their disease course (Aarsland et al., 1999; Brown & MacCarthy, 1990; Chaudhuri & 
Schapira, 2009; Emre et al., 2007; Kulisevsky, Pagonabarraga, Pascual-Sedano, García-
Sánchez, & Gironell, 2008; Lee & Weintraub, 2012; Marsh, 2000; Pedersen, Alves, 
Aarsland, & Larsen, 2009; Poewe et al., 2008; Riedel et al., 2010).  Those with PDD 
experience the highest rates of neuropsychiatric symptoms (Aarsland et al., 2007; Bronnick, 




with hallucinations and delusions are all prevalent in PDD (Emre et al., 2007; Marsh, 2000; 
Poewe et al., 2008). Neuropsychiatric symptoms have been identified as one of the 
precipitating factors for nursing home placement, as it is often too difficult and upsetting for 
family members to adequately care for such unpredictable individuals at home (Aarsland et 
al., 2010). The relationship between neuropsychiatric symptoms and progression to PDD will 
be further discussed in Chapter 6. 
2.4. Management and treatment of PD 
PD is difficult to manage because of its extremely variable presentation and progressive 
nature. Consequently, patient management is not standardised but tailored to individual 
patients and their needs (Guttman, Kish, & Furukawa, 2003). There is no cure and symptoms 
have to be managed as they occur, so as to provide the individual with the best possible 
quality of life. Treatment is thus symptomatic and varies between patients, depending on their 
disease progression and its interference with their daily life. It is best managed in a 
multidisciplinary setting, where all aspects of the disorder can be addressed together, 
including both motor and non-motor complications (Massano & Bhatia, 2012). Management 
is aimed at maximising an individual’s quality of life so as to function as normally as 
possible, but at the same time minimising side-effects from treatment (Guttman et al., 2003; 
Massano & Bhatia, 2012). There are a variety of medications – including levodopa and 
dopamine agonists available for managing the motor symptoms, as well as physiotherapy 
and, in appropriate cases, surgical therapies such as deep brain stimulation (Fox et al., 2011). 
Clinicians must continually re-evaluate patients to assess whether the treatment goals are 
being met and to monitor side-effects. Changes are therefore made when needed to enable the 
patient to function as normally as possible (Guttman et al., 2003). Treatment-related events 
include wearing-off, dyskinesia, on-off fluctuations and psychiatric manifestations. Levodopa 
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is still the most effective medication for controlling motor symptoms of PD and these positive 
effects on movement have been proven to last years (Schapira, Emre, Jenner, & Poewe, 
2009). Dopaminergic treatments (levodopa and dopamine agonists) are useful for treating 
some non-motor symptoms of PD, but in specific cases can exacerbate other symptoms, such 
as cognitive impairment, excessive daytime sleepiness, as well as precipitating impulse 
control disorders (Antonini, Tolosa, Mizuno, Yamamoto, & Poewe, 2009). Dementia in PD is 
frequently treated with cholinesterase inhibitors (Emre et al., 2010; Truong, Bhidayasiri, & 
Wolters, 2008), such as donepezil or rivastigmine (both are funded medications in New 
Zealand) or memantine which is unavailable in New Zealand, as cholinergic deficits are 
thought to be more pronounced in PDD than in Alzheimer's disease (Emre  et al., 2004; Leroi 
et al., 2004). However mild cognitive impairment prior to dementia in PD is usually not 
treated (Emre, Ford, Bilgic, & Uc, 2014). 
2.5. Summary 
PD is a complex, multisystem neurodegenerative disorder that over time affects nearly every 
brain region. Symptoms experienced can be both motor and non-motor, which together can 
have a crippling effect on a patient’s quality of life. There is no cure, so treatments are 
symptomatic and need to be continually re-assessed due to the evolving nature of PD. 
Psychiatric symptoms such as anxiety, hallucinations, depression and especially cognitive 
decline are common. Dementia (PDD) ultimately occurs in nearly 90% of patients and is a 
source of considerable burden to patients, families and the health system. It is therefore 
pertinent to have early indicators of imminent progression to PDD, particularly if/when a 
preventative therapy because available. In this thesis, I will (1) validate whether the several 
allowable variation in the PD-MCI Level II criteria permitted by the MDS-TF have the ability 
to capture patients at high risk of developing dementia (PDD) within a four-year follow-up 
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period, (2) determine whether a reduced neuropsychological test battery, but one which still 
meets Level II PD-MCI criteria, can be effective for identifying patients who have a high risk 
of developing PDD and (3) examine the relationship between neuropsychiatric symptoms and 
progression to PDD. The overall aim is to provide markers of early cognitive decline which 
can be applied not only in the selection of enriched patient samples for future intervention 
studies developed in the future but also in the clinic. 
2.6. Study aims and hypotheses 
This thesis looks to validate the MDS-TF PD-MCI criteria in terms of their ability to capture 
patients at high risk of dementia, by applying different variants of the accepted PD-MCI 
criteria to a four-year longitudinal PD cohort who live in the Canterbury region of New 
Zealand. It is expected that when different cut-off thresholds (SD) are applied to a cohort of 
patients each specific PD-MCI criterion will capture a different proportion of patients. 
Criterion’s which require more stringent impairment cut-off (i.e. 2SD) will capture fewer 
patients where as more lenient impairment cut-off scores (i.e. 1SD) will capture the majority 
of patients (Figure 2-6). When considering the PD-MCI criteria in terms of their ability to 
identify patient’s at-risk of developing PDD within the next four-years, it is a balance of 
trading sensitivity of the specific criterion (i.e. ensuring patients who develop PDD are 
classified as PD-MCI) for sensitivity to progression to PDD (i.e. minimising the number of 
false positives). Furthermore, additional variance will occur when the location of the two 
required impairments for PD-MCI classification are restricted to only occur with a cognitive 





The Thesis chapters will assess: 
1. The influence of different permitted impairment cut-off scores on relative rates of 
dementia in patients classified as PD-MCI at each cut-off level (i.e. the two impaired 
scores falling at -1SD, -1.5SD or -2SD below normative data). We hypothesised that the 
risk of PDD will differ across the three impairment level cut-off scores in PD-MCI (-1SD, 
-1.5SD and -2 SD) permitted by the MDS-TF recommendations within a defined four-
year follow-up period (Chapter 3). 
2. Whether there is a difference in relative risk of PDD in PD-MCI patients who have their 
impairments falling in a single cognitive domain or across multiple cognitive domains 
(but never in the same domain). We hypothesised that when the two impaired test scores 
occur within a single cognitive domain there would be a higher risk of PDD in this PD-
MCI group compared to the PD-MCI group defined by two impaired test scores which are 
instead spread across different cognitive domains (but never occur within the same 
domain; Chapter 3). 
3. Whether the neuropsychological test battery can be reduced to 10 neuropsychological 
tests and determine if this abbreviated test battery is still able to identify patients at a high 
risk of developing PDD. We hypotheses that when a reduced 10 neuropsychological test 
battery consisting of tests sensitive to progression to PDD, patients classified as PD-MCI 
will be at-risk of developing PDD four-years later. We expect that a relaxed PD-MCI 
where impairments are not restricted to occur only within or across cognitive domains 
could now be employed when a 10 neuropsychological test battery is used (Chapter 4+5). 
4. The relationship the relationship between neuropsychiatric symptoms and future 
progression to PDD. We hypotheses that some neuropsychiatric symptoms, particularly 
hallucinations and depression, will have a strong relationship to progression to PDD, 
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while others will not. We also anticipate that when compared to know predictors of future 
PDD, neuropsychiatric symptoms will not be as informative (Chapter 6). 
All aspects of this study will look at progression to PDD over a four-year period, which is a 
clinically relative period of time, when considering utility of PD-MCI criteria in future 
clinical intervention or therapy trials (Eberling et al., 2014). 
The studies in this thesis utilise a sub-sample of patients from the New Zealand Brain 
Research Institute’s Parkinson’s disease cohort. In Chapters 3 and 4 a sub-sample of 121 non-
dementing PD patients are analysed. In Chapter 5, the same sub-sample of 121PD patients are 
assessed plus an additional 17 PD patients, who have now been followed-up for four-years. In 
Chapter 6, 77 PD-N, 46 PD-MCI and 35 PDD patients were included in this study, with the 
majority of the non-demented PD patients having been included in the analysis of the 
previous 3 Chapters. 
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 Cognitive criteria and progression to PDD Chapter 3:
3.1. Background 
In Parkinson’s disease (PD), cognitive impairment and other non-motor symptoms have a 
greater impact on quality of life than do motor symptoms and are associated with early 
mortality (Lawson et al., 2014; Oosterveld et al., 2015). Some 60% of patients may develop 
dementia (PDD) within 12 years of their motor symptoms and over 80% ultimately reach 
PDD, although an individual’s time course to dementia is highly variable (Aarsland et al., 
2003; Buter et al., 2008; Hely et al., 2008). Risk factors include older age and severity of 
motor symptoms,
 
but recognition of early cognitive impairment is particularly important 
(Aarsland & Kurz, 2010; Palavra et al., 2013; Troster, 2011; Yarnall et al., 2013). Recently, 
studies have examined the progression to PDD from mild cognitive impairment (PD-MCI). 
While specific findings are variable, more PD-MCI patients than non-PD-MCI patients 
progress to PDD (19-62% vs 0-20%, respectively) when followed two to five years after 
showing PD-MCI (Broeders, de Bie, et al., 2013; Janvin et al., 2006; Pedersen et al., 2013). 
In a cohort that was followed for 16 years, 91% of PD-MCI patients reached PDD, over four 
times that of the non-PD-MCI patients (Hobson & Meara, 2015).
 
It is difficult to compare 
these studies however, as each used different diagnostic criteria to define PD-MCI. 
The heterogeneous methods to ascertain PD-MCI has led to substantial variation in 
the percentage of patients classified as PD-MCI (Aarsland et al., 2010; Dalrymple-Alford et 
al., 2011; Goldman et al., 2013; Janvin et al., 2006; Liepelt-Scarfone et al., 2011). To address 
this situation, standardized diagnostic criteria were proposed by the Movement Disorder 
Society PD-MCI Task Force (MDS-TF) (Litvan et al., 2012). The Task Force’s Level I 
criteria permit the use of global cognition scales or an abbreviated neuropsychological 
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assessment that includes fewer than two tests in each of five cognitive domains 
(attention/working memory; executive function; episodic memory; 
visuoperceptual/visuospatial function; language) or less than five cognitive domains assessed.  
More specific, comprehensive (Level II) criteria require the use of more than one test in each 
of the cognitive domains and PD-MCI is confirmed when any two (or more) impaired 
neuropsychological test scores are present but everyday function is generally preserved.  
Nonetheless, the Level II recommendations still permit several alternative criteria, for 
example, cut-offs ranging 1SD-2SD below normative data to define an impaired score 
(Litvan et al., 2012). 
We hypothesized that the risk of progression to PDD differs across three common cut-
off variants for PD-MCI (1SD, 1.5SD and 2 SD) permitted by the MDS-TF 
recommendations. Moreover, the high probability of eventual PDD for all patients means that 
the validity of PD-MCI criteria should be determined by whether they detect patients at 
increased risk of PDD within a defined period of time. Here, we specified a four-year 
window as a suitable period of time because we considered this relevant for the use of PD-
MCI in both clinical practice and potential therapeutic interventions (Eberling et al., 2014). 
There is, however, a second important issue that has also not been addressed: does the 
distribution of impaired scores across cognitive domains influence the risk of conversion to 
dementia? On the basis of evidence from the non-PD literature on MCI (Jak et al., 2009; 
Teng, Tingus, Lu, & Cummings, 2009), we hypothesized that having the minimum of two 
impaired test scores within a single cognitive domain would result in a higher risk of PDD 







A convenience sample of 184 PD patients was recruited from our research institute and 
movement disorders clinic. Comparison of the rate of progression to PDD in this sample was 
made by recruiting 54 age-, sex-, and education-similar healthy controls who volunteered in 
response to community advertisements and did not report subjective cognitive complaints. 
Figure 3-1 shows recruitment, exclusions, and retention of participants (Bossuyt et al., 2003), 
which resulted in a final followed-up sample of 121 PD patients, none of whom met PDD 
criteria (Emre et al., 2007) at baseline, and 36 controls. Patients were diagnosed using the UK 
Parkinson’s Society criteria (Hughes et al., 1992) and had motor symptoms present for at 
least 1 year at study entry (mean symptom duration = 6 years, SD = 4 years) to minimize the 
inclusion of those with dementia with Lewy bodies. Atypical parkinsonian disorder, other 
medical conditions (e.g. history of moderate/severe head injury, stroke, early-life learning 
disability, major psychiatric or medical illness in the previous six months), poor English 
(precluding testing) were exclusion criteria. Patients were also excluded at baseline if they 
had Parkinson’s disease with dementia (Emre et al., 2007). A PDD diagnosis at any point in 
the study required the presence of significant impairments (2SD below normative data) in at 
least two of five cognitive domains, plus evidence of significant impairment in everyday 
functional activities, not attributed to motor impairments. Everyday function was assessed 
from interviews with a significant other, based on evidence obtained from the Reisberg 
IADL-scale, Clinical Dementia Rating and Global Deterioration Scale to attribute non-
dementia status or PDD (Morris, 1993; Reisberg et al., 2008).
 
 Direct evidence from a 
significant other was not available, at baseline only, in 39 PD patients. However, we 
confirmed baseline non-dementia status in these cases from contemporaneous clinical notes 
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and from detailed patient interview by an experienced examiner, followed by consensus 
discussion. 
 
Figure 3-1. Participant recruitment, exclusions and total followed over 4 years. 
PD = Parkinson’s disease; PDD = Parkinson’s disease with dementia. 
a
 Assessments were conducted at baseline and every one to two years; patients with dementia 
were not followed further. 
 
Comprehensive neuropsychological assessments fulfilling the MDS-TF Level II 
requirements for PD-MCI (for tests see below) (Litvan et al., 2012) were undertaken at study 
entry and subsequently every one to two years, for up to 3.5–4.5 years later (mean = 46 
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months, SD = 8 months). Progression to PDD before the end of the 4.5-year period was 
treated as an a priori end-point, with no further follow-up. All participants took their usual 
medications on the day of testing to allow optimal performance during the morning test 
sessions. The study was approved by a local ethics committee of the New Zealand Ministry 
of Health, with informed consent provided by all participants. 
3.2.2. Neuropsychological assessment 
Five cognitive domains were examined, with tests conducted over two sessions (Dalrymple-
Alford et al., 2011; Lezak, Howieson, Bigler, & Tranel, 2012; Strauss, Sherman, & Spreen, 
2006).
 
Executive function was assessed using Stroop interference, letter fluency, category 
fluency and category switching (from the Delis-Kaplan Executive Function System (Delis, 
Kaplan, & Kramer, 2001a)), and action fluency and Trails B. Attention, working memory and 
processing speed was evaluated using digits forwards/backwards, digit ordering, map search 
task (from the Test of Everyday Attention), Stroop color reading, Stroop word reading, and 
Trails A. Episodic memory was measured with the California Verbal Language Test-II Short 
Form (CVLT-II SF; acquisition, short and long delays), and the Rey Complex Figure Test 
(RCF test; short and long delays); impairment in either or both delay components of each 
episodic memory test counted as one impairment. Visuoperceptual/visuospatial performance 
was determined using judgment of line orientation (JLO), fragmented letters test, the picture 
completion test and the RCF-Copy. Language was assessed using the Boston Naming Test, 
Dementia Rating Scale-2 (DRS-2) similarities sub-test, and the language component of the 
Alzheimer’s Dementia Assessment Cognitive Scale (ADAS-Cog; object and finger naming, 
commands, comprehension, spoken language and word finding difficulties). Scoring of the 
neuropsychological tests was conducted using age- and education-adjusted normative data. 
Participants also completed the Montreal Cognitive Assessment (MoCA). 
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3.2.3. Application of PD-MCI criteria 
There were two phases to the analysis. In Part One, we applied three commonly used and 
accepted PD-MCI cut-off criteria to examine their association with risk of progression to 
PDD, irrespective of whether the minimum of two impairments occurred within a cognitive 
domain or across different cognitive domains. In Part Two, we examined the additional issue 
of the distribution of impairments across cognitive domains, focusing on the optimal cut-off 
criterion resulting from the analysis in Part One. That is, we again determined risk of 
progression with a minimum requirement of two impairments, but first with both 
impairments within a single cognitive domain and then when there was only one impairment 
in each of two or more cognitive domains. 
3.2.3.1. Part One: Application of PD-MCI criteria 
In order to test the unique contribution of each PD-MCI criterion, we generated three 
mutually exclusive groups of PD-MCI patients using a step-wise process. The three primary 
SD cut-off scores were applied sequentially to signify impairment on any test measure 
(Figure 3-2A). First, we identified patients who had two scores that were 2SD or more below 
normative data, then we identified from the remainder those with two scores that were 1.5SD 
but better than 2SD below normative data, and lastly those with two scores that were 1SD but 
better than 1.5SD below normative data. Thus, each PD-MCI group in Part One consisted of 
an independent and discrete sample of patients for analysis purposes. In clinical practice, any 
patient who met a 2SD criterion would also by definition meet the 1.5SD or 1SD criterion 
(and similarly those meeting 1.5SD also exceed the 1SD criterion). It is important for the 
purpose of comparing the effectiveness of the cut-offs, however, that groups of patients 
classified under each criterion be mutually exclusive. For example, the effectiveness of the 
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1.5SD criterion cannot be meaningfully compared to the 2SD criterion if both capture 
overlapping groups of subjects. Thus, once a patient was identified as PD-MCI (for example 
under the 2SD criterion), they were excluded from the next step in the analysis so that 
effectiveness of a criterion was not influenced by the more severely impaired patients who 
would also be captured by a more stringent criterion. That is, we began by applying the 2SD 
criterion at baseline to all of the 121 non-dementing patients. The risk of progression to PDD 
was evaluated in this PD-MCI group relative to the remainder of the PD patients. This 2SD 
PD-MCI group was then excluded and, using only the remaining patients, the risk of PDD in 
patients who met the 1.5SD PD-MCI cut-off relative to those not meeting the 1.5SD criterion 
was determined. This 1.5SD PD-MCI group was in turn also excluded and the remaining 
sample reassessed. This final sample was used to assess the risk of PDD in patients now 
meeting only the 1SD cut-off relative to the risk in the remaining patients who did not meet 
any of the PD-MCI criteria at baseline. Following the MDS-TF recommendations, the 
minimum of two impairments at the cut-off required for any given criterion could appear 
anywhere within, or across, the five cognitive domains assessed. 
3.2.3.2. Part Two: Application of PD-MCI criteria 
The second part of the analysis was different in that it examined the influence of whether the 
minimum of two impaired scores occurred either within one cognitive domain or across two 
different cognitive domains. Impairments beyond two deficits did not change these 
allocations. This approach was used only for the optimal cut-off score (1.5SD), as determined 
by Part One (Figure 3-2). Here, we once more began with the entire followed-up sample and 
again followed a stepwise approach so that each PD-MCI group consisted of a discrete 
(independent) sample of patients. We first identified all patients with a minimum of two 
impairments at 1.5SD within a single cognitive domain at baseline (that is, all patients from 
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the entire sample of 121 patients who had two or more scores at or worse than the 1.5SD cut-
off score) and determined the risk of dementia within this group of PD-MCI patients relative 
to those who did not meet this criterion. Those meeting that criterion were then discarded. 
The remaining patients were then assessed by comparing risk in those patients who had the 
minimum of two impairments at the cut-off score of 1.5SD but the two impairments never 
occurred within a single cognitive domain (i.e. at least two cognitive domains each had a 
maximum of one impaired score) relative to the remaining patients who did not meet either of 
these two PD-MCI criteria. As any patient with multiple impairments within a single 
cognitive domain had been excluded in the previous stage, by definition this latter PD-MCI 
group all had only one impaired score within any one cognitive domain. In clinical practice, 
this second more relaxed 1.5SD criterion would also capture those with multiple impairments 




Figure 3-2. Allocation of non-dementing PD patients at baseline to different PD-MCI groups 
in Part One (using 2SD, 1.5SD and 1SD cut-off scores, respectively) and Part Two 
(alternative PD-MCI criteria for 1.5SD).  




3.2.4. Statistical analysis 
Confidence intervals for relative risk of PDD in each comparison were determined using 
bootstrap methods (Efron, 1979). In this procedure, statistical samples were generated by 
resampling with replacement from the parent sample under study and a relative risk 
calculated. This resampling was repeated 5000 times, resulting in an empirical distribution 
for the relative risk for the comparison in question. Permutation tests were used to derive 
exact p-values. The code and data used in this analysis is available upon request. 
3.3. Results 
3.3.1. Participants 
The mean patient age at baseline was 66 years (SD = 8 years). Table 3-1 summarizes the 
demographics and neuropsychological data of the patients and healthy control group at 
baseline. There was a 21% conversion rate to dementia for the PD patients in the four-year 
period (14 men and 11 women; 25 out of 121 patients). As expected, patients who later 
converted to PDD were older, had longer symptom duration, and worse motor symptoms, 
neuropsychological and functional measures at baseline than patients who did not convert to 
PDD. At baseline, 26 out of the 121 non-demented patients experienced hallucinations. A 
greater proportion of converters (13 vs. 12; 52%) relative to non-converters (13 vs. 83; 14%) 
experienced hallucinations at baseline (chi-square = 17.39, p < 0.0001; Table 3-1). Fifteen of 
the 25 patients (60%) who converted to PDD experienced hallucinations at the time of 
conversion, whereas only 24 of the 96 non-converters experienced hallucination at their last 
assessment (chi-square = 11.12, p < 0.001). Relatively few patients (9 out of 121) received 
medication that may affect their cognitive performance during the study. At baseline, only 
one patient who did not convert to PDD at follow-up was on antipsychotic medication and 
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one that did convert to PDD was receiving rivastigmine. Neither of these patients remained 
on these medications at their follow-up assessments. At follow-up, seven patients were on 
medication that could affect their cognition. Six of these seven patients were on antipsychotic 
medication (three of whom had progressed to PDD), and three were receiving donepezil (one 




Table 3-1. Demographics and neuropsychological data at study entry [mean (SD)] 
 Controls Non-converters to PDD Converted to PDD 
Sample size 36 96 25 
Sex, M:F 25:11 63:33 14:11 
Age 67.5 (8.6) 64.3 (8.2) 70.2 (5.7)
c 
Education (y) 13.7 (2.7) 13.1 (2.7) 12.5 (2.8) 
Premorbid IQ (WTAR) 112 (10.0) 111 (8.0) 109 (8.2) 





Reisberg IADL 0.2 (0.2) 0.4 (0.4) 1.1 (0.6)
b,c 
DRS-2 (AESS) 12.8 (2.1) 11.7 (2.0) 10.7 (2.1)
b 
ADAS-Cog 5.1 (2.1) 6.6 (2.9) 10.0 (2.5)
b 
Symptom duration (y)  5.3 (4.0) 7.8 (5.0)
c 
Hoehn and Yahr stage  1.9 (0.6) 2.5 (0.7)
c 
UPDRS (Motor)  31.4 (16.2) 40.7 (15.4)
c 
MoCA 26.9 (2.0) 26.1 (2.5) 23.6 (2.5)
b,c
 




1. Executive function  0.73 (0.56) 0.12 (0.71)b -0.81 (0.64)b,c 
2. Attention, working 
memory & processing 
speed  




3. Episodic memory 0.95 (0.81) 0.06 (0.88)b -1.05 (0.69)b,c 
4. Visuoperceptual/ 
visuospatial 




5. Languagea -0.07 (0.44) 0.12 (0.45) -0.36 (0.50)c 
Abbreviations: PDD = Patients who met Level II criteria for Parkinson disease with 
dementia; 1-5 = mean Z scores in each cognitive domain; Global Z score = mean derived 
from domains 1-4; ADAS-Cog = Alzheimer’s Dementia Assessment Scale-Cognitive; CDR = 
Clinical Dementia Rating; DRS-2 (AESS) = Dementia Rating Scale-2 (Age and Education 
Scaled Score); IADL = Instrumental Activities of Daily Living; MoCA = Montreal Cognitive 
Assessment; UPDRS (Motor) = Unified Parkinson’s Disease Rating Scale (Motor 
Component); WTAR = Wechsler Test of Adult Reading for premorbid IQ. 
a
 eight controls and 37 PD patients did not have language measures at baseline. 
b
 significantly different to controls, Tukey post hoc tests, p<0.05; 
c




3.3.2. Part One: Comparison of progression to PDD from PD-MCI defined by three cut-
offs 
3.3.2.1. Risk of PDD 
The first stage of analysis showed that the 46 patients classified as PD-MCI using the 2SD 
cut-off had a significantly higher risk of progression to PDD than the remaining 75 PD 
patients (Relative Risk, RR = 4.2, CI 2.2-10.1, p < 0.0001; Table 3-2). A similar finding was 
evident in the 10 patients missed by the 2SD classification but defined as PD-MCI using the 
1.5SD cut-off (RR = 4.9, CI 1.4-15.1, p = 0.005). By contrast, the additional group of 40 
patients classified as PD-MCI using the 1SD cut-off criterion did not show a significantly 
greater risk of PDD progression than the remaining 25 patients not classified as PD-MCI 
under any of these three initial criteria (RR = 1.9, CI 0.3-4.3, p = 0.13).  
3.3.2.2. Reversions from PD-MCI 
Under each criterion, there were individuals who at their latest follow-up were classified as 
reverting to a non-PD-MCI status (i.e. to relatively “normal” cognition under that criterion). 
For the 2SD cut-off, 20% (9/46) of patients had reverted to a non-PD-MCI status at their last 
assessment (i.e. no longer having two impairments below 2SD). Of these nine reverters, 
seven had scores that also remained below a 1.5SD cut-off, but no longer met the 2SD cut-
off.  There was just one reversion in the extra 10 patients identified as PD-MCI under the 
1.5SD criterion (i.e. in the group whose baseline scores reached the 1.5SD cut-off but not the 
2SD cut-off). The reversion rate in the group of patients who met only the 1SD criterion was 
20% (8/40).  
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Table 3-2. Conversion to PDD and reversion to non-PD-MCI status 
Criteria 
Three primary PD-MCI criteria 
Two alternative 1.5SD  
PD-MCI criteria 
2SD 1.5SD 1SD 
2 in 1 domain
 













































































Abbreviations: 95% CI = Confidence interval of relative risk; PDD = Parkinson disease 
patients who met Level II criteria for Parkinson disease with dementia at follow-up; PD-MCI 
= Parkinson disease patients with mild cognitive impairment at baseline; non-PD-MCI = 
patients not meeting the PD-MCI criterion. 
a
 Additional PD-MCI patients captured by the 1.5SD cut-off score, excluding the 46 who had 
already met the more stringent 2SD cut-off. 
b
 Additional PD-MCI patients captured by the 1SD cut-off score, excluding the 56 who had 
already met the more stringent 2SD and 1.5SD cut-offs. 
c
 PD-MCI patients, within the whole sample of 121 at baseline, who met the criterion of 
having two impairments at 1.5SD within a single cognitive domain. 
d
 Additional PD-MCI patients captured by this cut-off score excluding those who had already 
met the two impairments in one cognitive domain criterion. 
e
 Incidence rate in PD-MCI group divided by the incidence rate in the non-PD-MCI group, 
which is statistically significant when the lower bound of the CI is greater than 1. 
f
 The number of PD patients reverting back to normal cognition rather than remaining PD-
MCI or progressing to PDD, according to the PD-MCI cut-off criterion being examined. 
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3.3.2.3. Healthy control group Unlike the PD sample, none of the matched control group 
converted to dementia during the follow-up period. Only one control participant met the 2SD 
criterion at baseline (showing one impairment within each of two cognitive domains), two 
met the 1.5SD criterion (each showing one impairment within each of two cognitive 
domains) and 12 met the 1SD criterion for MCI. By the end of the four-year follow-up, 
however, the first control was no longer classified as MCI under the 2SD criterion (having 
one impairment within each of two cognitive domains, but now at 1.5SD) while the two who 
had met the 1.5SD criterion and six of those who had met the 1SD criterion no longer met 
any MCI criterion.  
3.3.3. Part Two: Influence of the distribution of impaired scores within or across cognitive 
domains 
 The analysis in Part One led us to select the 1.5SD cut-off as optimal for the second phase of 
analysis. The reason for this selection was that (1) the 1SD criterion failed to identify an 
increased risk of progression to PDD, (2) a similar RR of conversion to PDD was found for 
both the 2SD and 1.5SD criteria, (3) the reversion rate was lower in the 1.5SD criterion, and 
(4) combining the 2SD and 1.5 SD groups captured a greater percent of converters to PDD. 
We therefore re-examined the entire sample of followed patients to look at the influence of 
the distribution of impaired scores at baseline (that is, using all patients meeting a 1.5SD 
criterion, including those meeting a 2SD cut-off at baseline). The focus here was first to 
determine the relative risk of PDD when two (or more) impairments at 1.5SD were present 
within a single cognitive domain. We then examined risk when only a single impairment at 
1.5SD was evident across at least two cognitive domains (that is, never two impairments 
within any one cognitive domain, but rather just one impairment at 1.5SD in each of two or 
more cognitive domains). Of course, all of the PD-MCI patients classified using the 2SD 
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criterion by definition also met one of these 1.5SD criteria.  
3.3.3.1. PD-MCI at 1.5SD with two impairments within a single cognitive domain 
The group of 37 patients classified as PD-MCI at baseline using the criterion of two 
impairments at 1.5SD in one cognitive domain (of whom 51% converted to PDD), had a high 
relative risk of progression to PDD compared to 84 patients (of whom 7% converted to PDD) 
who did not meet this criterion (RR = 7.2, CI 3.4-16.6, p < 0.0001; Table 3-2; 76% of all 
conversions to PDD). This risk was not influenced solely by the subgroup of patients (n = 26; 
54% converted to PDD) who showed two impairments at 2SD within a single cognitive 
domain (RR = 4.7, CI 2.4-8.7, p < 0.0001), because the relative risk of the remaining 
subgroup of patients (n = 11; 45% converted to PDD) with two impairments at 1.5SD (but 
not 2SD) in one cognitive domain was also high (RR = 6.4, CI 2.2-15.6, p = 0.0001).  
3.3.3.2. PD-MCI at 1.5SD with a maximum of one impairment in each of two cognitive 
domains 
The additional group of 19 patients classified as PD-MCI using the criterion of only one 
impairment at 1.5SD in each of two (or more) cognitive domains (of whom 11% converted to 
PDD) did not show a significantly increased risk of progressing to PDD compared to the 
remainder of PD patients (RR = 1.7, CI 0.5-7.4, p = 0.13). 
3.3.3.3. Reversions from PD-MCI at 1.5SD 
The proportion of patients reverting to a non-PD-MCI status was only 3% with the 1.5SD 
criterion of two impairments in a single-domain, but was 16% with the 1.5SD criterion of one 
impairment in two cognitive domains. Combined across these two 1.5SD criteria, the 
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reversion rate was 5% (that is, including scores below either the 2SD or 1.5SD cut-off; 3 of 
56 patients). 
3.3.3.4. Progression over time and pattern of cognitive domain impairments 
Support for the conclusion that two impairments within a single cognitive domain was 
effective in identifying PD-MCI patients at risk of PDD over a four-year period was found 
when the progression of cognitive status was assessed in three groups of patients that were 
characterized differently at baseline using 1.5SD criteria. More than half of the patients who 
did not meet either of the 1.5SD criteria at baseline remained non-PD-MCI over the four-year 
period (Figure 3-3A.). It is pertinent that patients who met the PD-MCI criterion (at baseline) 
of a maximum of one impairment in each of two cognitive domains tended to progress to 
meet the alternative PD-MCI criterion of two impairments in one cognitive domain, rather 
than to PDD (Figure 3-3B.). In contrast those who met the PD-MCI criterion (at baseline) of 
two impairments in one cognitive domain tended either to remain stable at this criterion or 




Figure 3-3. Follow-up cognitive status in the non-PD-MCI group at baseline (A) and the PD-
MCI subgroups meeting the criterion of one impairment at 1.5SD in each of two cognitive 
domains (B) and the criterion of two impairments at 1.5SD in one cognitive domain (C). 
 
Figure 3-4 shows the pattern of domain impairments at baseline in the PD-MCI group 
who had at least two impairments at 1.5SD within at least one of the five cognitive domains. 
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Note that multiple domain impairments therefore meant that they had two impairments in 
each domain of two or more cognitive domains. Most of these PD-MCI patients (25 of 37) 
had multiple cognitive domain impairments (thus defined).  Sixty-four percent of the patients 
with multiple cognitive domain impairments converted to PDD (16 of 19) whereas only 25% 
of those with single cognitive domain impairments (3 of 12) converted to PDD.  All PD-MCI 
patients who had multiple cognitive domain impairments that included episodic memory, 
irrespective of conversion or not, had a mixture of other cognitive domains involved 
(episodic memory and executive, n = 5; episodic memory and visuospatial, n = 3; episodic 
memory, executive and attention, n= 4; episodic memory, executive and visuospatial, n = 1; 
episodic memory, executive, attention and visuospatial, n = 1. Multiple cognitive domain 
impairments that did not include episodic memory were: executive and attention, n = 5; 
executive and visuospatial, n = 3; and attention and visuospatial, n = 3. No PD-MCI patients 
had single cognitive domain impairments in visuospatial function or language. There was no 
obvious pattern to the cognitive domains impaired and conversion to PDD.  
 
Figure 3-4. Pattern of domain impairments at baseline in PD patients meeting the criterion 
of at least two impairments at 1.5SD in one cognitive domain. 
PDD = Patients who met Level II criteria for Parkinson’s disease with dementia; PD-MCI = 





The diagnosis of PD-MCI is important in facilitating patient management, prognosis and 
especially opportunities for novel therapeutic interventions (Eberling et al., 2014; Litvan et 
al., 2012; Palavra et al., 2013; Troster, 2011; Yarnall et al., 2013). The explicit intent of a 
PD-MCI diagnosis is to identify patients who are at risk of PDD, and this can only be 
determined by longitudinal follow-up of patients. Dementia is an outcome facing most PD 
patients as the disease unfolds and multiple brain networks become increasingly disrupted 
(Beach et al., 2009; Jellinger, 2012; Melzer et al., 2011; Melzer et al., 2013). The validity of a 
PD-MCI diagnosis is, therefore, most relevant in the context of the window of time when risk 
is evaluated. Our longitudinal study evaluated this risk over a four-year period, a pertinent 
medium-term time-frame from the patient and their carer’s perspective. 
 In a typically-aged group of patients (42 to 80 years, mean of 66 years; mean disease 
duration of 6 years at the start of the study), we found that the 1SD cut-off did not identify 
patients who were at higher risk of PDD over the next four years than patients who did not 
meet any PD-MCI criterion at baseline. By contrast, the criterion of impairments at 1.5SD 
below normative data, when at least two such deficits occurred within one cognitive domain, 
has high validity for PDD risk in a four-year period. This criterion classified a group with a 
51% progression rate to PDD, the highest proportion of conversions for the criteria we 
examined. The literature on MCI in non-PD populations has established that poor 
performance on multiple tests within a cognitive domain is likely to identify worsening 
cognition over time (Jak et al., 2009; Teng et al., 2009).
 
The alternative 1.5SD criterion, 
which did not require two impairments within a single cognitive domain, was similar to the 
1SD criterion in that it did not identify patients with a significantly increased risk of PDD 
progression over a four-year period. Indeed, this alternative 1.5SD criterion instead may 
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identify patients who were at an earlier stage of cognitive decline because many of these 
patients were more likely to convert to having two impairments within a single cognitive 
domain than to PDD. The option of 2SD as a cut-off criterion had good concordance with a 
consensus clinical diagnosis of PD-MCI when neuropsychological data were available for 
assessment (Goldman et al., 2013). However, the 2SD criterion applied to our sample 
produced a lower relative risk estimate because it missed the additional conversions to PDD 
captured by the 1.5SD cut-off, especially when two impairments occurred within one 
cognitive domain. The 2SD criterion also produced an apparent higher rate of reversion to a 
non-PD-MCI status at follow-up than did the specific 1.5SD criterion requiring two impaired 
scores within a single cognitive domain (20% vs. 3% respectively). A recent proposal 
suggested the use of 2SD cut-offs for PD-MCI criteria (Goldman et al., 2013; Goldman et al., 
2015), but that study used a cross-sectional design and thus did not assess progression over 
time to PDD. The longitudinal design of the present study suggests instead that a 1.5SD cut-
off is sufficient to maximize risk of progression to PDD. 
 PD-MCI criteria using different cut-off values resulted in a percentage of patients 
classified as impaired at a given point in time that can vary from as high as 92% to as low as 
10% (Aarsland et al., 2010; Dalrymple-Alford et al., 2011; Goldman et al., 2013; Liepelt-
Scarfone et al., 2011). The current consensus based on non-standardized PD-MCI criteria is 
that 25-30% of PD patients at any given time will demonstrate PD-MCI when the most 
common cut-off of 1.5SD is administered, but even then significant variation is found across 
centers (Aarsland et al., 2010). Similarly, within our study 46% of patients at baseline were 
PD-MCI when a 1.5SD cut-off with only a single impairment in each of two cognitive 
domains was applied across the entire sample, but 31% were PD-MCI when the minimum of 
two impairments within a single cognitive domain was met. The proportions differed again if 
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the entire sample was evaluated using 2SD or 1SD cut-offs (38% and 79%, respectively). 
Hence, different permissible MDS-TF cut-offs (1SD, 1.5SD or 2SD) contribute to 
considerable variation in the proportion of PD-MCI identified within a given sample of 
patients. More importantly, our four-year study illustrates that different cut-off variants 
identify groups of patients with markedly different relative risks of progression to PDD, and 
different rates of reversion to non-PD-MCI. 
 Several factors could influence conversion or not to PDD within any group of 
patients. The small proportion of PD patients who do not to progress to PDD until very old 
age may be protected by genetics and/or lifestyle factors that confer resilience to brain 
pathology (Hindle et al., 2013; Sebastiani et al., 2013).
 
Some patients may be misdiagnosed 
as PD-MCI because either their depleted dopaminergic function or their treatment regimens 
may induce various fronto-striatal dysfunctions that cause cognitive impairment that does not 
necessarily portend progression to PDD (Barker & Williams-Gray, 2014). There are also 
contributions to risk from general factors such as age, presence of REM sleep disorder, and 
additional neuropathology (Aarsland & Kurz, 2010; Anang et al., 2014; Irwin, Lee, & 
Trojanowski, 2013; Jellinger, 2012; Yarnall et al., 2013).  In some patients, the extent of 
decline from premorbid level of intellectual function may be more relevant than rigid cut-offs 
(Marras et al., 2013). Hence, consideration of age or other variables may improve the 
predictive value of the specific criterion suggested by our study. Like other studies of 
conversion to PDD from PD-MCI, we found similar rates of conversion to PDD between the 
sexes when the 1.5SD criterion was used (10 men and 9 women) (Janvin et al., 2006; 
Pedersen et al., 2013).
 
The pattern of cognitive domain impairments observed in the patients who met the 
criterion of two impairments at 1.5SD in a single cognitive domain showed no obvious 
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association with conversion to PDD, which is consistent with the heterogeneity of failing 
cognition in PD (Broeders, de Bie, et al., 2013; Jacobs et al., 1995; Janvin et al., 2006; 
Mahieux et al., 1998; Woods & Troster, 2003). Like other studies, multiple-domain 
impairments may be more common in PD-MCI (Goldman et al., 2013) and more likely to be 
associated with conversion to dementia (Broeders, de Bie, et al., 2013).  However, the 
frequency of multiple cognitive domain impairments will vary with the specific PD-MCI 
criteria that are applied. In some studies, most PD-MCI patients showed multiple 
impairments, often as high as four cognitive domains impaired, when only a single 
impairment per cognitive domain was required (Goldman et al., 2013; Marras et al., 2013). 
The present study had only one patient with 4 impaired cognitive domains, when using two 
impairments necessary for any cognitive domain to be considered deficient. Multiple deficit 
scores within a single cognitive domain, however, appear to be optimal to identify conversion 
to PDD within 4.5 years. Neither the language nor visuospatial domains showed single 
impairments using our criteria, so it is possible that worsening attention, executive function 
and memory may reflect the earlier signs of global cognitive decline in PD, similar to that 
reported by Pedersen et al. (2013). 
 The strength of the current study is its longitudinal design and the use of Level II 
assessments for both PD-MCI and PDD diagnoses. It evaluated for the first time the validity 
of different recommended PD-MCI criteria in relation to PDD progression. The use of a 
specified medium-term window for progression is highly relevant because the high rate of 
eventual progression PDD means that virtually all PD-MCI criteria will identify conversion 
to PDD if the follow-up period is sufficiently long. The four-year window is particularly 
relevant for patients and their families, as it meets their expectations for clinical management 
while also allowing for the assessment of potential therapeutic outcomes.  
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One limitation to our study, like similar studies, that is the sample size was modest (n 
= 121) and there was potential for bias due to an attrition rate of 18%. Our sample size was 
twice that of three studies that examined PDD progression over three-five years (n = 51-64) 
(Broeders, de Bie, et al., 2013; Hobson & Meara, 2015; Janvin et al., 2006), but smaller than 
one study that followed patients over three years (n = 167; Pedersen et al., 2013). Our 
attrition rate (18%) was half that of two of these studies (41% and 48%; Broeders, de Bie, et 
al., 2013; Hobson & Meara, 2015), equivalent to one study (18%; Janvin et al., 2006) and 
larger than another (8%; (Pedersen et al., 2013). The current data will, however, contribute to 
an international consortium to enable better statistical precision for determining relative risk 
of PDD from different cut-off options, and the ability to assess the influence of potential 
modifiers such as age and education (Geurtsen et al., 2014). 
A second limitation is that the identification of PD-MCI may depend on the number 
of tests we used per cognitive domain, and especially the sensitivity and psychometric 
qualities of our individual tests. The uneven number of tests per cognitive domain in our 
study could mean that the attention and executive functioning domains, which each consisted 
of six tests, may be more likely to detect impairment than, say, the visuospatial domain for 
which four tests were used. However, Goldman et al. (2015) found that having more than two 
tests in the attention and/or executive function domains did not increase the probability of 
detecting an impairment and that having more tests in memory, visuospatial functioning and 
language only increased by 5% the chance of finding more cognitive domain impairments. In 
terms of the sensitivity of tests, there is mixed evidence whether “frontal” or “posterior” 
cortical tests provide good predictors of decline to PDD (Barker & Williams-Gray, 2014; 
Jacobs et al., 1995; Janvin et al., 2006; Mahieux et al., 1998; Woods & Troster, 2003). 
Indeed, the allocation of tests to cognitive domains may also differ across experts because 
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tests vary in their domain purity. This issue is relevant to the current findings in which 
multiple impairments within a cognitive domain better identified those PD-MCI patients at 
risk of conversion to PDD, at least over a four-year period. For example, executive function 
tests can vary in their domain allocation (Goldman et al., 2013; Pedersen et al., 2013) and 
visuospatial tests range from specific measures through to more complex tasks that also 
involve orientation, attention, memory and executive function (Lezak et al., 2012). That is, 
the selection of tests and their domain purity may contribute to variation in the frequency of 
impairments reported across studies. These limitations emphasize the need for further 
evaluation of cognitive impairments and progression to PDD. 
3.5. Conclusions 
The conclusion from the current study is to adopt a specific PD-MCI criterion when 
the intent is to identify a medium-term (up to four years) risk of progression to PDD. For this 
purpose, the requirement of at least two deficits at 1.5SD below normative data within any 
single cognitive domain provides a valid PD-MCI diagnosis that optimizes the relative risk of 
progression to dementia. Deciding upon the selection and number of tests required remains as 







 Optimisation of tests to predict dementia Chapter 4:
4.1. Background 
Cognitive testing has been the most reliable and researched method of identifying PD 
patients who are at the greatest risk of future PDD.  Recently, it has been confirmed that 
meeting PD-MCI criteria is a significant risk factor for future PDD (Chapter 3; Broeders, 
Velseboer, et al., 2013; Hobson & Meara, 2015; Hoogland et al., 2017; Pedersen et al., 2013). 
The early identification of patients, who will later progress to PDD within a relatively short 
period after assessment (i.e. within four years) is a clinically-relevant issue for PD patients 
(Svenningsson, Westman, Ballard, & Aarsland, 2012; Yarnall et al., 2013). For example, 
early identification of those at imminent risk of developing PDD may facilitate selection of 
appropriate participants for novel disease-modifying interventions (Eberling et al., 2014). 
However, neuropsychological testing can be very time consuming and the value of different 
tests remains uncertain.  
 As discussed in earlier chapters, the specific PD-MCI criteria guidelines that have 
been developed by the MDS-TF (Litvan et al., 2012) allow a degree of ambiguity in terms of 
the number and specific tests required to classify an individual as PD-MCI. There is a 
minimum requirement of two tests in each of the five cognitive domains needed to meet 
Level II PD-MCI criteria, but no maximum number of tests allowed. Hence there can be 
variation between study sites in meeting Level II criteria. In Chapter 3, we determined that 
the PD-MCI criterion of ‘two impairments at 1.5SD in a single domain’ was the most suited 
criterion for identifying patients at the highest risk of PDD four-years later. This conclusion 
was based on a large battery of neuropsychological tests, with 24 measures, employed by the 
NZBRI to capture a range of potentially heterogeneous deficits in non-dementia patients 
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(Dalrymple-Alford et al., 2011). While this approach has been extremely useful, it is possible 
that errors in prediction are inflated by false positives due to tests that are insensitive to 
progression. Conversely, PD-MCI patients may be missed if a restricted test battery consisted 
of tests that produced impairments in some patients but which were not sensitive for future 
PDD.  
 Few studies have looked at identifying an optimal trade-off in terms of a reduced 
number of tests that are sufficiently sensitive in identifying patients at a high risk of 
developing PDD. An initial study by Goldman et al. (2015) used a least absolute shrinkage 
and selection operator (LASSO) logistic regression model to select the two most sensitive 
tests to PD-MCI within each cognitive domain for the five MDS-required cognitive domains. 
When using the full test battery of 19 tests over five cognitive domains, they determined that 
48 of their 76 patients had PD-MCI, with PD-MCI being determined by “expert consensus”. 
The restricted test battery of 10 tests captures 83% of PD-MCI patients from their original 
classification. A second study also used the LASSO approach to generate a reduced test 
battery of 10 tests, and reported a sensitivity of 73% and a specificity of 100% for classifying 
patients as PD-MCI, when compared to the PD-MCI patients classified using the original 23-
item test battery (Federico et al., 2017). Our NZBRI data contributed one of four sites in a 
recent MDS consortium study (Hoogland et al., 2017), which was the first study to examine 
progression to PDD using a neuropsychological test battery of only 10 neuropsychological 
tests. “Expert consensus” across the sites was used to select the 10 measures (two from each 
of the five cognitive domains) within each of the four different PD cohorts and then the risk 
of PDD in PD-MCI patients was examined. They reported that PD-MCI patients who were 
classified using a 10 neuropsychological test battery were at a greater risk of PDD, which 
suggests that even when applied to a 10 neuropsychological Level II test battery, PD-MCI 
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criteria can identify patients at a high risk of developing PDD. Cross-sectional studies, such 
as Biundo et al. (2014), have identified specific individual neuropsychological tests which are 
good at distinguishing between PD-MCI or PDD patients when compared to PD-N patients, 
but the merits of these tests have not been directly compared when they are part of cognitive 
domains consisting of multiple tests, unlike the Goldman et al. (2015) and Federico et al. 
(2017) studies. Longitudinal studies, however, have shown that specific cognitive tests can 
perform poorly when tracking progression to PDD over time (Jacobs et al., 1995; Janvin et 
al., 2006; Levy et al., 2002; Mahieux et al., 1998; Williams-Gray et al., 2013; Woods & 
Troster, 2003). In saying this, the PD-MCI classification used in these studies was not 
determined using currently accepted Level II criteria.  
The aim of this study was to determine the value of a reduced test battery, of 15 and 
10 neuropsychological tests, when compared to the original 24 neuropsychological test 
battery, (1) in terms of their ability to identify patients as PD-MCI and (2) evaluate the risk of 
developing PDD four-years later in these PD-MCI groups. A reduced test battery would be 
less demanding on patients, particularly those who are showing signs of cognitive decline. It 
would also reduce the resources needed to assess patients’ risk of PDD. The test battery was 
reduced by selecting the two or three tests per cognitive domain which identify the most 
impairment (i.e. the tests which show the most scores of -1.5SD or below). PD-MCI patients 
will be classified using these reduced 15- or 10 neuropsychological test batteries to determine 
the relative risk of PDD for two different PD-MCI groups compared to patients who do not 
meet the PD-MCI criteria. These relative risk scores will then be compared to the PD-MCI 
group risk scores when the original 24 neuropsychological test battery was used to determine 
whether the PD-MCI patients who develop dementia (PDD) were still able to be 
distinguished from those who did not progress to PDD four-years later. 
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4.2. Methods  
4.2.1. Participants 
A convenience sample of 121 non-dementing PD patients was recruited from our research 
institute and movement disorders clinic. This is the same sample described in Chapter 3 
(Figure 3-1). The comprehensive neuropsychological assessment, PD diagnostic procedure 
and exclusion criteria were the same as detailed in Chapter 3. As in chapter 3, progression to 
PDD before the end of the 4.5-year follow-up period was treated as an a priori end-point, 
with no subsequent follow-up. 
4.2.2.  Neuropsychological battery 
The same comprehensive neuropsychological assessment was administered as described in 
Chapter 3. A full description of each test used in the comprehensive neuropsychological test 
battery is in Appendix A. 
4.2.3. Test selection for the reduced cognitive test battery 
4.2.3.1. Part One: Test selection for the reduced cognitive test battery 
Each individual test was tallied to identify how many impairments were present across the 
entire sample, and were rank-ordered within each cognitive domain. An impairment was 
defined as a score of -1.5SD or more below the normative data for each specific test. The top 
three tests within each cognitive domain were selected and the two PD-MCI criteria were 
applied to this reduced test battery (three tests per domain, 15 tests total). Although this 
procedure confounds test selection with the subsequent identification of PD-MCI, it provided 
a preliminary approach towards test reduction in the absence of a separate validation cohort. 
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It is also recognised that we cannot ascertain whether the selected tests would outperform 
other test options that were not included in the original battery. 
4.2.3.2. Part Two: Test selection for the reduced cognitive test battery 
To further optimise the test battery, only two tests were then selected per cognitive domain 
using the same test selection method as Part One. This optimised test battery of two tests in 
each cognitive domain is the minimum number of tests that must be included to meet Level II 
PD-MCI criteria as advised by Litvan et al. (2012). The two PD-MCI criterions were then 
applied to the reduced test battery (two tests per domain, 10 tests total). 
4.2.4. Application of PD-MCI criteria 
In this study, we used two different PD-MCI criteria, based on the findings of Chapter 3. The 
PD-MCI criteria were applied to both the full and reduced test batteries (Figure 4-1). We 
tested two reduced test batteries: (1) three tests per domain, and (2) two tests per domain. 
Like Chapter 3, a stepwise approach was used so that each PD-MCI group consisted of a 
discrete (non-overlapping) sample of patients. Firstly, we identified all patients with a 
minimum of two impairments at -1.5SD within at least one cognitive domain at baseline (that 
is, all patients from the entire sample of 121 patients who had two or more scores at or worse 
than the -1.5SD cut-off score) using the full test battery. The risk of dementia within this 
group of PD-MCI patient’s relative to those who did not meet this criterion was then 
determined using relative risk. The remaining patients who did not meet the previous 
criterion (two or more scores at or worse than -1.5SD) were then assessed by comparing 
relative risk in those patients who had the minimum of two impairments at the cut-off score 
of -1.5SD but in whom the two impairments did not occur within a single cognitive domain 
(i.e. at least two domains each had a maximum of one impaired score) relative to the 
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remaining patients, who did not meet either of these two PD-MCI criteria. As any patient 
with multiple impairments within a single cognitive domain had been excluded in the 
previous stage, by definition this latter PD-MCI group all had only one impaired score within 
any one cognitive domain. In clinical practice, this second, more relaxed 1.5SD criterion 
would also capture those with multiple impairments within a cognitive domain, but for 
analysis purposes we kept the samples independent. This two-step process of identifying 
patients as PD-MCI for both criteria was repeated using (1) three tests per domain, and then 
again for the (2) two tests per domain comparison. The risk of PDD conversion was then 
compared between PD-MCI groups who had been determined using the full and each of the 
reduced test batteries (i.e. three tests per domains and then two tests per domain) to evaluate 





A.  Baseline (n = 121) 




PD-MCI: 2 impairments in 1 domain 
(n = 37) 
PD-MCI: 1 impairment in each of 2 





Two impairments at 1.5SD across 
multiple domains? 
n = 84 remaining 
PD-N: Did not meet either PD-MCI 
criteria 
n = 65 remaining 
B.  Baseline (n = 121) 




PD-MCI: 2 impairments in 1 domain 
(n = 29) 
PD-MCI: 1 impairment in each of 2 





Two impairments at 1.5SD across 
multiple domains? 
n = 92 remaining 
PD-N: Did not meet either PD-MCI 
criteria  
n = 69 remaining 
C.  Baseline (n = 121) 




PD-MCI: 2 impairments in 1 domain 
(n = 25) 
PD-MCI: 1 impairment in each of 2 





Two impairments at 1.5SD across 
multiple domains? 
n = 96 remaining 
PD-N: Did not meet either PD-MCI 
criteria  
n = 70 remaining 
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Figure 4-1. PD-MCI criterion application. (A) PD-MCI selection when applied to the full 
neuropsychological test battery. (B) PD-MCI selection when applied to the reduced three 
tests per cognitive domain neuropsychological test battery. (C) PD-MCI selection when 
applied to the reduced two tests per cognitive domain neuropsychological test battery. 
 
4.2.5. Assessing the efficacy of the reduced test battery 
Baseline demographic and cognitive differences were compared between the PD-N, PD-MCI 
‘one impairment in each of two domains’ and the PD-MCI ‘two impairments in one domain’ 
groups using ANOVA, with Tukey post hoc tests. Relative Risk (RR) was used to determine 
whether the group of patients classified using each of the PD-MCI criterions when applied to 
the reduced 15 or 10 neuropsychological test batteries were able to capture patients who were 
at a greater risk of PDD compared to those who did not meet the PD-MCI group criteria. The 
RR scores from the restricted test batteries were then compared to the RR scores of the full 
test battery to evaluate how well the restricted test battery could capture the at-risk PD-MCI 
patients. This analysis was conducted using R (v3.3.2). Patient groups (i.e. PD-MCI ‘one 
impairment in each of two domains’ versus the remaining PD-N patients) were deemed as 
being at significantly more risk of developing PDD if the lower boundary of the 95% 
confidence interval (CI) was above 1.0. 
4.3. Results 
4.3.1. Participants 
Table 4-1 summarizes the demographic and neuropsychological data of the patients used in 
this study at baseline. The average patient’s age at study entry was 65.5 years (SD = 8.1 
years). There was a 21% conversion rate to dementia for all PD patients in the four-year 
follow-up period (25 out of 121 patients; 14 men and 11 women).  There were no significant 
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differences between age, level of education, premorbid IQ (WTAR) and symptom duration 
across the PD-N, PD-MCI ‘one impairment in each of two domains’ and the PD-MCI ‘two 
impairments in one domain’ groups.  
Full neuropsychological battery. The PD-MCI ‘two impairments in one domain’ group had 
significantly higher ADL, DRS-2, Hoehn and Yahr and UPDRS (Motor) scores than the PD-
N group. They also had worse CDR, ADAS-Cog and MoCA scores than both the PD-MCI 
‘one impairment in each of two domains’ and the PD-N groups. The PD-MCI ‘one 
impairment in each of two domains’ group had significantly higher CDR scores than the PD-
N group. Regarding cognitive performance, the PD-MCI ‘two impairments in one domain’ 
group had significantly lower global cognition scores than the PD-MCI ‘one impairment in 
each of two domains’ and the PD-N groups, as well as some poorer scores in the executive 
function, attention, episodic memory and visuospatial domains. In the language domain, the 
PD-MCI ‘two impairments in one domain’ group had significantly lower scores than the PD-
N, but not the PD-MCI ‘one in each of two domains’ group. The PD-MCI ‘one in each of two 
domains’ group had poorer global cognition than the PD-N groups and had lower scores in 








‘One impairment in 
each of two domains’ 
PD-MCI: 
‘Two impairments in 
one domain’ 
Sample size (n) 65 19 37 
Convert to PDD (n) 4 2 19 
Sex, M:F 41:24 11:8 25:12 
Age 64(8) 66(7) 68(8) 
Education (y) 13(3) 13(3) 13(3) 





Reisberg IADL 0.3(0.4) 0.6(0.7) 0.7(0.6)
b 
DRS-2 (AESS) 12.4(1.9) 11.6(2.1) 10.2(1.8)
b 
ADAS-Cog 5.7(2.4) 7.0(2.5) 10.0(2.7)
b,c 
Symptom duration (y) 4.8(4.0) 7.2(4.6) 6.7(4.5) 
Hoehn and Yahr stage 1.9(0.7) 2.0(0.5) 2.4(0.6)
b 
UPDRS (Motor) 30.0(16.4) 31.0(12.1) 40.5(16.5)
b 
MoCA 26.7(2.3) 26.1(2.0) 23.5(2.5)
b,c 




1. Executive function +0.25(0.59) -0.14(0.47)b -1.00(0.63)b,c 












5. Languagea +0.57(0.98) +0.17(0.70) -0.08(0.77)b 
Abbreviations: PDD = Patients who met Level II criteria for Parkinson disease with dementia; 
Global Z score = mean derived from attention, executive function, visuospatial and episodic 
memory domains; ADAS-Cog = Alzheimer’s Dementia Assessment Scale-Cognitive; CDR = 
Clinical Dementia Rating; DRS-2 (AESS) = Dementia Rating Scale-2 (Age and Education 
Scaled Score); IADL = Instrumental Activities of Daily Living; MoCA = Montreal Cognitive 
Assessment; N/A = Not Applicable; NPI = Neuropsychiatric Inventory; UPDRS (Motor) = 
Unified Parkinson’s Disease Rating Scale (Motor Component); WTAR = Wechsler Test of 
Adult Reading for premorbid IQ. 
a 
Thirty-seven PD patients did not have two language measures at study entry.
 
b 
Significantly different from PD-N, Tukey post hoc tests, p<0.05. 
c 
Significantly different from PD-MCI: ‘One impairment in each of two domains’, Tukey post 




4.3.2. Selecting tests  
The rank-ordered tests, based on each measure’s ability to identify impairment (i.e. the 
number of scores below -1.5SD) per cognitive domain is displayed in Table 4-2. 
4.3.2.1. Part One: three tests per cognitive domain 
In the Attention domain, Map Search identified an impairment most frequently, followed by 
Digit Ordering, and Trails A. In the Executive domain, Action Fluency identified the most 
frequent impairments, followed by Trails B and Stroop Interference. Rey Copy was the test 
which most frequently identified an impairment in the Visuospatial domain, followed by JLO 
and then Picture Completion. In the Memory domain, Rey Short Delay identified impairment 
most frequently, followed by CVLT-II SF Short Delay and then CVLT-II SF Free Recall. 
The short delay versions of the CVLT-II SF and Rey were selected because impairments in 
either the short or long delay components in each of these tests were counted as one 
impairment. Furthermore, patients who were impaired after only a short delay generally were 
impaired to the same degree or more during the long delay component of the test. Finally, in 
the language domain the DRS-2 Similarities test identified the most impairment, followed by 
the ADAS-Cog Language measures, and then the Boston Naming Test. 
4.3.2.2. Part Two: Two tests per cognitive domain 
Table 4-2 has the tests rank-ordered per cognitive domain that identify the most impairments. 
When the test battery was restricted to two tests per cognitive domain, we find that Trails A 
drops out of the Attention domain. In the executive functioning domain, Stroop Interference 
is no longer included. Picture Completion drops out of the visuospatial domain and CVLT-II 
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SF Free Recall in the Memory domain. Finally, in the Language domain the Boston Naming 
Test is no longer included in the 10 neuropsychological test battery. 
Table 4-2. Ranking of tests per domain and the number of impairments identified 
Domain Test 









TEA Map Search 28 
Digit Ordering 26 
Trails A 16 
Stroop colour 8 
Stroop word 2 















Action Fluency 36 
Trails B 21 
Stroop Interference 15 
Category Switching 14 
Letter Fluency 6 










Rey Copy 27 
JLO 13 














Rey Short delay 32 
CVLT-II SF Short delay 16 
CVLT-II SF Free recall 10 
Rey Long delay 25 







Language ADAS-Cog Z-score 4 
Language DRS-2 Similarities Z-score 3 
Boston Naming Test 0 (only 21 received test) 
Abbreviations: ADAS-Cog = Alzheimer’s Dementia Assessment Scale-Cognition; CVLT-II SF 
= California Verbal Learning Test – Second Edition, Short Form; DRS-2 = Dementia Rating 
Scale-2; JLO, Judgement of Line Orientation; TEA Map Search, Test of Everyday Attention: 
Map Search; VOSP, Visual Object and Space Perception test battery. 
NB. The short delay versions of the CVLT-II SF and the Rey were selected because 
impairments in either the short or long delay components in each of these tests were counted 





4.3.3. Effect of reduced test battery on selection of PD-MCI groups 
4.3.3.1. Part One: Reducing the test battery to three tests per cognitive domain 
Having three neuropsychological tests in each of the five cognitive domains had a small 
effect on the number of patients classified as PD-MCI, across both criteria used, when 
compared to the full 24 neuropsychological test battery. When the test battery was reduced to 
three tests per cognitive domain, the group selected by the PD-MCI ‘two in one domain’ 
criterion changed from 37 patients (19 converted to dementia; 51%), to 29 patients, 17 of 
whom converted to PDD (59%; Figure 4-1A and Figure 4-1B). The number of patients in the 
PD-MCI ‘one in each of two domains’ group increased from 19 (2 of who converted to PDD; 
11%), to 23 patients (4 of whom converted to PDD; 17%) when the criterion was applied to 
the reduced 15 neuropsychological test battery (Figure 4-1A and Figure 4-1B).  
4.3.3.2. Part Two: Reducing the test battery to two tests per cognitive domain 
Having only two neuropsychological tests per cognitive domain in the cognitive battery again 
reduced the number of patients classified as PD-MCI using the ‘two in one domain’ criterion 
when compared to the full cognitive test battery (Full 24 neuropsychological test battery = 37 
patients, Reduced 10 neuropsychological test battery = 25 patients; Figure 4-1A and Figure 
4-1C). The proportion of patients who developed dementia during the follow-up period 
remained stable however (Full 24 neuropsychological test battery, 19 patients develop PDD 
at follow-up, Reduced 10 neuropsychological test battery, 13 patients develop PDD at follow-
up). The number of patients classified as PD-MCI using the ‘one in each of two domains’ 
criterion increased when a reduced test battery consisting of two tests per cognitive domain 
was used (Full 24 neuropsychological test battery = 19 patients, Reduced 10 
neuropsychological test battery = 26 patients; Figure 4-1A and Figure 4-1C). The PD-MCI 
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criterion of ‘one in each of two domains’ when applied to the reduced test battery (two tests 
per cognitive domain) was able to capture substantially more patients who develop PDD 
during the study compared to when it was applied to the full test battery (Full 24 
neuropsychological test battery = 2 patients develop PDD at follow-up, Reduced 10 
neuropsychological test battery = 8 patients develop PDD at follow-up). 
4.3.4. Risk of PDD progression 
4.3.4.1. Part One: Progression to PDD and three tests per cognitive domain 
The relative risk (RR) of progressing to PDD in the PD-MCI ‘two impairments in one 
domain’ group was similar to the full test battery (RR of full 24 neuropsychological test 
battery = 7.2, 95% CI = 3.3-15.8; RR of reduced 15 neuropsychological test battery = 6.7, 
95% CI = 3.3-13.5). There was no evidence to suggest that the patients classified as PD-MCI 
using the ‘one in each of two domains’ criterion were more at-risk of developing PDD four-
years later than the PD-N group when using the 3 tests per cognitive domain battery (RR of 
full 24 neuropsychological test battery = 1.7, 95% CI = 0.5-6.8; RR of reduced 15 
neuropsychological test battery = 3.0, 95% CI = 0.9-9.8). 
4.3.4.2. Part Two: Progression to PDD and two tests per cognitive domain 
When the test battery was reduced to two tests per cognitive domain, both PD-MCI criteria 
captured patients who were at significant risk of developing dementia. There was no evidence 
of a difference in RR of progression to PDD in the PD-MCI ‘two in one domain’ group 
classified using the full 24 neuropsychological test battery compared to when this criterion 
was applied to the reduced 10 neuropsychological test battery as the CI’s are overlapping 
(95% CI of full 24 neuropsychological test battery = 3.3-15.8; RR of reduced 10 
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neuropsychological test battery = 4.2, 95% CI = 2.2-7.8). This criterion was able to 
significantly identify at risk patients (i.e. a higher rate of patients who were classified using 
this criterion progressed to PDD four-years later than the remaining patients who did not 
meet this criterion) when applied to both the full 24- and reduced 10 neuropsychological test 
batteries. When the PD-MCI criterion of ‘one in each of two domains’ was applied to the 
reduced 10 neuropsychological test battery, it captured patients at a higher risk of dementia 
progression within four-years than the PD-N group (RR = 5.4, 95% CI = 1.9-15.0), as the CI 
no longer intercepts one. This was not the case when the PD-MCI criterion of ‘one in each of 
two domains’ was applied to the full 24 neuropsychological test battery (RR = 1.7, 95% CI = 
0.5-6.8). 
When using a reduced 10 neuropsychological test battery, both PD-MCI criteria are able to 
identify patients who had a greater risk of developing PDD four-years later. We therefore 
decided to combine these two groups of patients into one PD-MCI group. This meant that we 
were no longer restricting the PD-MCI group to either (1) having both of their impairments 
solely within a cognitive domain or (2) having the two impairments only across two or more 
of the five cognitive domains, but never both in a single cognitive domain. The new PD-MCI 
group was comprised of all of the patients who had ‘two impairments anywhere across the 
five domains’ (n = 51; 21 patients develop PDD at follow-up). This new group of patients 
had a high risk of developing PDD than the PD-N patients (RR = 7.2, 95% CI = 2.9-18.5) 
when this criterion was applied to the two tests per cognitive domain reduced test battery. 
4.3.5. Pattern of domain impairments when the test battery is reduced to two tests per 
cognitive domain 
Figure 4-2 shows the pattern of domain impairments at baseline in the PD-MCI group who 
74 
 
(A) had at least ‘two impairments at -1.5SD within a single cognitive domains’ (Figure 
4-2A), (B) had ‘one impairment at -1.5SD in each of two and domains’ (never two in the 
same cognitive domain; Figure 4-2B) and (C) had at least ‘two impairments at -1.5SD 
anywhere’ (Figure 4-2C) when applied to a reduced 10 neuropsychological battery (Part Two 
analysis). Note that multiple cognitive domain impairments are therefore different due to the 
criterions. In Figure 4-2A, multiple cognitive domain impairments are defined as two 
impairments in each of two or more domains, while in Figure 4-2B and Figure 4-2C multiple 
cognitive domain impairments are defined as two impairments across two or more cognitive 
domains.  
4.3.5.1. PD-MCI group defined as having at least ‘two impairments at -1.5SD within a 
single cognitive domain’ 
Figure 4-2A shows the pattern of domain impairments at baseline in the PD-MCI group who 
had at least two impairments at 1.5SD within at least one of the five cognitive domains, when 
a reduced battery of two tests per cognitive domains was used (Part Two analysis). Note that 
multiple cognitive domain impairments therefore meant that they had two impairments in 
each of two or more cognitive domains. Nine of the 25 PD-MCI patients had multiple 
cognitive domain impairments (defined above). Eighty-nine percent of the patients with 
multiple cognitive domain impairments converted to PDD (8 of 9), whereas 31% of those 
with single cognitive domain impairments (5 of 16) converted to PDD.  All PD-MCI patients 
who had multiple cognitive domain impairments that included memory, irrespective of 
conversion or not, had a mixture of other cognitive domains involved (episodic memory and 
executive, n = 1; episodic memory and visuospatial, n = 2; episodic memory and attention, n= 
1; episodic memory, executive, attention and visuospatial, n = 1). Multiple cognitive domain 
impairments that did not include memory were: executive and attention, n = 2; executive and 
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visuospatial, n = 1; and attention and visuospatial, n = 1. None of the PD-MCI patients had 
single cognitive domain impairments in the language domain. The rest of the single cognitive 
domain impairments were spread over the other four cognitive domains (memory, n = 3; 
executive, n = 6; visuospatial, n = 3; and attention, n = 4). There was no obvious pattern to 
the cognitive domains impaired and conversion to PDD, but over half of the patients who 
later converted to PDD had impairments in multiple cognitive domains. 
4.3.5.2. PD-MCI group defined as having ‘one impairment at -1.5SD in each of two 
cognitive domains’ (but never two in the same domain) 
In Figure 4-2B, all 26 PD-MCI patients in this category had multiple cognitive domain 
impairments due to this definition of the PD-MCI. The PD-MCI patients who had multiple 
cognitive domain impairments that included episodic memory, irrespective of conversion or 
not, had a mixture of other cognitive domains involved (episodic memory and executive, n = 
3; episodic memory and attention, n = 2; episodic memory, executive and attention, n = 3; 
episodic memory, attention and visuospatial, n = 1; episodic memory, executive, attention 
and visuospatial, n = 2; episodic memory, attention, executive, and language, n = 3; episodic 
memory, attention and visuospatial, n = 2; episodic memory and language, n = 1; episodic 
memory and visuospatial, n = 3; and episodic memory, visuospatial and language, n = 1). 
Multiple cognitive domain impairments that did not include episodic memory were: 
executive and attention, n = 3; executive and visuospatial, n = 1; and attention, executive, 
visuospatial, n = 1. There was no obvious pattern to the cognitive domains impaired and 





4.3.5.3. PD-MCI group defined as having at least ‘two impairments at -1.5SD on any of the 
restricted set of tests 
In Figure 4-2C, only one patient out of 51 who met this PD-MCI criterion had a single 
cognitive domain impairment (Executive domain: Figure 4-2C) and this patient was not a 
converter to PDD four-years later. Again, most patients who met this PD-MCI criterion had 
multiple cognitive domain impairments that included episodic memory, irrespective of 
conversion or not. Alongside the episodic memory impairment there were a mixture of other 
cognitive domains involved (episodic memory and attention, n = 3; episodic memory, 
attention and executive, n = 5; episodic memory, attention, executive and language, n = 3; 
episodic memory, attention and visuospatial, n = 5; episodic memory, attention, executive 
and visuospatial, n = 9; episodic memory and executive, n = 5; episodic memory, executive 
and visuospatial, n = 4; episodic memory, executive, visuospatial and language, n =1; 
episodic memory and language n = 1; episodic memory and visuospatial, n = 3; episodic 
memory, visuospatial and language, n = 1; and episodic memory, executive, visuospatial and 
language, n = 1). Multiple cognitive domain impairments that did not include episodic 
memory were: attention and executive, n = 4; attention, executive and language, n = 1; 
attention, executive and visuospatial, n = 3; and attention and visuospatial, n = 1. Again, there 




Figure 4-2. Pattern of Domain Impairments using a reduced 10 neuropsychological test 



































‘one impairment in each of two domains’. (C) PD-MCI ‘two impairments at -1.5SD 
anywhere’. The grey bars represent the percentage of patients who had two or more 
impairments in a simple cognitive domain only or two or more impairment in each of two or 
more cognitive domains and did not develop PDD. The black bars represent the percentage 
of patients who had two or more impairments in a simple cognitive domain only or two or 
more impairment in each of two or more cognitive domains and did develop PDD four-years 
later. The numbers above the bars show the number of patients who have that impairment out 
of the sub-group. 
NB. Multiple cognitive domain impairments are not equivalent in A, B and C. In A, a multiple 
cognitive domain impairment is defined as two impairments in each of (or more) domains, 
while in B and C, a multiple domain impairment is defined as two or more tests impaired 
across two (or more) domains. This is due to the PD-MCI criteria being different. 
  
4.4. Limitations and Conclusions 
In this study, we used a simple method for reducing the number of tests within each cognitive 
domain to the minimum number required to still meet Level II criteria. We found that when 
using the reduced test battery, it is still possible to identify PD-MCI patients at high risk of 
imminent dementia (i.e. within 4 years). However, the PD-MCI criterion of ‘two impairments 
at -1.5SD occurring in a single domain’, which classified the highest at-risk proportion of 
patients who would later progress to PDD as PD-MCI in Chapter 3, was likely not as 
effective at identifying at-risk patients when a reduced battery was used. Rather a combined 
PD-MCI criterion of ‘two impairments in any domain at -1.5SD’ was likely more effective at 
identifying at-risk PD-MCI when using the reduced test battery.  
The difference in the specific PD-MCI criteria which identified the patients with the 
highest risk of progression to PDD in this Chapter compared to Chapter 3, is a direct result of 
applying each criterion to the reduced neuropsychological test battery. When there are only 
two or three tests in a cognitive domain compared to four-six tests, the possibility of ‘failing’ 
a test by chance reduces. Goldman et al. (2015) found that the probability of detecting an 
impairment increased when a cognitive domain consisted of more than two tests, but in the 
attention and executive domains, this chance of detecting impairment did not increase when 
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there were three or four tests in these cognitive domains. In the other cognitive domains 
(memory, visuospatial and language) there was only a five percent increased chance of 
finding an impairment when the cognitive domains consisted of more than two tests 
(Goldman et al., 2015). Furthermore, it is much more difficult to fail two tests within a single 
cognitive domain when there are only two or three possible tests. We saw in the present study 
that the total number of PD-MCI patient classified using the alternative PD-MCI criteria did 
not drastically change compared to Chapter three, but those that originally met the PD-MCI 
criterion of ‘two impairments in a single cognitive domain’ when a comprehensive test 
battery was employed now meet the PD-MCI criterion of ‘one impairment in each of two 
domains’. Additionally, we found when the combined PD-MCI criterion, which did not 
restrict the impairments to occur within or across cognitive domains (‘two impairments in 
any of the 10 tests’), captured the patients who had the highest risk of PDD. This differed 
from what we found when this combined criterion was applied to the comprehensive 24 
neuropsychological test battery. This is clearly evident in the literature as more patients are 
identified as being PD-MCI when a PD-MCI criterion is used which does not restrict the 
impairments only to a single cognitive domain or across multiple cognitive domains but 
allows them to occur in any two tests in any of the cognitive domains (i.e. they can occur in 
any of the tests which are assessed; Dalrymple-Alford et al., 2011; Liepelt-Scarfone et al., 
2011). 
Despite this finding, the methodology used to select the ‘best’ tests per domain in this 
present study was not the optimal approach. I have developed another approach which is 
discussed in the next chapter (Chapter 5). The evaluation of the usefulness of a test based 
solely on the number of patients who receive a score of -1.5SD or below could bias which 
tests are selected as not all neuropsychological tests are of equal importance. Some tests are 
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more stringent than others, due to the poor normative data used for the generation of z-scores 
(Crawford & Howell, 1998), floor and ceiling effects and as well as the overall difficulty of 
the task being assessed. Issues surrounding the normalisation of data have been long argued, 
with some studies commenting that age- and education-corrected neuropsychological data is 
not necessary in brain-injured populations (Reitan & Wolfson, 1995), because it can lead toad 
to a loss predictive power when looking for cognitive impairment or dementia (M Sliwinski, 
Lipton, Buschke, & Wasylyshyn, 2003; Martin Sliwinski, Buschke, Stewart, Masur, & 
Lipton, 1997), and the over-correction of the data can lead to an increase in false positives 
being identified (M. E. O'Connell, Tuokko, Graves, & Kadlec, 2004). However, in the 
context of a neuropsychological test battery, which includes multiple measures to assess 
across multiple cognitive domains, this loss in sensitivity is not as important, as any loss 
would likely be offset by the use multiple test measures (Megan E. O'Connell & Tuokko, 
2010). There is still the danger that when selecting only two or three tests per cognitive 
domain, using the approach described in this chapter, we are selecting tests which have 
inflated levels of impairment (i.e. scores below -1.5SD). 
Despite normalised scores potentially having an effect when not used within a 
comprehensive test effect, there is consistent evidence for their use. Younger and/or more 
educated individuals consistently perform better than individuals who are older in age and/ or 
less educated (Lezak, 2004; Strauss et al., 2006; Vanderploeg, Axelrod, Sherer, Scott, & 
Adams, 1997). In saying this, the value of data normalisation does lie within the population 
with which the normalisation is based upon and this is better in some neuropsychological test 
than others (Crawford & Howell, 1998). This evidence strongly suggests that it is important 
to use normalised scores, but the methodology used to select tests in this study could have 
been influenced as normalised scores were the basis of test selection. 
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Due to this limitation, we subsequently developed a different method to reduce the 
test battery, using logistic regression (Chapter 5). Logistic regression was selected since it 
enables selection of tests in relation to progression to PDD four-years later. Thus, we can 
create a logistic regression model which is sensitive to progression to PDD within each 
cognitive domain and then find the two tests per cognitive domain which fit the progression 








 Optimising the test battery to 10 neuropsychological tests Chapter 5:
sensitive to future Dementia 
5.1. Aims 
The previous chapter looked to reduce the test battery to 15 and 10 neuropsychological tests 
using the frequency of PD-MCI level impairments (i.e. scores of -1.5SD or below) in any 
given test to rank-order the tests based on sensitivity of identifying an impairment. From this 
we then selected the two or three tests per cognitive domain to form our 10 and 15 
neuropsychological reduced test batteries. Here, we used logistic regression models to instead 
select two sensitive tests within each cognitive domain that are associated with progression to 
dementia. Baseline scores were used to assess a specific test’s ability to distinguish between 
patients who progressed to PDD four-years later from those that did not. We then evaluated 
whether the PD-MCI criterion recommended in Chapter 3 (‘two impairments at -1.5SD in a 
single domain’) was still able to identify patients who were at a high risk of developing PDD 
four-years later, once applied to the resulting reduced 10 neuropsychological test battery. 
5.2. Methods 
5.2.1. Participants 
A convenience sample of 138 non-demented PD patients was recruited from our research 
institute and movement disorders clinic. There were 17 additional patients included in this 
study, compared to the sample discussed in Chapters 3 and 4. During or after the studies in 
Chapter 3 and 4 were completed, an additional 27 PD patients were recruited to the study. 
Nine of these patients were excluded before baseline testing, while 18 received baseline 
assessments. Seven patients were found to have PDD and were not included in this analysis 
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and a further two patients were not available for follow-up assessments as they were not 
assessed during the follow-up window of 3.5-4.5 years after baseline testing. This left nine 
patients who completed their four-year follow-up assessments or progressed to PDD during 
the follow-up period and were therefore included in this study. An additional eight patients 
(seven PD-N and one PD-MCI ‘two impairments in one domain’) were also included in the 
study, even though they were assessed beyond the 3.5-4.5 year follow-up window. They were 
included as they had not progressed to PDD when they were next assessed (1-13 months after 
the 3.5-4.5 year follow-up window) and thus they would not have progressed to dementia 
during the 3.5-4.5 year follow-up window. This resulted in 138 patients being included in this 
study. 
The comprehensive neuropsychological assessment, PD diagnostic procedure and 
exclusion criteria were the same as detailed in Chapter 3. At study entry, the average duration 
of motor symptoms was 5.8 years (SD = 4.3 years) and the average follow-up period was 
46.6 months (SD = 9.7 months). As in chapter 3, progression to PDD before the end of the 
4.5-year follow-up period was treated as an a priori end-point, with no subsequent follow-up. 
All participants took their usual medications on the day of testing to allow optimal 
performance during the morning test sessions. The study was approved by a local ethics 
committee of the New Zealand Ministry of Health, with informed consent provided by all 
participants. 
5.2.2. Neuropsychological assessment 
The same comprehensive neuropsychological assessment outlined in Chapter 3, which fulfils 
the MDS-TF Level II PD-MCI criteria (Litvan et al., 2012). A full description of each test use 
is in Appendix A. 
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5.2.3. est selection for the reduced cognitive test battery 
Logistic regression was used to select two tests sensitive to progression to dementia within 
each of the five cognitive domains, based on whether each test could distinguish between 
patients who developed PDD and those who did not at follow-up. Baseline scores from all 
tests within a single cognitive domain were entered into a logistic regression (LR) model, 
with PDD status at follow up as the outcome variable (PDD or non-PDD). A new LR model 
was created for the four cognitive domains tested to determine which two tests would be 
included in the reduced test battery. The odds ratios generated from each LR model were 
rank-ordered according the tests association with progression to PDD. The Language domain 
was not examined as there were only two tests in any case that could be included in this 
analysis. If a test score was missing, the individual was excluded from that domain’s logistic 
regression analysis. In any instances where there were fewer than two tests in a cognitive 
domain which were significantly associated with future progression to PDD, 
neuropsychological assessment expertise was used by my primary supervisor, Prof. John 
Dalrymple-Alford, and I to select additional tests included in the reduced 10 
neuropsychological test battery. Considerations such as the composition of tests included 
within a cognitive domain (i.e. in the Episodic Memory domain including a measure of verbal 
as well visual memory impairments) and unpublished observations on the suitability of tests 
to identify the progression to PDD. If there were more than two significant tests associated 
with progression to PDD within a cognitive domain, that same neuropsychological 
assessment expertise procedure was used to select the two tests. This analysis was conducted 




5.2.4. Application of PD-MCI criteria 
Based on the findings of Chapter 3, we used the same two PD-MCI criterions here (as in 
Chapter 4). Each of the PD-MCI criteria was applied to the full 24 neuropsychological and 
reduced 10 neuropsychological test batteries. As in Chapters 3 and 4, a stepwise approach 
was used so that each PD-MCI group consisted of a discrete (non-overlapping) sample of 
patients (see Chapter 4.2.4. for methodology of PD-MCI criteria application).  
5.2.5. Assessing baseline group differences, when grouped using the 24 
neuropsychological test battery 
Baseline demographic and cognitive differences were compared between the three groups 
(PD-N, PD-MCI ‘one impairment in each of two domains’ and the PD-MCI ‘two 
impairments in one domain’) using ANOVA, with pairwise Tukey post hoc tests. The 
cognitive groups shown on Table 5-1 were determined using the original 24 
neuropsychological test battery. 
5.2.6. Assessing the efficacy of the reduced test battery 
Like in Chapter 3, confidence intervals for relative risk of PDD in each comparison were 
determined using bootstrap methods (Efron, 1979). Relative Risk (RR) was used to evaluate 
whether the different PD-MCI criteria applied to the reduced 10 neuropsychological test 
battery captured patients who converted to dementia over 3.5-4.5 years. The RR scores 
between the PD-MCI criteria when applied to both the full 24 neuropsychological and 
reduced 10 neuropsychological test batteries will be observed. The RR analysis was 
conducted in R (3.3.2.), with a statistic deemed significant when the 95% confidence 





The average patient age at study entry was 65.7 years (SD = 8.0 years). Table 5-1 
summarizes the baseline demographic and neuropsychological data used in this study, with 
the cognitive groupings determined using the original 24 neuropsychological test battery. 
There was a 20% conversion rate to dementia for the PD patients in the four-year follow-up 
period (28 out of 138 patients; 16 men and 12 women). There were no significant differences 
between the level of education or premorbid IQ (WTAR) across the groups (PD-N, PD-MCI 
‘one impairment in each of two domains’ and the PD-MCI ‘two impairments in one 
domain’). 
The PD-MCI ‘one impairment in each of two domains’ group and PD-N group 
showed no evidence of a difference in age or symptom duration at study entry. When the PD-
MCI ‘one impairment in each of two domains’ group were compared to the PD-N group we 
found that they had significantly higher CDR and ADAS-Cog scores. They also performed 
significantly worse than PD-N’s in the executive, attention, episodic memory and 
visuospatial domains, and as a result also had worse global cognition. 
The PD-MCI ‘two impairments in one domain’ group however were significantly 
older, had longer symptom duration than the PD-N group. The PD-MCI ‘two impairments in 
one domain’ group also had higher ADL’s, Hoehn and Yahr and UPDRS (motor) scores than 
PD-N’s.  They also had significantly higher CDR, DRS-2, ADAS-Cog and MoCA scores 
than PD-N’s and preformed significantly worse across all the five cognitive domains. In 
addition to this, the PD-MCI ‘two impairments in one domain’ group also had significantly 
lower global cognitive Z score than the PD-N group. 
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When the two PD-MCI groups were compared at study entry, there was no evidence 
of differences in age or symptom duration at study entry. The PD-MCI ‘two impairments in 
one domain’ group did however have significantly higher CDR, DRS-2, ADAS-Cog and 
MoCA scores than the PD-MCI ‘one impairment in each of two domains’ group. They also 
preformed significantly worse across all five cognitive domains and had a significantly lower 








‘One impairment in 
each of two domains’ 
PD-MCI: 
‘Two impairments in 
one domain’ 
Sample size (n) 74 22 42 
Convert to PDD (n) 4 3 21 
Sex, M:F 49:25 13:9 27:15 
Age 64 (8) 67 (7) 68 (8)
b 
Education (y) 13.1(2.8) 12.4(2.7) 12.8(3.0) 





Reisberg IADL 0.4(0.4) 0.6(0.7) 0.8(0.6)
b 






Symptom duration (y) 4.7(3.9) 6.6(4.6) 6.7(4.4)
b 
Hoehn and Yahr stage 1.9(0.7) 2.0(0.5) 2.3(0.7)
b 
UPDRS (Motor) 29.2(16.1) 32.0(11.6) 38.9(17.0)
b 
MoCA 26.7(2.4) 26.3(2.1) 23.3(2.8)
b,c 




6. Executive function +0.39(0.61) -0.06(0.42)b -0.84(0.70)b,c 
7. Attention, working 













10. Languagea +0.22(0.35) -0.03(0.58) -0.37(0.55)b,c 
Abbreviations: PDD = Patients who met Level II criteria for Parkinson disease with dementia; 
Global Z score = mean derived from attention, executive function, visuospatial and episodic 
memory domains; ADAS-Cog = Alzheimer’s Dementia Assessment Scale-Cognitive; CDR = 
Clinical Dementia Rating; DRS-2 (AESS) = Dementia Rating Scale-2 (Age and Education 
Scaled Score); IADL = Instrumental Activities of Daily Living; MoCA = Montreal Cognitive 
Assessment; NPI = Neuropsychiatric Inventory; UPDRS (Motor) = Unified Parkinson’s 
Disease Rating Scale (Motor Component); WTAR = Wechsler Test of Adult Reading for 
premorbid IQ. 
a 
forty-two PD patients did not have two language measures at study entry.
 
b 
Significantly different from PD-N, Tukey post hoc tests, p <0.05. 
c 
Significantly different from PD-MCI: ‘One impairment in each of two domains’, Tukey post 




5.3.2. Selecting the most sensitive tests 
Table 5-2 outlines the odds ratios and rankings of each test from the Attention, Executive 
Function, Episodic Memory, and Visuospatial domains. Both the tests that were selected in 
the Attention and Visuospatial domains, respectively, were significantly related to 
progression to PDD. However, in the episodic memory domain only CVLT-II SF Free recall 
was significantly associated with future progression to PDD. Rey Short Delay was selected, 
as from a practical standpoint, I suggested it was better to have two different types of 
episodic memory tests within the cognitive domain to ensure that patients who have both 
language-based and spatial-based memory deficits can be assessed using this reduced test 
battery. In the Executive Functioning domain, Trails B was selected as second test based on 
the test’s ability to predict progression to PDD from an unpublished observation made by Dr 
Daniel Myall, it also should be noted that Trails B was only marginally non-significant in this 
analysis. This resulted in a 10 neuropsychological test battery consisting of the Map Search 
Test and Digit Ordering (Attention), Stroop Interference and Trails B (Executive), Picture 
Completion and Rey Copy (Visuospatial), and CVLT-II SF Free Recall and Rey Short Delay 
(Episodic Memory). In the Language domain, no odds ratios were calculated as too few 
patients received the Boston Naming Test at baseline, leaving only two tests in the cognitive 
domain (DRS-2 similarities sub-test, and ADAS-Cog language components).   
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Table 5-2. Ranking and odds ratio of each neuropsychological test assessed per cognitive 
domain (excluding the language domain)
 
Domain 








TEA (Map Search) 0.19 (0.08-0.38)a 
Digit Ordering 0.53 (0.28-0.90)a 
Stroop word 0.64 (0.21-1.83) 
Trails A 0.85 (0.44-1.62) 
Stroop colour 1.02 (0.39-2.86) 
















Stroop Interference 0.38 (0.21-0.64)a 
Trails B 0.61 (0.35-1.04) 
Category Fluency 0.65 (0.34-1.20) 
Category Switching 0.73 (0.39-1.32) 
Action Fluency 0.99 (0.58-1.69) 










Picture Completion 0.51 (0.26-0.93)a 
Rey Copy 0.64 (0.41-0.96)a 
JLO 0.69 (0.41-1.15) 












 CVLT-II SF Free recall 0.44 (0.19-0.91)
a 
CVLT-II SF Short delay 0.72 (0.32-1.54) 
Rey Short delay 0.74 (0.22-2.32) 
Rey Long delay 0.84 (0.24-2.92) 
CVLT-II SF Long delay 1.24 (0.53-3.09) 
Abbreviations: CVLT-II SF, Californian Verbal Learning Test - Second Edition, Short Form; 
JLO, Judgement of Line Orientation; TEA, Test of Everyday Attention; VOSP, Visual Object 
and Space Perception Battery. 
aSignificant, p < 0.05. Here, odds ratio refers to the odds of a patient who develop PDD four-
years later performing poorly on a specific neuropsychological test compared to the odds of a 
patient who does not progress to PDD performing poorly on the same test.  
 
5.3.3. Effect of reduced test battery on selection of PD-MCI groups 
When the restricted 10 neuropsychological test battery was used (two tests per cognitive 
domain, ten in total), the number of patients in each PD-MCI group changed, relative to the 
full 24 neuropsychological battery. Using the PD-MCI ‘two in one domain’ criterion, the size 
of the group reduced from 42 patients to only 22 patients, whereas using the PD-MCI ‘one in 
each of two domains’ criterion the group grew from 22 patients to 25 patients (Figure 5-1A 
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and Figure 5-1B). The percentage of patients captured by each of the PD-MCI groups, 
respectively, who later converted to PDD increased when a restricted 10 neuropsychological 
test battery was employed increased for both PD-MCI criteria (PD-MCI ‘two impairments in 
one domain’, Full 24 neuropsychological test battery: 50% converted, n = 21; Reduced 10 
neuropsychological test battery: 73% converted, n = 16; PD-MCI ‘one in each of two 
domains’ Full 24neuropsychological test battery: 14% converted, n = 3; Reduced 10 
neuropsychological test battery: 24% converted, n = 6). An increase in the proportion of 
patients who converted to PDD at follow-up within each PD-MCI group was due to patients 
who did not progress to PDD no longer meeting PD-MCI criteria when applied to a 10 
neuropsychological test battery. This was expected as when more sensitive tests are used, a 
smaller number of patients will meet each PD-MCI criterion, but the proportion of patients 




Figure 5-1. PD-MCI criterion application. (A) PD-MCI selection when applied to the full 24 
neuropsychological test battery. (B) PD-MCI selection when applied to the reduced 10 
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5.3.4. Risk of PDD progression 
There was no evidence of a difference in relative risk (RR) of developing PDD between the 
groups classified using the PD-MCI ‘two impairments in one cognitive domain’ criterion, 
when applied to the reduced 10 neuropsychological test battery or the full 24 
neuropsychological test battery (Full 24 neuropsychological test battery RR = 6.9, 95% CI 
3.3-14.6; Reduced 10 neuropsychological test battery RR = 7.0, 95% CI 3.8-12.6). Both were 
also able to identify patients at significantly higher risk of developing PDD four-years later 
then the group of patients did not meet each of these criterions, respectively. Unlike when 
applied to the full 24 neuropsychological test battery, the PD-MCI ‘one impairment in each 
of two domains’ (but never both within a single cognitive domain) group identified using the 
reduced 10 neuropsychological test battery group had an increased risk of PDD compared to 
the remaining PD-N patients, unlike when this criterion was applied to the full 24 
neuropsychological test battery (Full 24 neuropsychological test battery RR = 2.5, 95% CI 
0.7-8.8; Reduced 10 neuropsychological test battery RR = 3.6, 95% CI 1.3-9.5). 
As both PD-MCI criteria identified patients who were at an increased risk of future 
PDD, we decided to combine them. This means that we are no longer restricting the PD-MCI 
patient’s impairments to being within or across cognitive domains. This new combined PD-
MCI criterion of ‘two impairments at -1.5SD anywhere’ identified patients who were at a 
greater risk of imminent PDD (n = 47; 47% converted to PDD; RR = 7.1, 95% CI 3.2-16.1). 
There was no evidence, however, of a difference when the RR was compared to the PD-MCI 
group who had ‘two impairments in one cognitive domain’ using the reduced 10 
neuropsychological test battery, even though all the patients who met the criterion for PD-
MCI ‘one impairment in each of two domains’ are captured by this combined criterion. This 
suggests that when a restricted 10 neuropsychological test battery that consists of sensitive 
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tests is used, it can identify at risk PD-MCI patients who have impairments within a single 
cognitive domain and across multiple cognitive domains. 
5.3.5. Pattern of domain impairments when the test battery is reduced 10 
neuropsychological test battery 
Figure 5-2 shows the pattern of domain impairments at baseline in the PD-MCI group who 
(A) had at least ‘two impairments at -1.5SD within a single cognitive domain’ (Figure 5-2A), 
(B) had ‘one impairment at -1.5SD in each of two domains’ (never two in the same cognitive 
domain; Figure 5-2B) and (C) had at least ‘two impairments at -1.5SD anywhere’ (Figure 
5-2C) when applied to a reduced 10 neuropsychological battery. Note that multiple cognitive 
domain impairments are therefore different due to the criterions. In Figure 5-2A, multiple 
cognitive domain impairments are defined as two impairments in each of two or more 
cognitive domains (i.e. at least four impairments), while in Figure 5-2B and Figure 5-2C, 
multiple cognitive domain impairments are defined as two impairments across two or more 
cognitive domains (i.e. only two or more impairments).  
5.3.5.1. PD-MCI group defined as having at least ‘two impairments at -1.5SD within a 
single cognitive domain’ 
In Figure 5-2A, nine of the 22 patients who met the PD-MCI criterion of ‘two impairments in 
a single domain’ had multiple cognitive domain impairments (defined above). Eighty-nine 
percent of these patients converted to PDD at follow-up (8 of 9). Sixty-two percent of those 
with single cognitive domain impairments (8 of 13) converted to PDD. The PD-MCI patients 
who had multiple cognitive domain impairments that included episodic memory, irrespective 
of conversion or not, had a mixture of other cognitive domains involved (episodic memory 
and executive, n = 2; episodic memory and attention, n = 1; and episodic memory, executive 
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and attention, n = 1). Multiple cognitive domain impairments that did not include episodic 
memory were: executive and attention, n = 3; attention and visuospatial, n = 1; and executive, 
attention and language, n = 1. None of the PD-MCI patients had single cognitive domain 
impairments in the language domain. The rest of the single cognitive domain impairments 
were spread over the other four cognitive domains (episodic memory, n = 4; executive, n = 4; 
visuospatial, n = 1; and attention, n = 4). Again, there was no obvious pattern to the cognitive 
domains impaired and conversion to PDD, but about half of the patients who later converted 
to PDD had impairments in multiple cognitive domains. 
5.3.5.2. PD-MCI group defined as having ‘one impairment at -1.5SD in each of two 
domains’ (but never two in the same cognitive domain) 
In Figure 5-2B, all 25 PD-MCI patients in this category had multiple cognitive domain 
impairments due to this definition of the PD-MCI. The PD-MCI patients who had multiple 
cognitive domain impairments that included episodic memory, irrespective of conversion or 
not, had a mixture of other cognitive domains involved (episodic memory and executive, n = 
1; episodic memory and attention, n = 5; episodic memory, executive, attention and 
visuospatial, n = 3; episodic memory, attention, executive, and language, n = 4; episodic 
memory, attention and visuospatial, n = 1; episodic memory, executive and visuospatial, n = 
1; episodic memory and language, n = 1; episodic memory and visuospatial, n = 3; and 
episodic memory, visuospatial and language, n = 1). Multiple cognitive domain impairments 
that did not include episodic memory were: executive and attention, n = 1; attention and 
visuospatial, n = 2; executive, attention and language, n = 1, and attention, executive, 
visuospatial and language, n = 1. There was no obvious pattern to the cognitive domains 
impaired and conversion to PDD, as everyone had multiple cognitive domain impairments. 
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5.3.5.3. PD-MCI group defined as having at least ‘two impairments at -1.5SD on any of the 
restricted set of 10 tests’ 
In Figure 5-2C, only one patient out of 47 who met this PD-MCI criterion had a single 
cognitive domain impairment (Executive domain: Figure 5-2C) and this patient was not a 
converter to PDD four-years later. Most patients who met this PD-MCI criterion had multiple 
cognitive domain impairments that included episodic memory, irrespective of conversion or 
not. Alongside the episodic memory impairment there were a mixture of other cognitive 
domains involved (episodic memory and attention, n = 6; episodic memory, attention and 
executive, n = 4; episodic memory, attention, executive and language, n = 4; episodic 
memory, attention and visuospatial, n = 3; episodic memory, attention, executive and 
visuospatial, n = 9; episodic memory, attention, executive, language and visuospatial, n =1; 
episodic memory and executive, n = 2; episodic memory, executive and visuospatial, n = 4; 
episodic memory, executive, visuospatial and language, n =1; episodic memory and language 
n = 1; episodic memory and visuospatial, n = 3; and episodic memory, visuospatial and 
language, n = 1). Multiple cognitive domain impairments that did not include episodic 
memory were: attention and executive, n = 1; attention, executive and language, n = 1; 
attention, executive and visuospatial, n = 1; attention and visuospatial, n = 4, and attention, 
executive, visuospatial and language, n = 1. Again, there was no obvious pattern to the 
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Figure 5-2. Pattern of Domain Impairments using a reduced 10 neuropsychological test 
battery. (A) PD-MCI ‘two impairments at -1.5SD in a single cognitive domain’. (B) PD-MCI 
‘one impairment in each of two cognitive domains’. (C) PD-MCI ‘two impairments at -1.5SD 
anywhere’. The grey bars represent the percentage of patients who had two or more 
impairments in a simple cognitive domain only or two or more impairment in each of two or 
more cognitive domains and did not develop PDD. The black bars represent the percentage 
of patients who had two or more impairments in a simple cognitive domain only or two or 
more impairment in each of two or more cognitive domains and did develop PDD four-years 
later. The numbers above the bars show the number of patients who have that impairment out 
of the sub-group. 
NB. Multiple cognitive domain impairments are not equivalent in A, B and C. In A, a multiple 
cognitive domain impairment is defined as two impairments in each of (or more) cognitive 
domains, while in B and C, a multiple cognitive domain impairment is defined as two or more 




We successfully identified a reduced 10 neuropsychological test battery from a 
comprehensive 24 neuropsychological test battery that both meets standard Level II PD-MCI 
criteria, and identifies patients who have a high risk of PDD in four-years’ time. Our reduced 
10 neuropsychological test battery consists of the Map Search and Digit ordering for the 
Attention domain, Stoop interference and Trails B for the Executive functioning domain, 
Picture completion and Rey copy for the Visuospatial domain, CVLT-II SF Free recall and 
Rey short delay for the Episodic Memory domain and DRS-2 similarities and the language 
components of the ADAS-Cog for the Language domain. Both PD-MCI criteria used in this 
study captured at risk patients who developed PDD four-years later. That is, when a reduced 
battery is used that is sensitive to progression to PDD, a PD-MCI criterion that does not 
restrict the two impairments to only a single cognitive domain is now also able to identify 
patients who are at high risk of future PDD. While this finding needs to be replicated, it 
suggests that the most critical factor of PD-MCI when looking at the progression to PDD is 
not where the impairments are located, but rather that the tests used for the evaluation of PD-
100 
 
MCI status are sensitive at identifying future PDD. 
There was no obvious pattern of domain impairment in terms of which cognitive 
domains were important for progression to PDD. The domain impairment patterns did 
however indicate that having only one impaired test in each of two or more cognitive 
domains did not increase an individual’s risk of developing PDD four-years later. In fact, the 
cognitive domain impairment comparison across the three PD-MCI groups, showed that a 
PD-MCI criterion where a multiple cognitive domain impairment requires ‘two impairments 
in each of two domains’ (i.e. at least four impaired scores) does provide a useful indicator of 
PDD four-years later. This variation in cognitive domain impairment is consistent with the 
heterogeneous cognitive profile of PD patients who experience cognitive decline (Broeders, 
de Bie, et al., 2013; Jacobs et al., 1995; Janvin et al., 2006; Mahieux et al., 1998; Woods & 
Troster, 2003). Patients who had ‘two impairments in each of two or more domains’ were 
more likely to develop PDD by the end of the four-year follow-up period. Whereas PD-MCI 
patients who had ‘two impairments in a single domain’ were not as likely to progress to PDD 
at follow-up. The non-PD specific MCI literature supports the notion that impaired 
performance on multiple tests within a cognitive domain increases the likelihood of future 
cognitive decline (Jak et al., 2009; Teng et al., 2009). Other studies, using both reduced 10 
neuropsychological and comprehensive neuropsychological test batteries and different PD-
MCI criterions, have also found that multiple-domain impairments were more common in 
their PD-MCI cohorts (Goldman et al., 2013; Goldman et al., 2015; Marras et al., 2013) and 
can be associated with the conversion to dementia (Broeders, de Bie, et al., 2013). Due to the 
variation between the findings of this study and the literature, it is essential to ensure that PD-
MCI Level II criteria recommendations are met and thus PD patients are assessed across all 
five cognitive domains. As PD-MCI patients who progress to PDD can exhibit a broad range 
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of different impairments, particularly impairments across multiple cognitive domains. 
The sensitive tests selected for the reduced 10 neuropsychological test battery in this 
study are limited by the initial tests that were included in the comprehensive 24 
neuropsychological test battery at the NZBRI. If different tests had been used, the 10 
neuropsychological tests selected might be different. This is important to note, that if the 
same test selection methodology were applied to a different comprehensive 
neuropsychological test battery from an independent PD researching site, a test that was 
deemed sensitive in this study may not be selected. This difference in test selection is due to 
the specific composition of tests grouped together in each cognitive domain, thus if the tests 
are not identical to the tests which were employed in our original 24 neuropsychological, then 
there is a chance that different tests will be selected. For instance, Goldman et al. (2015) and 
this study had seven tests in common when comparing both studies comprehensive test 
batteries. In both cases, Digits forwards and backwards was not selected in the respective 
reduced 10 neuropsychological batteries, while Trails B was. In the Goldman et al. (2015) 
study, they selected category fluency and Boston naming as the two language tests, JLO as a 
visuospatial test and Trails A as an attention domain test in their reduced 10 
neuropsychological test battery. All of these measures were part of our 24 
neuropsychological test battery but none were selected as being sensitive to progression to 
PDD. In addition, tests were grouped into cognitive domains differently in the Goldman et al. 
(2015) study compared to our study, with category fluency classified as an executive 
functioning task in our study, but a language measure in Goldman et al. (2015). Similar 
variations were present when the reduced 10 neuropsychological test battery from this study 
was compared to the tests identified by Federico et al. (2017). Like Goldman et al. (2015), 
Federico et al. (2017) selected category fluency in their 10 neuropsychological test battery as 
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an executive functioning measure (same cognitive domain as our study). Like our study, 
Trails A, JLO, Digits forwards and backwards and Boston naming were not selected in the 10 
neuropsychological battery, and Trails B was in selected in both studies. An important 
distinction to make is that in both of these comparison studies, tests were selected based on 
their ability to identify PD-MCI, whereas in this study tests were selected to identify 
progression to PDD four-years later. This alone should explain the variation in test selection 
between these studies, despite having some test overlap. This does, however, raise the 
interesting question of whether tests which are most sensitive to identifying PD-MCI are the 
same as tests most sensitive to progression to PDD. Given the tests selected by Goldman et 
al. (2015) and Federico et al. (2017) it would suggest that there could be differences in a tests 
ability to distinguish between the two cognitive conditions. 
Although the test selection approach used in this study is a marked improvement 
compared to the approach used in Chapter 4, there are still significant limitations. Firstly, 
excluding patients who have missing tests score in the LR could have biased our results is an 
obvious limitation of this analysis. Instead, missing test scores could have been imputed 
using a method such as Flexible Imputation of Missing Data (Van Buuren, 2012). Secondly, 
using the logistic regression model to determine which two tests per cognitive domain are 
sensitive to future PDD conversion, and then validating PD-MCI criteria on their RR of 
future PDD leads to a degree of double dipping. This means the performance of the reduced 
test battery is likely to be worse than indicated. This could have been overcome by selecting 
the tests using the logistic regression model in the existing cohort and then testing the 
reduced test battery on an independent cohort to establish each PD-MCI criteria’s ability to 
identify patients at a high risk of future PDD. Thirdly, LR was used without any form of 
regularisation, which can result in a poor method for feature selection, especially when 
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variables are correlated. Here, this is a real issue as the features are neuropsychological tests 
which are all measuring cognitive performance within the same cognitive domain, thus they 
will be highly correlated. In addition, using significance as a threshold is also a poor method 
for deciding what features to select in a multi-variable LR. To overcome these limitations a 
LASSO, elastic net, LR model could be used where there is a penalty for large coefficients in 
a model and regularisation to aid with not fitting to noise. This would also improve out-of-
sample performance for the reduced 10 neuropsychological test battery generated. This 
approach to reducing the test battery will be investigated outside of this thesis, given time 
constraints. 
To overcome the small number of patients who converted to PDD during the follow-
up period, bootstrapping was used to calculate the CI in the RR analysis. This would have 
improved the generality of RR scores to other populations, but their use will not overcome 
the bias resulting from the above limitations. At the NZBRI, we are currently following a 
new cohort of patients and with time the findings from this analysis can be properly tested by 
using this second group of patients. The approach used in this Chapter (5) is, however, still a 
large improvement from that of the previous chapter (4), which based test selection on each 
test’s ability to identify PD-MCI level impairment (i.e. scores below -1.5SD), which was 
most likely biased due to neuropsychological test constraints. Further improvements could 
also be made by adopting a leave one out approach. This would enable us to select tests 
deemed sensitive to progression and then evaluate their utility on an independent patient to 
determine whether the PD-MCI criterion applied is able to capture patients who later develop 
PDD. 
There were different tests identified in the reduced 10 neuropsychological test 
batteries selected in Chapter 4 and 5. This is a direct result of the methods used to select the 
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reduced 10 neuropsychological batteries, as the method used in Chapter 4 selected tests based 
on the identification of impairment, while in Chapter 5 the tests were selected on their 
sensitivity to future PDD four-years later. Another approach we could have taken would be to 
preform ROC tests on the entire tests battery to determine which combination of tests, 
regardless of which cognitive domain they are from, are the most sensitive to progression to 
PDD four-years later. This may have highlighted a slightly different combination of tests as 
being the most sensitive to progression to PDD. Using these different methods to select the 
neuropsychological tests included in the reduced test batteries could explain why tests 
identified as being able to differentiate between PD-MCI and PDD in cross-sectional studies 
have performed poorly when applied to longitudinal studies which look at cognitive decline 
over time (Biundo et al., 2014; Jacobs et al., 1995; Janvin et al., 2006; Levy et al., 2002; 
Mahieux et al., 1998; Williams-Gray et al., 2013; Woods & Troster, 2003). Of the two 
approaches discussed in Chapters 4 and 5, I would recommend the Chapter 5 reduced 10 
neuropsychological test battery to be used when one wants to identify patients at risk of 
progression to PDD over the next four-years. Although the methodology used to reduce the 
test battery to 10 neuropsychological has clear limitations, the Chapter 5 10 
neuropsychological battery does perform better than that of Chapter 4. If this 10 
neuropsychological test battery was to be implemented at the New Zealand Brain Research 
Institute it would take about one-and-a-half hours to conduct the neuropsychological 
assessment compared to the four-hours that the full 24 neuropsychological test battery 
currently takes. This would save a significant amount of time and money. 
5.5. Conclusions 
We have shown that a restricted test battery, consisting of only 10 neuropsychological tests, 
is able to identify PD patients as PD-MCI who are at an imminent risk of PDD (~4yrs). We 
105 
 
also found that once sensitive tests are used, the two impairments needed for PD-MCI 
classification do not have to fall only in a single cognitive domain to be able to identify 
patients at the highest risk of future PDD, unlike Chapter 3. Thus, we reconcile the problem 
of whether the two impairments needed for PD-MCI classification need to occur within a 
single cognitive domain or across cognitive domains, as there was no evidence of a difference 
between the RR of progression to PDD when the impairments were and were not restricted to 
a single cognitive domain. External validation using an independent patient cohort to verify 
whether the tests selected are able to identify PD-MCI patients at-risk of PDD is still needed. 
This is essential to confirm the utility of this restricted test battery for future clinical research 







 Neuropsychiatric symptoms and progression to dementia Chapter 6:
6.1. Background 
Neuropsychiatric or behavioural symptoms, such as depression, anxiety and hallucinations, 
are common in Parkinson’s disease (PD; Aarsland et al., 1999; Brown & MacCarthy, 1990; 
Kulisevsky et al., 2008; Lee & Weintraub, 2012; Riedel et al., 2010). There is an association 
between cognitive decline and an increase in neuropsychiatric symptoms in PD, particularly 
visual hallucinations (Aarsland et al., 2007; Aarsland et al., 2017; Fenelon, Mahieux, Huon, 
& Ziegler, 2000; Kulisevsky et al., 2008). Both cognitive decline and neuropsychiatric 
symptoms are precipitating factors for placement in full time residential care (Aarsland, 
Larsen, Tandberg, & Laake, 2000). 
  The highest burden of neuropsychiatric symptoms, particularly depression and 
hallucinations, occurs in those with dementia (PDD; Bronnick et al., 2005). For example, 
Aarsland et al. (2007) reported that 89% of patients with PDD experienced at least one 
neuropsychiatric symptom and 77% experienced two or more.  In contrast, the reported 
presence of neuropsychiatric symptoms in non-demented PD patients has varied between 
22% and 87% (Kulisevsky et al., 2008; Lee & Weintraub, 2012). When comparing the 
presence of neuropsychiatric symptoms, particularly depression, and cognitive status, most 
studies have found no differences between PD patients classified as having normal cognition 
(PD-N) and those classified as having mild cognitive impairment (PD-MCI; Dalrymple-
Alford et al., 2010; Hobson & Meara, 2015; Pedersen et al., 2013). Broeders, de Bie, et al. 
(2013), however, reported that PD-MCI patients experienced more depression and anxiety 
symptoms than PD-N patients. There is a higher prevalence of depression, hallucinations and 
global neuropsychiatric symptoms in PDD than PD-N patients (Dalrymple-Alford et al., 
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2010; Hobson & Meara, 2015) and of depression in PDD compared to PD-MCI patients 
(Hobson & Meara, 2015). 
Despite the fact that neuropsychiatric symptoms often increase in PDD, few studies 
have directly examined the predictive validity of neuropsychiatric symptoms and progression 
to PDD. Some of the studies that have looked at the predictive value of neuropsychiatric 
symptoms, have found that anxiety and/or depression did not predict cognitive decline in PD 
patients five-years later (Broeders, Velseboer, et al., 2013; Pedersen et al., 2013). Whereas 
other studies have reported that visual hallucinations, visual illusions, thought disorders, 
depression and apathy were associated with the progression to dementia four-six years later 
(Anang et al., 2014; Fitts et al., 2015; Janvin et al., 2006; Pedersen et al., 2009). All of the 
studies which have found a relationship between neuropsychiatric symptoms and future PDD 
have not used Level II criteria to cognitively classify their patient samples. 
Hallucinations are the most thoroughly studied behavioural symptom in regard to 
future PDD. In contrast to other behavioural symptoms, there is consistent evidence that 
hallucinations are linked to cognitive decline and are predictive of future dementia (Aarsland 
et al., 2003; Aarsland et al., 2004; Anang et al., 2014; Factor et al., 2003). All of these studies 
found that hallucinations were associated with progression to PDD two-eight years later. In 
contrast, Fenelon et al. (2000) found that cognitive impairment was an independent predictor 
of visual hallucinations, but they did not measure the relative influence of cognitive 
impairment in relation to hallucinations. Thus, it is unclear whether hallucinations are 
predictive of future PDD. In chapter 3 we observed that a greater proportion of patients who 
converted to PDD four-years later experienced hallucinations at study entry compared to 
those who did not develop PDD (Wood et al., 2016), but we did not determine whether the 
increased occurrence of hallucinations at study entry was predictive of future PDD. 
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A series of recent studies have confirmed a link between mild cognitive impairment in 
PD (PD-MCI) and the progression to dementia (Broeders, Velseboer, et al., 2013; Hobson & 
Meara, 2015; Janvin et al., 2006; Pedersen et al., 2013), but the relationship between 
neuropsychiatric symptoms in a Level II PD-MCI population and future progression to PDD 
has never been explored. In Part One of this study, we investigated the differences between 
three cognitive groups of PD patients (PD-N, PD-MCI and PDD) from a perspective of a 
range of neuropsychiatric measures (such as hallucinations, depression and apathy) reported 
by the patient and their significant other. In Part Two, we then examined prospectively the 
longitudinal cognitive outcome of the non-dementing patients (i.e. PD-N and PD-MCI 
patients) to determine whether there were differences in baseline neuropsychiatric measures 
between patients who developed PDD four-years later and those that did not. Finally, in Part 
Three, we examined whether the neuropsychiatric measures that were potentially predictive 
of future PDD could provide any additional value over and above global cognitive function, 
age and motor function, which are all known predictors of future PDD. 
6.2. Methods 
6.2.1. Participants 
A convenience sample of 158 PD patients were used for Part One of the study, which 
evaluated the differences between neuropsychiatric symptoms and cognitive status (see 
Figure 6-1). This sample consisted of 77 PD-N, 46 PD-MCI and 35 PDD patients all of 
whom received comprehensive Level II neuropsychological and neuropsychiatric 
assessments (Table 6-1). Part Two of the study, which examined the association between the 
presence of neuropsychiatric symptoms at study onset and future progression to PDD (4 years 
later), comprised of the 123 non-demented PD patient sub-set of the Part One sample, that is, 
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those with PD-N and PD-MCI. The neuropsychological and neuropsychiatric assessments 
were repeated at the four-years follow-up assessment (range, 3.5-4.5 years; Figure 6-1). At 
study entry, two patients in the PDD group did not receive the Geriatric depression scale 
(GDS) and one of these patients also did not receive the Parkinson’s disease questionnaire 
(PDQ).  One PD-N patient, two PD-MCI patients and one PDD patient were not evaluated at 
baseline only with the Unified Parkinson’s Disease Rating Scale (UPDRS). The 
comprehensive neuropsychological assessment, PD diagnostic procedure and exclusion 
criteria were the same as those detailed in Chapter 3. The average length of motor symptoms 
experienced by patients in this study was 5.8 years (SD = 4.3 years).  
 As in chapter 3, progression to PDD before the end of the 4.5-year follow-up period 
was treated as an a priori end-point, with no subsequent follow-up. All participants took their 
usual medications on the day of testing to allow optimal performance during the morning 
testing sessions. The study was approved by a local ethics committee of the New Zealand 




Figure 6-1. Participant recruitment, exclusions and total followed over 4 years. PD = 
Parkinson’s disease; PDD = Parkinson’s disease with dementia. 
a
 Assessments were conducted at baseline and then again every one to two years later; 
patients with dementia were not followed further. 
  
Total PD patients Recruited 
n = 213 




n = 123 
PDD at baseline, n = 35 
Not followed-up 
n = 35 
Excluded n = 37 
Abnormal MRI scans, n = 6; 
Intercurrent illness, n = 2; 
Withdrew consent, n = 8; 
Atypical PD, n = 3; 
Severe depression, n = 2; 
Learning Disability, n = 1; 
No NPI at baseline, n = 15;  
Not available for follow-up 
n = 18 (of 141) 
Relocated, n = 1; 
Missed window, n = 6;  
Died, n = 9; 
Stroke, n = 1; 




Table 6-1. Demographics and neuropsychological data at study entry [mean (SD)] 
 PD-N PD-MCI PDD 
Demographics    
Sample size (n) 77 46 35 
Converted to PDD (n) 6 21 N/A 
Sex, M:F 48:29 32:14 27:8 
Age 66(8) 68(7) 73(7)
a,b 
Education (y) 13(3) 13(3) 13(3) 
PD Specific Measures    
PD duration (y) 6.0(4.0) 6.7(4.1) 11.3(7.4)
a,b 



















Cognitive Assessments    
Premorbid IQ (WTAR) 111.5(8.4) 108.8(8.40) 106.5(10.7)
a
 

















Abbreviations: PDD = Patients who met Level II criteria for Parkinson’s disease with 
dementia; PD-MCI = Patients who met Level II criteria for Parkinson’s disease with mild 
cognitive impairment; PD-N = The remaining patients who did not met criteria for PDD or 
PD-MCI were classified as having normal cognition; PD duration = defined as the duration 
from the first symptom experienced by the patient; Global Z score = mean derived from 
attention, executive function, visuospatial and episodic memory domains; ADAS-Cog = 
Alzheimer’s Dementia Assessment Scale-Cognitive; CDR = Clinical Dementia Rating; DRS-
2 (AESS) = Dementia Rating Scale-2 (Age and Education Scaled Score); IADL = 
Instrumental Activities of Daily Living; MoCA = Montreal Cognitive Assessment; N/A = Not 
Applicable; UPDRS (Motor) = Unified Parkinson’s Disease Rating Scale (Motor 
Component); WTAR = Wechsler Test of Adult Reading for premorbid IQ. 
a
Significantly different from PD-N, ANOVA followed by Tukey post hoc tests, p<0.05. 
b




6.2.2. Determination of cognitive status 
Patients were classified as PDD as described in Chapter 3 using established Movement 
Disorder Society-Task Force (MDS-TF) PDD criteria (Emre et al., 2007). The remaining 
patients were classified as either PD-MCI or PD-N. Patients were classified as PD-MCI using 
the PD-MCI criterion of ‘two impairments at -1.5SD in a single cognitive domain’, which 
was consistent with MDS-TF Level II PD-MCI criteria. As before, all remaining patients who 
did not meet either the PD-MCI or PDD criteria were classified as having ‘normal’ cognition 
(PD-N). 
6.2.3. Materials 
6.2.3.1. Neuropsychological assessment 
The same comprehensive neuropsychological assessment was administered as described in 
Chapter 3 (see Appendix A for neuropsychological test details).  
6.2.3.2. Neuropsychiatric assessment 
The Neuropsychiatric Inventory (NPI) was used to assess the frequency and severity of 12 
common neuropsychiatric symptoms (delusions, hallucinations, agitation/aggression, 
depression/dysphoria, anxiety, elation/euphoria, apathy/indifference, disinhibition, 
irritability/lability, aberrant motor behaviour, sleep and night-time behaviour disorders and 
appetite/eating changes) as reported by each patient’s caregiver or significant other 
(Cummings, 1997; Cummings et al., 1994). The caregiver rated the frequency of each 
symptom experienced on a scale of one-four and the severity of each symptom on a scale of 
one-three, based on scripted questions. These two scores were then multiplied together to 
generate a sub-score for each neuropsychiatric symptom. The sub-scores for each 
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neuropsychiatric symptom were then added together to produce a total NPI 10-item score 
(scores from the sleep and night-time behaviour disorders and appetite/eating changes sub-
scales were excluded in this total score). The original 10-item version of the NPI is a valid 
measure and is widely used. We decided to use the 10-item version in this study but also 
collected the additional information from the newer two-items (sleep and night-time 
behaviour disorders and appetite/eating changes). 
 The short form 15-point GDS (D'Ath, Katona, Mullan, Evans, & Katona, 1994) is 
comprised of 15 questions with yes or no answers, based on the patient’s self-report of how 
they have been feeling over the past week. The GDS is recommended for use in PD 
populations by Weintraub, Saboe, and Stern (2007). The initial four questions act as 
screening questions and the questionnaire is terminated after these initial four questions if the 
individual’s responses to all four indicate an absence of depression symptoms. Otherwise the 
questionnaire is continued until all 15 questions have been answered. Each question that is 
answered positively for a depression symptom is scored as one point, with 15 points being the 
highest (i.e. worst) possible total score. 
The PDQ (Peto, Jenkinson, Fitzpatrick, & Greenhall, 1995) comprises 39 PD-specific self-
rated questions. Patients are required to rate how their PD has affected them over the past 
month on a scale of zero-four (never, occasionally, sometimes, often or always/cannot do at 
all). In this study, only the hallucinations, distressing dreams and the four-items from the 
emotional well-being sub-section (totalling six items) of the PDQ were used. 
 Two items, indicative of hallucinations and depression, were extracted from Part I of 
the original UPDRS (Fahn, Elton, & Committee, 1987) and again from the revised Movement 
Disorders Society-UPDRS (MDS-UPDRS; (Goetz et al., 2008). Each patient rated their 
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experience of each symptom over the past week on a severity scale of zero-four (normal, 
slight, mild, moderate and severe). Two different versions of the UPDRS were employed in 
the study as the newer MDS-UPDRS scale was released in 2008 after the initial data 
collection had begun and it was therefore introduced after baseline testing had commenced. 
Seventy-seven patients received the original UPDRS and 77 received the revised MDS-
UPDRS, with four patients receiving neither scale. These two versions of the UPDRS are 
comparable (Goetz et al., 2008). The only difference in the hallucination scales of the two 
versions is that the MDS-UPDRS does not include vivid dreams. The depression items are 
conceptually similar in each version but the emphasis is slightly different (Goetz et al., 2008). 
With both versions of the UPDRS being comparable we took each patient’s score for the 
hallucinations and then depression items and combined each scale to form a single UPDRS 
score for hallucinations and then depression for each patient, termed the ‘Unified 
Hallucination’ and ‘Unified Depression’ scores respectively.  
6.2.4. Analysis 
In Part One, we compared several baseline neuropsychiatric symptoms across the three 
cognitive groups (n = 158; PD-N vs. PDD; PD-MCI vs. PDD; PD-MCI vs. PD-N) using 
paired Receiver Operator Curve (ROC) tests to determine whether the prevalence of 
behavioural symptoms differed across groups. In Part Two, the association between 
progression to PDD four-years later and baseline neuropsychiatric symptoms was examined 
using paired ROC tests in all non-demented patients (n = 123). If two tests which measured 
the same neuropsychiatric symptom were associated with future progression to PDD, the 
difference between these two ROCs was tested to determine whether one measure was a 
better discriminator than the other. In Part Three, a logistic regression model, comprising of 
cognition, age, motor function and those neuropsychiatric symptoms that were associated 
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with progression to PDD, was used to determine whether neuropsychiatric symptoms added 
any additional predictive value over and above cognition, age and motor function in terms of 
future progression to PDD. The ROC and logistic regression analyses were conducted in R 
(v.3.3.2) using the pROC open-source package developed by Robin et al. (2011) with 
confidence intervals produced by a bootstrapping procedure.   
6.3. Results 
6.3.1. Part One: Neuropsychiatric symptoms and cognitive status at study entry 
Table 6-1 describes the demographic and neuropsychological profiles of the three groups of 
patients included in this study at study entry. There was approximately double the number of 
males than females in each of the three cognitive groups but no significant differences in 
levels of education. The PDD group was significantly older, had experienced PD symptoms 
for longer, had more advanced Hoehn and Yahr staging, UPDRS III, ADL, ADAS-Cog, total 
NPI, GDS, lower MoCA and global cognitive scores than both the PD-N and PD-MCI 
groups. The PDD group had significantly lower premorbid IQ, higher CDR and lower DRS-2 
scores than the PD-N group, but there were no differences on these measures between the 
PDD and PD-MCI groups. The PD-MCI group did however have significantly worse Hoehn 
and Yahr staging, UPDRS III, ADL, ADAS-Cog scores, MoCA and global cognitive scores 
than the PD-N group. 
 Table 6-2 shows the baseline neuropsychiatric scores for each of the cognitive groups 
(PD-N, PD-MCI and PDD). There were no differences in any of the neuropsychiatric 
measure scores between the PD-N and PD-MCI groups. In contrast, the PDD group had 
higher aggression, apathy, delusion and NPI total scores on the NPI, were more isolated and 
lonely and had more distressing dreams on the PDQ, had higher hallucination and depression 
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scores on the UPDRS and higher GDS scores then both the PD-N and PD-MCI groups, 
respectively. The PDD group also had higher hallucination scores on the NPI, hallucination, 
depression, anxiety and aggression scores on the PDQ compared to the PD-N group.  
Table 6-2. Neuropsychiatric measures at study entry [mean (SD)] 
 PD-N PD-MCI PDD 
NPI    
Total score 4.0(7.2) 4.2(7.5) 9.8(8.1)
a,b 
Hallucinations 0.2(1.2) 0.5(1.7) 1.4(3.0)
a 
Depression 0.7(1.8) 1.0(2.3) 1.5(2.6) 
Anxiety 0.8(1.9) 1.4(2.1) 1.5(2.2)
 
Aggression 0.2(1.5) 0.2(1.3) 1.3(2.2)
a,b 










Irritability and Liability 0.6(2.0) 0.2(1.0) 0.7(1.7) 
Aberrant Motor Behaviour 0.2(1.4) 0.2(0.5) 0.3(0.9) 
Sleep and Night time Behaviour Disorders 1.3(2.5) 1.4(2.6) 1.3(2.5) 













Anxiety 1.0(0.9) 1.2(1.0) 1.5(1.2)
a 
Aggression 0.4(0.7) 0.4(0.7) 0.8(1.0)
a 
Isolated and Lonely 0.4(0.8) 0.3(0.5) 0.9(1.0)
a,b 
Weepy and Tearful 0.6(1.0) 0.8(1.1) 0.6(0.7) 
Worried about future 1.1(1.1) 1.0(1.2) 1.1(1.0) 
Distressing dreams 0.5(0.9) 0.5(0.8) 1.3(1.4)
a,b 
UPDRS    
Unified Hallucinations 0.3(0.6) 0.7(0.9) 1.2(1.2)
a,b 
Unified Depression 0.4(0.8) 0.4(0.6) 1.1(1.0)
a,b 
GDS 0.9(2.4) 1.2(2.3) 2.8(3.2)
a,b 
Abbreviations: PDD = Patients who met Level II criteria for Parkinson’s disease with 
dementia; PD-MCI = Patients who met Level II criteria for Parkinson’s disease with mild 
cognitive impairment; PD-N = The remaining patients who did not met criteria for PDD or 
PD-MCI where classified as having normal cognition; GDS = Geriatric Depression Score; 
NPI = Neuropsychiatric Inventory; PDQ =Parkinson’s disease Questionnaire; UPDRS = 
Unified Parkinson’s disease Rating Scale. 
a
Significantly different from PD-N, ANOVA followed by Tukey post hoc tests, p<0.05. 
b




Figure 6-2 depicts the ROC AUC values for each neuropsychiatric symptom to describe their 
ability to distinguish between the cognitive groups (PD-N vs. PDD; PD-N vs. PD-MCI; PD-
MCI vs. PDD).  Several symptoms were assessed across each of the NPI, PDQ and UPDRS 
scales and these measures provided consistent evidence of greater levels of hallucinations, 
depression, anxiety, and aggression in PDD versus PD-N groups. There were also sub-
components of the NPI and PDQ which indicated greater levels of apathy, loneliness, and 
distressing dreams in PDD versus PD-N groups. When the PDD group was compared to the 
PD-MCI group, a similar overall pattern persisted. However, the ROC AUC values were 
generally smaller, and there was reduced evidence for differences in several of the sub-
components measured, especially in anxiety, hallucinations and depression. There were few 
differences between the PD-N and PD-MCI groups, with only UPDRS hallucinations 








6.3.2. Part Two: Progression to PDD and neuropsychiatric symptoms 
Part one confirmed that PDD patients have a greater prevalence of behavioural symptoms 
than non-dementing PD patients, while there were few differences between the PD-N and the 
PD-MCI groups. Next, the relationship between conversion to PDD during the 4-year follow-
up period and neuropsychiatric symptoms was examined. In the non-demented patients at 
study entry, baseline neuropsychiatric symptoms were examined for differences in those who 
converted to PDD over the follow-up period (n = 27; 21 PD-MCI, 6 PD-N) in comparison to 
those that did not develop dementia (n = 96).  
There were very few neuropsychiatric symptoms which indicated an ability to 
distinguish patients who converted to PDD from those that did not convert over the four-year 
follow-up period (Figure 6-3). NPI total score (AUC = 0.62, 95% CI = 0.50-0.75) exhibited a 
small association with future progression to PDD. Most of the NPI sub-scale scores and GDS 
(AUC all < 0.62) were not significantly associated with PDD conversion, except for the 
anxiety sub-scale of the NPI which showed a marginal relationship to future PDD (AUC = 
0.62, 95% CI = 0.50-0.73). Patient-reported hallucinations, using items from the PDQ and 
UPDRS, had the strongest relationship of all the neuropsychiatric symptoms to future 
conversion to PDD (PDQ: AUC = 0.70, 95% CI = 0.60-0.80; UPDRS: AUC = 0.69, 95% CI 
= 0.57-0.80). In contradistinction, the hallucination sub-scale score on the NPI (reported by 
the significant other) was not significantly associated with progression to PDD (AUC = 0.55, 
95% CI = 0.48-0.62). Furthermore, when the AUCs of the three hallucination scales were 
directly compared, those from the PDQ and UPDRS each had a stronger relationship to future 
dementia than the NPI sub-scale (p < 0.05). In contrast to the majority of the neuropsychiatric 




0.73, 95% CI = 0.63-0.84) and motor function (AUC = 0.78, 95% CI = 0.64-0.91) were all 









Of the 27 patients who converted to PDD during the four-year follow-up period, 21 
were classified as PD-MCI and six as PD-N at baseline. Due to the small number of patients 
who converted to PDD from the PD-N baseline group we were only able to examine the 
relationship between behavioural symptoms and future progression to PDD in the PD-MCI 
sub-group of 21 patients. Once again there were few behavioural measures that were 
associated with progression to PDD four-years later. Patient-reported hallucinations on the 
PDQ and UPDRS were associated with progression to PDD (PDQ: AUC = 0.67, CI = 0.54-
0.81; UPDRS: AUC = 0.66, CI = 0.51-0.81), but this association was weaker than when the 
entire group of non-demented PD patients was considered. The baseline characteristics with 
the strongest associations to future progression in the PD-MCI sub-group were cognition 
(AUC = 0.80, CI = 0.67-0.93) and age (AUC = 0.76, CI = 0.62-0.90). 
  Of the 21 PD-MCI patients who converted to PDD four-years later, 11 reported 
hallucinations on the PDQ hallucinations question (scores ranging from one-three), 12 
reported hallucinations on the UPDRS hallucinations question (scores ranging from one-
three) but only four were reported to experience hallucinations by their significant other on 
the NPI hallucinations sub-scale. Of the six patients in the PD-N group at study entry who 
converted to PDD, five experienced hallucinations according to the PDQ hallucinations 
question (scores ranging from one-two), three according to the UPDRS hallucinations 
questions (scores ranging from one-two) and none were reported to experience hallucinations 




6.3.3. Part Three: Are patient-reported hallucinations indicative of future progression to 
PDD? 
Previously (Chapter 3) we reported that patients classified as PD-MCI using the specific 
criterion of ‘two impairments at -1.5SD in a single cognitive domain’ were at a much greater 
risk of developing dementia than those not captured by this criterion (Relative Risk = 7.2, 
95% CI 3.4-16.6, p <0.001). Patient-reported hallucinations were the only neuropsychiatric 
symptom found to be associated with future PDD from the ROC analysis. A logistic 
regression model was developed to assess whether patient-reported hallucinations added any 
extra predictive value on top of age, cognitive ability and motor function to progression to 
PDD. The model was first applied to all the non-demented baseline PD patients (n = 123) and 
then again to the PD-MCI sub-group (n = 46) only. The model comprised of each patient’s 
global cognitive Z scores, age, motor function and unified hallucinations score. The unified 
hallucination score was used as the patient-reported hallucination measure because clinically 
it is more widely utilised than the PDQ hallucination measure. When we interrogated the 
model with all 123 non-dementing PD patients we found that neither hallucinations (OR = 
1.70, 95% CI = 0.73-4.03) nor motor function (OR = 1.02, 95% CI = 0.97-1.09) added any 
significant information when distinguishing patients who progressed to PDD 4 years later 
from those that did not beyond that provided by their global cognitive ability (OR = 26.34, 
95% CI = 6.24-184.71) or age (OR = 1.28, 95% CI = 1.11-1.54). In the model looking only at 
PD-MCI patients, we once again found that global cognitive ability (OR = 40.63, 95% CI = 
3.42-1605.52) and age (OR = 1.21, 95% CI = 1.05-1.48) were useful and that neither patient-
reported hallucinations (OR = 1.52, 95% CI = 0.58-4.32) or motor function (OR = 1.01, 95% 




PDD 4 years later and those that who did not. This suggests that patient-reported 
hallucinations at baseline are not very useful when age and cognitive ability is known. 
6.4. Discussion 
The main finding from this study was that most neuropsychiatric and behavioural measures, 
especially those reported by a significant other, were not useful in predicting future 
conversion to dementia (PDD) over four years in non-demented Parkinson’s patients. 
However, NPI total score and the NPI anxiety sub-scale showed a small association with 
increased risk of developing PDD four-years later. Patient-reported hallucinations (as 
ascertained from the PDQ and UPDRS) had the strongest relationship to future PDD but 
hallucinations were not found to be as useful as already established predictors, such as age 
and cognitive ability, when distinguishing between those who developed PDD and those who 
did not.  
 The patients classified as having dementia at baseline experienced more 
neuropsychiatric symptoms compared to those classified as PD-MCI and PD-N. PDD patients 
as a group were also older, had significantly worse motor function (UPDRS III) and poorer 
cognition than the PD-N group. There was consistent evidence across all measures for a 
greater prevalence of hallucinations (both patient and significant other reported), depression, 
anxiety, and aggression in PDD compared to PD-N group. In addition, there was an 
indication that there were higher rates of apathy, loneliness, and distressing dreams in the 
PDD group compared to the PD-N group, however, only one measure was used to assess the 
presence of each of these symptoms. When the PDD group were compared to the PD-MCI 
group, a similar overall pattern persisted, where the PDD group showed higher rates of 




and apathy reported on the NPI only, as well as greater reports of loneliness and distressing 
dreams reported on the PDQ in the PDD group. The ROC AUC values, however, were 
generally smaller than those seen when comparing the PDD and PD-N groups, especially in 
the hallucinations and depression sub-components. There was also no difference in anxiety 
levels reported between the PDD and PD-MCI patient groups. The only difference between 
the PD-N and PD-MCI groups in terms of neuropsychiatric symptoms was on the UPDRS 
hallucinations measure, were the PD-MCI group reported experiencing more hallucinations 
than the PD-N group. These cross-sectional findings at study entry are in line with other 
studies which have looked the prevalence of neuropsychiatric symptoms across cognitive 
groups in PD, with PDD patients have more marked differences when compared to the PD-N 
and PD-MCI groups respectively (Bronnick et al., 2005; Dalrymple-Alford et al., 2010; 
Hobson & Meara, 2015). Thus, it is clear that PDD patients have a higher neuropsychiatric 
burden than non-dementing PD patients.  
The PD-MCI group had significantly worse cognition, as expected, and slightly worse 
motor function than the PD-N group. In contradistinction, there were no differences in the 
prevalence of behavioural symptoms experienced, except UPDRS hallucinations, when the 
PD-MCI and PD-N groups were directly compared. These observations accord with the 
previous findings of Dalrymple-Alford et al. (2010), who reported no differences in terms of 
depression and NPI total scores, and Hobson and Meara (2015), who found no difference in 
levels of depression and hallucinations, in these two non-demented PD groups. We did find 
that PD-MCI patients experience greater amounts of hallucinations than PD-N patients, 
unlike Hobson and Meara (2015), but we only saw this on the UPDRS measure and not on 
the hallucination measures in the NPI and PDQ. In contrast to our findings, Broeders, de Bie, 




than those classified as PD-N. This difference could be due to the fact that different tests 
were used to measure depression and anxiety. We used a selection of tests to measure 
depression (NPI depression score, PDQ depression score, UPDRS depression and the GDS) 
and anxiety (NPI anxiety and PDQ anxiety), while Broeders, de Bie, et al. (2013) used the 
Hospital Anxiety and Depression Scale (HADS) to measure these two neuropsychiatric 
symptoms. Like our study, the GDS was used as the depression measure in both Dalrymple-
Alford et al. (2010) and Hobson and Meara (2015), thus variations in the test employed to 
measure each neuropsychiatric symptom could be the cause of these differences between 
studies.  
There were few differences when behavioural symptoms in non-demented patients 
who progressed to PDD four-years later were compared to those patients who did not 
progress.  This was the dominant and more novel finding in this study. In fact, cognition, 
rather than the increased presence of neuropsychiatric symptoms, was a better predictor of 
progression to PDD. The observation that most neuropsychiatric symptoms, such as anxiety 
or depression, with the notable exception of patient-reported hallucinations, showed no 
evidence of an association with progression to PDD supports some of the literature (Broeders, 
Velseboer, et al., 2013; Pedersen et al., 2013). Unlike other studies we did not find an 
association between apathy (Fitts et al., 2015; Pedersen et al., 2009) or depression (Anang et 
al., 2014; Janvin et al., 2006) and future progression to PDD. These differences are probably 
due to difference in cognitive classification, as we used Level II criteria for PD-MCI 
classification whereas the other studies did not. This suggest that while neuropsychiatric 
symptoms are commonly experienced in non-demented PD populations (Kulisevsky et al., 




Marsh, 2000), they are not useful on their own (i.e. independently) in the prediction of future 
progression to PDD. 
We did, however, find an association between hallucinations and the progression to 
PDD. This association between the presence of hallucinations and the future development of 
PDD has also been reported by others (Aarsland et al., 2003; Aarsland et al., 2004; Anang et 
al., 2014; Factor et al., 2003), our study however is the first to find this relationship when 
Level II PD-MCI criteria has been used to classify patients cognitively. All of these studies 
used the hallucination measure from the UPDRS, except Factor et al. (2003) who used 
clinical data, to determine the presence of hallucinations, which was one of the patient-
reported hallucination measures we found to be associated with future PDD in our study. 
The association between hallucinations and the progression to PDD however, was 
only present when patient-reported hallucination scales were used (PDQ and UPDRS), not 
significant-other reported hallucination scales (NPI). This inconsistency between patient-
reported and significant-other-reported symptoms is not a new observation and can be 
influenced by many different factors. These factors include the amount of insight a patient 
has about their own symptoms, how much the patient is willing to sharing with the 
significant-other, whether the symptom is observable or not, the relationship between the 
patient and their significant-other, as well as the scales used to report the symptoms. (Fenelon 
et al., 2000; Martinez-Martin et al., 2016; McKinlay et al., 2008). The finding that patient-
reported hallucinations are associated with progression to PDD four years later but not the 
hallucination scale reported by their significant other could suggest that patients are under-
reporting the existence and/or extend of the hallucinations they experience to those around 
them or that the significant-other is under-reporting to either protect the patient or as a means 




of the study were not showing signs of dementia when they reported that they experienced 
hallucinations. This would suggest that they had sufficient insight. One can therefore assume 
that the inconsistencies between patient-reported and significant-other reported hallucinations 
was due to a relationship or scale factor, rather than the patient unreliably reporting the extent 
of their hallucinations during the study period.  
On some neuropsychiatric sub-scales, such as the Delusions, Euphoria, and Aberrant 
Motor Behaviour measures from the NPI, there were very few patients who experienced 
certain symptoms despite including 123 patients in the study. This could be due in part to the 
lack of sensitivity for detecting neuropsychiatric/behavioural symptoms of some of the sub-
scales and items employed in this analysis. Aside from the GDS, all the other measures used 
were quite restricted in extent and not specifically designed to be used as single measures in 
isolation, separate from the more encompassing scales within which they sit. Thus, those 
scores may not be as sensitive in detecting the true extent and prevalence of neuropsychiatric 
symptoms in this population of PD patients. I recognise that the use of a single item from 
larger scales, especially when trying to determine the predictive nature of specific 
neuropsychiatric symptoms, is a limitation if this study. In saying this, in most other studies 
which have look at hallucinations and their relationship future PDD, single hallucination 
measures from the UPDRS (Aarsland et al., 2003; Aarsland et al., 2004; Anang et al., 2014) 
have also been used. It would therefore be useful to repeat this study using specific targeted 
neuropsychiatric symptom scales (such as the Psychosis and Hallucinations Questionnaire 
(Shine et al., 2015) or the Hospital Anxiety and Depression Scale) in order to confirm (or not) 





There were only six patients in the PD-N group who developed PDD over the four-
year follow-up period and thus it was difficult to determine whether there were 
neuropsychiatric symptoms measured in this study that were predictive of future PDD. For 
instance, five of the six PD-N patients who converted to PDD reported to experience 
hallucinations on one or more of the hallucination scales. This could perhaps suggest that 
hallucinations have the potential to be helpful when identify patients with intact cognition 
who are at risk of developing dementia over the next four-years, but could also be 
coincidental in this dataset. Thus, further research into this relationship between 
hallucinations and the imminent progression to PDD should be conducted using a larger 
sample and targeted neuropsychiatric symptom scales, such as the Psychosis and 
Hallucinations Questionnaire (Shine et al., 2015) or the Hospital Anxiety and Depression 
Scale to more thoroughly test this finding. 
6.5. Conclusions 
This study found that patients classified with PDD experience a greater number of 
neuropsychiatric symptoms than those who were classified as PD-MCI or PD-N. Only 
patient-reported hallucinations were associated with an increased probability of conversion to 
PDD within four-years, but with hallucinations reported by a patient’s significant-other were 
not helpful in this regard. However, hallucinations do not appear to add any independent 





 Summary, limitations and concluding remarks Chapter 7:
7.1. Summary 
This thesis examined the relationship between cognitive and neuropsychiatric symptoms and 
the progression to dementia in Parkinson’s disease over a four-year period. The first two 
studies addressed uncertainty in the MDS-TF PD-MCI Level II criteria, which allow a wide 
margin of variation within the specified guidelines. By applying key variations to those 
criteria, we contributed to a validation of specific PD-MCI criteria as a signal for future 
progression to dementia over a four-year period. First, using the complete cognitive test 
battery in use at the NZBRI, we found that the PD-MCI criterion defined as ‘two impairments 
at -1.5SD in a single cognitive domain’ identified patients who were at a 7-fold increased risk 
and thus high risk of progressing to PDD within the next four-years. Second, we found that 
an abbreviated 10 neuropsychological Level II neuropsychological test battery was also 
effective for identifying patients at high risk of progressing to dementia. We used two 
different approaches to reduce the test battery from 24 items to 10, such that two tests 
remained within each cognitive domain. However, the second approach was optimal, in 
which tests were selected based on their sensitivity to future PDD. Furthermore, we found 
that when applied to this reduced 10 neuropsychological test battery, the PD-MCI criterion 
could then be relaxed to ‘two impairments at -1.5SD anywhere’, irrespective of whether the 
impairments fell within a single cognitive domain or across multiple cognitive domains. That 
is, we no longer needed to restrict the two impairments to occur only within a single 
cognitive domain, as had been suggested by the first study when all 24 measures were 
employed. When sensitive tests are used (i.e., tests included within the reduced, 10 
neuropsychological battery), two impairments occurring anywhere is sufficient to capture the 




performance and age have the strongest association with risk of progression to PDD, patient-
reported hallucinations at study entry were also found to have a moderate relationship with 
future PDD. Our study was the first to examine the predictive nature of neuropsychiatric 
symptoms in a PD population who had received Level II cognitive testing. Interestingly, 
patient-reported hallucinations were the only neuropsychiatric symptom that was associated 
with future conversion to PDD four-years later. All the other neuropsychiatric symptoms 
measured, including reports of hallucinations by the patient’s significant other, had no 
predictive utility for identifying patients at risk of developing PDD over the next four years.  
7.2. Implications for Parkinson’s disease 
In this thesis, 
1. We validated the MDS-TF Level II PD-MCI criteria for use as an early identification of 
patients at high risk of progression to PDD within the next four years. By using the PD-
MCI criterion of ‘two impairments at -1.5SD in a single cognitive domain’, an enriched 
patient sample can be selected for future intervention or treatment studies. Based on the 
findings of this thesis we would expect at least 50% of patients who meet this PD-MCI 
criterion should develop PDD over the next four years. Thus, the PD-MCI criterion of 
‘two impairments at -1.5SD in a single cognitive domain’ could be used to evaluate the 
efficacy of potential therapeutic treatments that are developed in the future and potential 
biomarkers for such treatments. 
2. We showed that even an abbreviated 10 neuropsychological battery, when it included 
tests sensitive for progression, can be used to identify MDS-TF PD-MCI Level II patients 
at risk of progressing to PDD. Moreover, a PD-MCI criterion of ‘two impairments at -




test battery to only 10 neuropsychological tests consistent with MDS-TF Level II PD-
MCI criteria would mean that cognitive testing times for each patient could be reduced 
from four hours to only one-and-a-half hours at the New Zealand Brain Research 
Institute. Implementing such a battery would have a direct benefit on patients and 
assessors by reducing fatigue and freeing up resources. 
3. We demonstrated that neuropsychiatric symptoms do not have a strong predictive value 
of progression to PDD over a four-year follow-up period. Furthermore, only patient-
reported hallucinations demonstrated an association with future progression. Global 
cognitive ability and age were much stronger predictors of progression to PDD than 
patient-reported-hallucinations when compared in a Logistic regression model.  
The overall findings of this thesis are supported by a recent review by Aarsland et al. 
(2017), which highlighted both cognitive impairment and hallucinations as the most robust 
clinical features of dementia risk in PD patients. However, we have illustrated that cognition 
is a far better predictor of future cognitive decline whereas hallucinations add no additional 
predictive value even in PD-MCI patients. 
7.3. Limitations 
The major strength of this study was the prospective use of longitudinal data and detailed 
assessments at frequent follow-up intervals. Like any long-term research project, however, 
there are a number of limitations. One such limitation, as mentioned in Chapter 3, was that 
this thesis had a modest sample size (sample size of 121-138 patients across analyses) and 
there was potential for bias due to an attrition rate of 13-18% across analyses. Nonetheless, 
the sample size was among the largest included in a separate validation of the predictive 




categorised into separate MCI subgroups, the number of converters within each group was 
small. This was particularly true for the PD-N groups (n ≤ 6 for PD-N converters across the 
three samples used). Although this suggests that the PD-MCI criteria utilised in this study are 
sensitive to progression to PDD, it did limit the conclusions that we could draw from the 
comparison PD-N group. This was primarily a statistical issue when doing the RR analysis, 
but we were able to overcome this issue with bootstrapping. This was particularly an issue 
when looking for differences between the PD-MCI and PD-N converters. The current data 
has, however, contributed to an international consortium which looked to validate the MDS-
TF PD-MCI criteria with a much larger sample (Geurtsen et al., 2014; Hoogland et al., 2017). 
That larger sample meant that there was better statistical precision for determining the risk of 
PDD, and especially the ability to assess the influence of potential modifiers such as age and 
education. Hoogland et al. (2017) found that cognitive impairment, as defined by Level II 
PD-MCI criteria increased the risk of dementia, but age and the severity of motor symptoms 
had a weaker influence. The finding that Level II PD-MCI is related to progression to PDD in 
their study mirrors what we found in our smaller cohort of PD patients. 
Another limitation of this thesis concerns the methodology employed to reduce the 
neuropsychological test battery to an optimised 10 neuropsychological battery (Chapters 4 
and 5). The logistic regression approach was a marked improvement on my first attempt to 
select the ‘best’ 10 tests. It was, however, limited due to confounding factors such as a small 
group of patients who converted to PDD over the four-year period. This meant we were 
unable to properly validate our findings in an independent population of patients. Upon 
consultation with my co-supervisor Dr Daniel Myall, we devised a new approach to 
optimising the test battery to include only the tests useful in classifying patients at high risk 




regression combined with a leave-one-out procedure. Unfortunately, this approach could not 
be completed within the time frame of my thesis, but our research group will publish the 
findings from this alternative approach in the near future. 
A third limitation of this study was the neuropsychiatric scales used to investigate the 
relationship between neuropsychiatric symptoms and progression to PDD, as discussed in 
Chapter 6. The data available for this aspect of my thesis was limited, aside from measures of 
depression (GDS). Some scales, such as the Hospital Anxiety and Depression scale, were 
only included in the longitudinal assessment after the majority of patients included in this 
thesis had completed their baseline assessment. Of greatest relevance, the findings have 
highlighted that we should explore additional scales that may provide more informative 
information about the nature of particular hallucinations. Our hallucination measures were 
limited to sub-sections of larger tests, such as the NPI or MDS-UPDRS. 
7.4. Future Directions 
An alternative perspective on cognition and progression to PDD, the focus of this thesis, is 
the ‘dual-syndrome hypothesis’ of Kehagia et al. (2012). These authors suggest that different 
underlying neural correlates of PD lead to heterogeneous cognitive impairment profiles in PD 
patients. In this thesis, there was clear evidence of heterogeneity in cognitive impairments in 
PD-MCI patients (Chapter 3-5). There was no specific pattern of impairment that could 
distinguish between patients who progressed to PDD and those that did not. Kehagia et al. 
(2012) proposed that two independent processes contribute to cognitive impairments in PD. 
The first process is based on the traditional view of PD pathology, where dopaminergic 
dysfunction disrupts fronto-striatal pathways, causing cognitive impairment. However, they 




first process is instead a progressive fronto-striatal disorder that affects all PD patients. This 
disruption is exacerbated by decline in the mesofrontal dopaminergic network and is the 
pathology which underpins dysexecutive symptoms commonly identified in patients with PD. 
The second process interferes with posterior cortical networks and this different disruption is 
the catalyst for progression to PDD, which is exacerbated by a failing cholinergic forebrain 
system. If true, PD-MCI may incorporate two separate sub-groups of patients, which would 
explain why some patients progress to PDD while others remain relatively stable cognitively 
for a longer period of time. Addressing this dual-syndrome hypothesis to further characterise 
PD patients who are a part of the New Zealand Brain Research Institute’s longitudinal study 
would be useful. This future direction would involve looking at the ‘dual-syndrome 
hypothesis’ in the context of a well-characterised longitudinal cohort from an imaging, 
neuropsychological and neuropsychiatric perspectives to determine whether dual-syndromes 
do exist in PD populations and, if so, evaluate their usefulness as markers of future cognitive 
decline in PD populations. 
In Chapter 6, we demonstrated that patient-reported hallucinations have some 
relevance to progression to PDD, but are a relatively weak predictor compared to cognition 
and age. Moreover, this association did not hold for hallucinations reported by the patients’ 
significant others. This is a clinically relevant finding, as clinicians frequently rely on reports 
from a patient’s spouse or carer rather than that of the individual diagnosed with Parkinson’s. 
This is particularly the case when the patient suffers from cognitive impairment. A future 
direction of this study would be to further explore the relationship between patient- and 
caregiver-reported hallucinations, as this is a relatively unexplored area of Parkinson’s 
research. A collaboration with Prof. Lewis at the University of Sydney is planned, as he and 




designed as a patient-reported hallucination scale (Shine et al., 2015) and the second is an 
equivalent scale for caregiver-reported hallucinations (currently under-review). Both scales 
report the type, frequency and severity of hallucinations. We hope that the use of these 
hallucination measures will provide (1) more informative hallucination data and (2) 
additional information about their role in progression to PDD. 
Another application of these findings is to use MR imaging techniques to help us 
further understand the differences between patients who develop PDD relatively quickly at 
any given point in time and those who will remain dementia-free for prolonged periods. The 
BrainAGE framework, developed by Franke, Ziegler, Klöppel, and Gaser (2010), is one such 
method. BrainAGE uses structural MRI scans to define a pattern of normal brain ageing, 
based on healthy control data. The model can then be used to predict an individual’s 
structural “brain age” from their MRI scan. The difference between the individual’s 
chronological age and the model’s predicted age is termed their BrainAGE score, with 
positive BrainAGE scores indicative of accelerated brain ageing (that is, predicted age > 
chronological age). The relative effects of PD, including mild cognitive impairment, could 
then be quantified. Baseline, cross-sectional data could be used from the longitudinal PD 
study at the New Zealand Brain Research Institute to categorise brain ageing across PD-N, 
PD-MCI and PDD groups. In addition to this, the BrainAGE metrics could be used to track 
cognitive decline within this existing longitudinal cohort, with a particular focus on the PD-
MCI patient group. The BrainAGE model has already been applied to several other 
conditions which affect brain health, such as Alzheimer’s disease, traumatic brain injury and 
type II diabetes, but it has yet to be tested in a PD population (Cole, Leech, & Sharp, 2015; 
Franke & Gaser, 2012; Franke, Gaser, Manor, & Novak, 2013; Gaser, Franke, Kloppel, 




7.5. Concluding remarks 
Specific PD-MCI criteria may be a valuable tool when enriching samples for disease 
modifying interventions, due to high progression rates to dementia. In this thesis, we were the 
first to look at the predictive nature of neuropsychiatric symptoms in a PD sample who met 
Level II PD-MCI criteria. We found that patient-reported hallucinations were moderately 
associated with progression to PDD; however cognitive ability and age were stronger 
predictors. In addition to this, most neuropsychiatric symptoms, especially those reported by 
a patient’s significant other, were not useful for predicting future PDD. We have also shown 
that the MDS-TF PD-MCI Level II criteria do have utility in the early identification of 
patients at a high risk of developing PDD, even when applied to a reduced 10 
neuropsychological test battery. We have shown that over a four-year follow-up period, the 
PD-MCI criterion of ‘two impairments of -1.5SD in a single domain’ is optimal for capturing 
those who develop PDD during this period, when applied to a comprehensive 24 
neuropsychological test battery. When a reduced 10 neuropsychological test battery of tests 
sensitive to future dementia is used, the PD-MCI criterion of ‘2 impairments at -1.5SD 
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Appendix A: Description of the standardised neuropsychological and 
neuropsychiatric tests 
A.1. Premorbid intelligence tests 
A.1.1. Wechsler Test of Adult Reading (WTAR) 
The WTAR is a premorbid IQ test that provides assessors with a measure that reflects an 
individual’s intellect before they developed cognitive difficulties. The WTAR uses 50 spelt 
words that are commonly used. Patients are asked to pronounce each word out loud and are 
scored accordingly (Holdnack, 2001). 
A.2. Global cognitive functioning 
A.2.1. Montreal Cognitive Assessment (MoCA) 
The Montreal Cognitive Assessment (MoCA) is used as a measure of global cognitive 
function. It is more sensitive to PD-MCI than the Mini Mental State Examination (MMSE), 
as the tasks are more difficult and test a wider range of cognitive domains, including 
visuospatial, executive function, memory and attention. Naming ability, language, abstraction 
and orientation to time/place are also tested (Nasreddine et al., 2005). This measure is scored 
out of 30, with higher scores indicating better performance. If a patient has 12 or less years of 
education, then one point is added to their total score to account for a lower level of 
education. Scores below 26 are considered to indicate PD-MCI and those below 21 indicate 






A.2.2. Alzheimer’s Disease Assessment Scale-Cognition (ADAS-Cog) 
The ADAS-Cog consists of 11 tasks, measuring a range of cognitive abilities which are 
thought to be affected in AD (Mohs et al., 1997). These tasks assess word recall, naming 
objects and fingers, ability to follow commands, constructional praxis, ideational praxis, 
orientation, word recognition, remembering test directions, spoken language, comprehension 
and word-finding difficulties. Scores are out of 70, with higher scores representing a greater 
level of cognitive impairment. 
A.2.3. Dementia Rating Scale-2 (DRS-2) 
The DRS-2was originally developed as a brief, standardised tool which could be used to track 
cognitive change over time in impaired individuals. It is comprised of 37-items which cover 
five global cognitive domains (Attention, Initiation/Perseveration, Construction, 
Conceptualisation and Memory; Jurica, Leitten, & Mattis, 2001). 
A.3. Executive functioning domain 
A.3.1. Action Fluency 
Action fluency requires patients to name as many verbs (action words) as they can in one 
minute (Piatt, Fields, Paolo, & Troster, 1999; Strauss et al., 2006). 
A.3.2. Trials B 
The Trails B test requires patients to draw a line connecting a number, then a letter, then the 
next number, then the next letter, and so on. The numbers span from 1-13 and letters from A-




They are corrected by bringing them back to their last correct answer when mistakes are 
made (Reitan & Wolfson, 1985). 
A.3.3. Stroop Interference 
The Stroop test measures attention and response inhibition, thought to be involved in 
executive function. Stroop interference is the last condition of three from the Delis-Kaplan 
Executive Function System (D-KEFS) version. In the interference condition participants are 
timed and asked to name the ink colour each word is printed in, not the colour of the word 
itself. This creates a conflict between the written word and the ink colour (Delis et al., 
2001a). 
A.3.4. Category Switching 
Category switching requires patients to name as many fruit – furniture word pairings they can 
in one minute (Delis et al., 2001a). 
A.3.5. Letter Fluency 
Letter fluency is measured for three different letters (F, A and S). To assess a participant’s 
ability, they are asked to name as many words as they can, starting with a specific letter of the 
alphabet (e.g. ‘F’), in one-minute (Strauss et al., 2006). 
A.3.6. Category Fluency 
Category Fluency is measured by asking participants to name as many words as they can, 
relating to a specific category in one minute. The two separate categories we use are animals 
and boy’s names. PD patients tend to have a greater impairment in category fluency than 




A.4. Attention domain 
A.4.1. Map Search Test of Everyday Attention (TEA) 
The Test of Everyday Attention-Map Search tests selective attention, working-memory and 
attention. Participants search a realistic map of Philadelphia and circle targets (e.g. restaurant 
symbols) among distractors for two sets of one-minute. Their total score is the number of 
targets found per minute, with their first minute score used in the analysis of this thesis. This 
test is based on an established theory of attention (Strauss et al., 2006). 
A.4.2. Digit Ordering 
Digit ordering requires patients to listen while an assessor reads out loud a series of numbers. 
They then must repeat it back to the assessor in ascending orders, including saying numbers 
twice if necessary. The trials are staged and after two successful recalls the numbers series 
increases by one (Wechsler, 2008a, 2008b). 
A.4.3. Trials A 
Similar to Trails B, Trails A requires patients to draw a line connecting numbers. The 
numbers span from 1-25. The test is timed and patients are required to complete the task as 
quickly as possible. They are corrected by bringing them back to their last correct answer 
when mistakes are made (Reitan & Wolfson, 1985).  
A.4.4. Stroop Colour 
Stroop Colour is one of three conditions from the D-KEFS version. In the colour condition 





A.4.5. Stroop Word 
Stroop word is one of three conditions from the D-KEFS version. In the word condition 
participants read colour words printed in black ink row by row as quickly as they possible 
(Delis et al., 2001a).  
A.4.6. Digits Forward and Backward 
The Digit span (forwards and backwards) is used to measure working memory and attention. 
Participants must repeat back to the assessor a series of random numbers; firstly, in the 
forwards direction (i.e. exactly how the assessor reads the number series to them), and then in 
the backwards order (i.e. the reverse order from how the assessor reads the number series to 
them). Their score is the maximum number of digit spans that they correctly recalled 
(Wechsler, 2008a, 2008b). 
A.5. Episodic memory domain 
A.5.1. CVLT-II SF Free Recall 
This test requires patients to listen carefully while the assessor reads out a list of nine words. 
These words are each related to one of three categories (fruit, clothing or tools). Once the 
assessor has finished reading the patient must recall as many words as they can. This is then 
repeated three more times (Delis, 2000). 
A.5.2. CVLT-II SF Short Delay 
This test comes about one minute after the CVLT-II SF-II Free Recall section has finished. In 




from one-hundred until they are asked to stop (approximately 30 seconds later). At this point 
they are asked to recall all the words they can from the free recall list (Delis, 2000). 
A.5.3. CVLT-II SF Long Delay 
Like the CVLT-II SF short delay component, the long delay task requires patients to recall as 
many words as they can, but this time after a period of about 10 minutes (Delis, 2000). 
A.5.4. The Rey Complex Figure Test (RCFT) Immediate Delay 
The Rey Immediate Delay requires patients to draw the Rey figure from memory after a 
delay of approximately three minutes (Meyers & Meyers, 1995). Time to completion and 
organisation of the reproduced drawing are recorded. 
A.5 5. .RCFT Long Delay 
The Rey Long Delay requires patients to draw the Rey figure from memory after a delay of 
approximately thirty minutes (Meyers & Meyers, 1995). Time to completion and organisation 
of the reproduced drawing are recorded. 
A.6. Visuospatial domain 
A.6.1. RCFT Copy 
The Rey copy test requires patients to copy the complex Rey figure onto a piece of blank 
paper as accurately as they can. This is done with the original figure in front of them (Meyers 
& Meyers, 1995). The time it takes for them to finish copying the figure and the thinking 





A.6.2. Judgement of Line Orientation (JLO) 
The Judgement of Line Orientation (JLO) measures visuospatial/visuoperceptual ability. 
Participants are required to identify the orientation of two lines from eleven possible options. 
Their score is the number of line pairs that are correctly orientated. It has a good internal 
consistency (Strauss et al., 2006) and PD patients have shown a consistent pattern of 
visuospatial impairments (Alegret et al., 2001). 
A.6.3. Picture Completion 
The participant is presented with a picture of an object or a scene, where one element in the 
drawing is missing. Within the specified time of 25 seconds, the patient must tell the assessor 
what important part of the drawing is missing. There are 25 pictures in total (David Wechsler, 
2011). 
A.6.4. Visual Object and Space Perception Assessment (VOSP) 
The incomplete letters task in VOSP is a measure of visuospatial/visuoperceptual 
performance. Participants must identify letters that have been visually degraded. The 
degradation continues until most of the cognitive features are removed, resulting in a better 
visuoperceptual test (James & Warrington, 1991). 
A.7. Language domain 
A.7.1. Boston Naming 
The revised 15-item Boston Naming test is used to assess language ability in our patients. 
This test was revised by Lansing, Ivnik, Cullum, and Randolph (1999) and requires patient to 




A.7.2. ADAS-Cog Language Components 
The ADAS-Cog Language Components uses five sub-scale tasks from the wider ADAS-Cog 
scale; naming objects and fingers, commands, comprehension, word-finding difficulty and 
spoken language (Mohs et al., 1997). For the naming objects and fingers task, patients have 
presented with 12 different objects which they have to name. The assessor then points to each 
of the patient’s fingers on one hand and asks what each finger is called. During the 
commands task, the patient is asked to do five commands, which increase in difficulty. 
Comprehension, word-finding and spoken language are all assessed by the assessor and then 
rated to quantify impairment in each of these areas. 
A.7.3. DRS-2 Similarities 
Tasks W-Z from the DRS-2 are used as a composite language measure. These tasks involve 
identifying similarities between items (Jurica et al., 2001). 
A.8. Significant Other (S.O.) measures 
A.8.1. Activities of Daily Living (ADL-IS) 
The ADL scale comprises of everyday activity items that are related to global and cognitive 
decline. These 40 items relate to 13 wider categories of activities. This assessment is not done 
with the patient themselves but with their chosen significant other. The S.O. is asked to rate 
the patient’s performance on a scale of 0-4 for each of the various day to day activities 






A.8.2. Clinical Dementia Rating Scale (CDR) 
The CDR is global, clinical staging measure of dementia in older populations The CDR has 
good reliability at being able to distinguish between older adults who have a range of 
cognitive abilities. The CDR is a semi-structured interview which comprises of six domains 
of functioning: memory, orientation, judgement and problem solving, community affairs, 
home and hobbies, and personal care of the participant. (Hughes, Berg, Danziger, Coben, & 
Martin, 1982). 
A.8.3. The Functional Activities Questionnaire (FAQ) 
The patient is rated by the significant on 10 complex higher order abilities using the FAQ. 
These range from keeping track of current events through to coping with balancing finances. 
Each of the 10-items are rated on a zero-four scale, where zero means no difficulty with the 
task and four means that they are dependent on others to do the task for them (Pfeffer, 
Kurosaki, Harrah Jr, Chance, & Filos, 1982). 
A.8.4. Questionnaire for Impulsive-Compulsive Disorders in Parkinson’s Disease- Rating 
Scale (QUIP-RS) 
The QUIP-RS measures the severity of symptoms related to impulse control disorders in PD. 
This measure is administered both with patients and their S.O. to ensure that they are not 
suffering from this condition, as it can be exacerbated by PD medications (Weintraub et al., 
2012). 
A.8.5. Functional Assessment Staging (FAST) 
FAST is a reliable measure for tracking functional change over time which was originally 




functional issues that occur throughout the progression of a disease, even in the more severe 
stages (Reisberg, 1988). 
A.8.6. Global Deterioration Scale 
The global deterioration scale is used to categories individuals with cognitive decline into 
stages. These stages range from (1) no impairment living independently, (2) very mild 
cognitive impairment but still living independently, (3) mild cognitive decline, still remaining 
independent and (4) moderate cognitive decline and needs supervision (Reisberg, Ferris, de 
Leon, & Crook, 1982). 
A.9. Neuropsychiatric measures 
A.9.1. The Neuropsychiatric Inventory (NPI) 
As described in Chapter 6, the NPI is used to assess the frequency and severity of 12 common 
neuropsychiatric symptoms (delusions, hallucinations, agitation/aggression, 
depression/dysphoria, anxiety, elation/euphoria, apathy/indifference, disinhibition, 
irritability/lability, aberrant motor behaviour, sleep and night-time behaviour disorders, and 
appetite/eating changes) as reported by each patient’s caregiver or significant other 
(Cummings, 1997; Cummings et al., 1994). The caregiver rated the frequency of each 
symptom experienced on a scale of one-four and the severity of each symptom on a scale of 
one-three, based on scripted questions. These two scores were then multiplied together to 
generate a sub-score for each neuropsychiatric symptom. The sub-scores for each 
neuropsychiatric symptom were then added together to produce a total NPI 10-item score 
(scores from the sleep and night-time behaviour disorders and appetite/eating changes sub-




A.9.2. Geriatric Depression Scale (GDS) 
As described in Chapter 6, the short form 15-point GDS (D'Ath et al., 1994) is comprised of 
15 questions with yes or no answers, based on the patient’s self-report of how they have been 
feeling over the past week. The initial four questions act as screening questions and the 
questionnaire is terminated after these initial four questions if the individual’s responses to all 
four indicate an absence of depression symptoms. Otherwise, the questionnaire is continued 
until all 15 questions have been answered. Each question that is answered positively for a 
depression symptom is scored as one point, with 15 points being the highest (i.e. worst) 
possible total score. 
A.10. PD scales 
A.10.1. Parkinson’s Disease Questionnaire – 39 (PDQ) 
As described in Chapter 6, the PDQ (Peto et al., 1995) comprises of 39 PD-specific self-rated 
questions. Patients are required to rate how their PD has affected them over the past month on 
a scale of zero-four (never, occasionally, sometimes, often or always/cannot do at all). 
A.10.2. Unified Parkinson’s Disease Rating Scale (UPDRS) 
The original UPDRS (Fahn et al., 1987) and the revised Movement Disorders Society-
UPDRS (MDS-UPDRS; (Goetz et al., 2008) are both used in this study. Both versions, which 
have been used on the PD patient cohort in this thesis, comprise of three parts. All questions 
are based on the participant’s average experiences in the past week. Part One concerns Non-
motor aspects of PD that affect daily living, such as mod, sleep and cognition. Part Two 
concerns Motor aspects of PD that affect daily living, including speech, handwriting and 




their PD. High scores equal higher levels of impairment. Each patient rated their experience 
of each symptom over the past week on a severity scale of zero-four (normal, slight, mild, 
moderate, or severe). Two different versions of the UPDRS were employed in the study as 
the newer MDS-UPDRS scale was released in 2008 after the initial data collection had begun 
and it was therefore introduced after baseline testing had commenced. These two versions of 
the UPDRS are comparable (Goetz et al., 2008). 
A.10.3. Modified Hoehn and Yahr Scale 
The Hoehn and Yahr scale is a commonly used clinical rating scale of motor impairments in 
PD. The scale ranges from one-five, where one is ‘unilateral involvement only’ and five is 
‘wheelchair bound or bedridden unless aided’ (Goetz et al., 2004). 
